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ABSTRACT
FACILITATING AND ENHANCING BIOMEDICAL KNOWLEDGE
TRANSLATION: AN IN SILICO APPROACH TO PATIENT-CENTERED
PHARMACOGENOMIC OUTCOMES RESEARCH
by
Kourosh Ravvaz
The University of Wisconsin-Milwaukee, 2015
Under the Supervision of Professor Peter J Tonellato

Current research paradigms such as traditional randomized control trials
mostly rely on relatively narrow efficacy data which results in high internal
validity and low external validity. Given this fact and the need to address
many complex real-world healthcare questions in short periods of time,
alternative research designs and approaches should be considered in
translational research. In silico modeling studies, along with longitudinal
observational studies, are considered as appropriate feasible means to
address the slow pace of translational research. Taking into consideration this
fact, there is a need for an approach that tests newly discovered gene
variants, via an in silico enhanced translational research model (iS-TR) to
conduct patient-centered outcomes research and comparative effectiveness
research studies (PCOR CER).
In this dissertation, it was hypothesized that retrospective EMR analysis and
subsequent mathematical modeling and simulation prediction could facilitate
and accelerate the process of generating and translating pharmacogenomic
knowledge on comparative effectiveness of anticoagulation treatment plan(s)
tailored to well defined target populations which eventually results in a
decrease in overall adverse risk and improve individual and population
ii

outcomes. To test this hypothesis, a simulation modeling framework (iS-TR)
was proposed which takes advantage of the value of longitudinal electronic
medical records (EMRs) to provide an effective approach to translate
pharmacogenomic anticoagulation knowledge and conduct PCOR CER
studies.
The accuracy of the model was demonstrated by reproducing the outcomes of
two major randomized clinical trials for individualizing warfarin dosing. A
substantial, hospital healthcare use case that demonstrates the value of iS-TR
when addressing real world anticoagulation PCOR CER challenges was also
presented.
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1.1.) Statement of the Problem
Translational research in genomics aims to move promising genomic
applications to clinical and public health practice for population health benefit
(Cleeren, 2011). Despite demonstrable health benefits of many new genomic
discoveries, there remain large barriers between the explosive growth of
healthcare related scientific discovery and dramatic improvements in
technology and the implementation of this new knowledge and technology to
improve health outcomes. There is great optimism that systematic
translational research will address these gaps and remove these barriers
while appropriately evolving patient-centered care practice to improve the
health of individuals and populations (Glasgow, 2012; Waldman, 2010).
A fifteen year study to evaluate predictors of and time required for the
translation of highly promising basic research into clinical applications,
showed that only about 5% of the basic science findings were licensed for
clinical use and only 1% were extensively used for licensed indications
(Contopoulos-Ioannidis, 2003).
Since the completion of the Human Genome Project in 2003 (Collins, 2003),
advances in genetic science discoveries have led to mounting expectations in
regard to their impact on health care and disease prevention. Translating
genetic discoveries into lab tests, improved individual care and ultimately into
public health improvements, has emerged as an important, but difficult,
objective in biomedical research. It is widely recognized that the current
translational process is slow, very expensive and often results in an
incomplete transfer of research findings into practice, and consequently failure
of comparative effectiveness studies used to translate the findings into
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substantial changes in patient care and health disparities (Khoury, 2007).
Although pharmacogenomics is one of the first clinical applications of the new
genomic era, so far, few human genomic discoveries have led to evidencebased applications for medicine and public health and its implementation in
clinical practice still involves significant challenges (Swen, 2007; Burke,
2006).
The delay in systematic use of the rapidly expanding collection of clinically
valuable genomic discoveries is created by significant problems in the clinical
research enterprise including the lack of clinical and biomedical informatic
methods, tools and infrastructure required to facilitate the successful
translation of the discoveries to practical clinical use. To date, the primary
focus of initiatives is to improve the technology, clinical science collaboration
and training, and methodologies supporting rapid discovery and regulatory
approval of genetic, genomic, and biological markers, associations, and
targets. However, efforts to translate discoveries and processes to generate
and evaluate evidence in genomic areas (e.g., pharmacogenomics) require
prohibitively expensive clinical trial and clinical study validation that are
severely hindered by regulatory, technical and validation barriers not easily
conducted using current clinical-research or clinical enterprise environments.
As an example of these conundrum, highly-sensitive pharmacogenomic (PGx)
tests that detect variant alleles combined with increasing genomic knowledge
offer physicians the ability to individualize a patient’s drug treatment. If
pharmacogenomic treatment is successful, one anticipates a large reduction
in adverse drug reactions leading to improved patient care, improved
outcomes, reduced treatment periods, and overall lower costs.
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One notable case is the estimation of initial and managing the maintenance
dose of warfarin, the most commonly prescribed oral anticoagulant for the
treatment and prevention of thromboembolic events. Many studies have
proven warfarin’s effectiveness for the prevention of recurrent stroke,
ischemic stroke in patients with atrial fibrillation, thromboembolism in patients
with mechanical prosthetic heart valves, and myocardial infarction in patients
with coronary artery disease (Reynolds, 2007). Warfarin is also effective for
the prevention of pulmonary embolism (PE) and deep venous
thromboembolism (DVT) in patients requiring orthopedic surgery and in those
with a history significant for venous or arterial thromboembolism. Although
warfarin remains the therapy of choice, its narrow therapeutic index creates
challenges for proper management of anticoagulation, as maintaining the
balance of sufficient dosage to prevent thromboembolism while avoiding
overdosing to prevent bleeding events is critical. The correct initial dose of
warfarin differs widely between individuals with intra-individual variability
contributions from factors including age, gender, race, body size, drug
interactions, genetics (i.e., mainly VKORC1 and CYP2C9 genes) and
compliance. The challenge of warfarin dosing and promise of
pharmacogenomics (PGx) have resulted in tens of dosing algorithms including
a large number of PGx-based warfarin dosing algorithms.
To date, PGx-based dosing algorithms have not been adequately tested for
their impact on clinical outcomes across large hospital diverse patient
populations in prospective, controlled trials as it is extremely expensive and
time-consuming to conduct the full array of clinical trials required to test and
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identify the correct combination of genotypes, phenotypes, clinical and
personal data necessary to accurately model drug response, test treatment
options and produce the optimal protocol. For example, in most clinical trials
the study population is dominated by a specific racial or sub-population group
(e.g., about 95% of CoumaGen-I & II study populations were white) which
leads to questions on the effectiveness of the PGx testing for different subpopulations and also failure of comparative effectiveness studies and health
disparities. Accordingly, there is insufficient evidence, at this time, to
recommend for or against routine CYP2C9 and VKORC1 testing in patients
under warfarin. Consequently, the use of PGx testing in clinical practices has
remained limited. In short, the translation of pharmacogenomic knowledge to
clinical practices is associated with challenges and no practical approach to
identify the optimal anticoagulation treatment plan exists for large
heterogeneous patient populations that accounts for individual risk factors,
drug and protocol options, and achieves minimal risk to adverse reactions.

1.2.) Translational Research, Patient-Centered Outcomes
Research and Comparative Effectiveness
As mentioned, translational research is designed to move knowledge gained
from the basic sciences to its application into clinical and community settings
thus improving healthcare outcomes. This process is usually described in
phases of translation (i.e., "T-phases"). Recognizing that there are a number
of ways to frame the phases, a 5-phase model of translational research
process proceeds in iterative and bidirectional phases, research to identify a
problem and the discovery of an opportunity or approach to tackle a health
issue (T0), research involves basic genome-based discoveries to develop
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promising applications such as tests and drugs (T1), research involves
evaluating efficacy of such applications and developing evidence-based
recommendations (T2), research includes investigations designed to increase
uptake and implementation of evidence-based recommendations into practice
and public health programs (T3), and research involves evaluation of the
effectiveness and cost-effectiveness of genomic applications in the "real
world" and in diverse populations (T4) (Khoury, 2012). The translation process
is guided by ongoing and updated knowledge synthesis and translation that
applies to all phases of translation (Khoury, 2010).
Focusing on these phases, each of which addresses different issues and
requires somewhat different methods, provides greater clarity about what is
needed if evidence-based approaches are to be successfully implemented
and sustained in real-world settings. One of the main methods used in almost
all phases from T2 through T4 is conducting clinical trials. Given the
complexity and cost of clinical trials, most funded and published genomic
research remains in the early phases of translation (Schully, 2012).
Consequently, the evidence base for genomics in practice remains limited.
In the light of existing challenges in translating pharmacogenetic knowledge of
anticoagulants and given the burden of managing anticoagulation therapy
using medications with high and variable adverse event risks across diverse
populations, there is a clear need for prospective clinical trials that provide
direct evidence of the benefits, disadvantages, and costs associated with the
genetic testing in the setting of warfarin dosing as well as patient-centered
outcomes research and comparative effectiveness studies (PCOR CER).
PCOR CER studies are to assist patients, clinicians, and other stakeholders in
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making informed decisions by advancing the quality and relevance of
evidence concerning the manner in which anticoagulation therapy can
effectively and appropriately be managed through research and evidence
synthesis that considers variations in patient subpopulations and the
dissemination of research findings with respect to the relative health
outcomes, clinical effectiveness, and appropriateness of the medical
treatments.
Comparative effectiveness research (CER), as a main practical approach to
the PCOR, is defined by the Institute of Medicine as "the generation and
synthesis of evidence that compares the benefits and harms of alternative
methods to prevent, diagnose, treat, and monitor a clinical condition or to
improve the delivery of care” (IOM, 2009). In the context of anticoagulation
therapy, PCOR CER studies could address questions such as: "Given my
personal characteristics, conditions and preferences, what should I expect
from different anticoagulation therapy protocols?", "What are my
anticoagulation therapy options and what are the potential benefits and harms
of those options?", "What can I do to improve the outcomes of my
anticoagulation therapy given my health condition?", and "How can clinicians
and the care delivery systems they work in help me make the best decisions
about my anticoagulation-related health?" (PCORI, 2014).

1.3.) An In Silico Translational Research Model for
Patient-Centered Outcomes Research and Comparative
Effectiveness Studies
Current research paradigms such as traditional randomized control trials
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mostly rely on relatively narrow efficacy data which results in high internal
validity (i.e., extent to which systematic error, bias, is minimized in clinical
trials under optimal conditions) and low external validity (i.e., extent to which
results of trials provide a correct basis for generalization to other
circumstances) (Glasgow, 2012; Nelson, 2006; Juni, 2001; Kessler, 2011).
Given this fact and the need to address many complex real-world healthcare
questions in short periods of time, alternative research designs and
approaches should be considered in translational research. In silico modeling
studies, along with longitudinal observational studies, are considered as
appropriate feasible means to address the slow pace of translational research
(Glasgow, 2012). Taking into consideration this fact, there is a need for an
approach that tests newly discovered genetic variants, via an in silico
enhanced translational research model (iS-TR) to conduct patient-centered
outcomes research and comparative effectiveness studies (Figure 1.1).
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Figure 1.1. Conceptual framework of iS-TR: an iterative and
bidirectional translational research framework enhanced
with an in Silico knowledge synthesis platform to facilitate
pharmacogenetic PCOR and CER studies.

1.4.) Objective of this work:
In this dissertation, we hypothesize that retrospective EMR analysis and
subsequent mathematical modeling and simulation prediction can facilitate
and accelerate the process of generating and translating pharmacogenomic
knowledge on comparative effectiveness of anticoagulation treatment plan(s)
tailored to well defined target populations which eventually results in a
decrease in overall adverse risk and improve individual and population
outcomes. To test this hypothesis, we present a simulation modeling
framework, in silico enhanced model of translational research (iS-TR), which
takes advantage of the value of longitudinal electronic medical records
(EMRs) to provide an effective approach to translate pharmacogenomic
anticoagulation knowledge and conduct PCOR CER studies.
We, first, introduce “iS-TR”, a translational research model enhanced with in
silico knowledge synthesis that expedites testing newly discovered genetic
variants and eventually facilitates conducting PCOR CER studies (Figure 1.1).
Second, we demonstrate the accuracy of the framework by reproducing the
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outcomes of two major randomized and clinical effectiveness trials of
CoumaGen I and II comparing pharmacogenetic algorithms and standard care
for individualizing warfarin dosing. Third, we present a substantial, hospital
healthcare Use Case that demonstrates that the value of iS-TR when
addressing real world anticoagulation PCOR CER challenges.

1.5.) Organization of the Dissertation
This dissertation consists of 7 chapters. An introductory chapter presents the
statement of problem and the objectives.
Chapter 2 presents a background on models of translational research, our in
silico enhanced model of translational research (iS-TR), anticoagulation and
anticlotting, pharmacogenetics, in silico clinical trial studies, and application of
the iS-TR to a patient-centered pharmacogenetic outcomes research problem,
Chapter 3 describes the details of our in silico translational model of genetics
testing in patient-centered anticoagulation outcomes research,
Chapter 4 focuses on the details of development of an EMR-based
longitudinal comparative effectiveness anticoagulation/anticlotting research
database,
Chapter 5 describes a few in silico translational research pharmacogenetic
comparative effectiveness studies using iS-TR,
Chapter 6 presents a PCOR CER study conducted using iS-TR and WiAD to
address warfarin therapy differences in different subpopulations,
Chapter 7 contains a summary of the important results and conclusions and it
also discusses directions for future work in this area using in siIico
translational research.
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2.1.) Translational Research
The progression of scientific knowledge that advances discoveries from
“bench to bedside” occurs through a process called translation. The term
“translation” which defines and describes the advancement of knowledge
through multiple successive phases of research transformation from basic
scientific discoveries to public health impact is a complex process that
involves different resources and actions and requires both research (e.g.,
bench-work and clinical trials) and nonresearch activities (e.g.,
implementation) (Drolet, 2011). The application of findings derived in basic
science to the development of new understanding of disease mechanisms,
diagnoses, and therapeutics in humans is known as “Translational Research”
(Nathan, 2002). Despite an ongoing discussion on the number and nature and
stages of translational research, the general consensus is that translational
research involves highly iterative and interrelated stages of research in
advancing from scientific discoveries to population health (Glasgow, 2012).
In this section, we review the current models and terminology of translation
and translation research. We consider the widely adopted models of
translational research that have been proposed for different areas of medicine
and public health and investigate its applicability to genomic medicine using
some examples.
Although the gap between bench and bedside and knowledge translation
have been discussed in the last few decades, the translation process has
been at the center of attention in biomedical science for only last few years.
The Institute of Medicine (IOM) acknowledged the difficulty and importance of
translating basic scientific discoveries to clinical applications in its 2001
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“Crossing the Quality Chasm” report (Institute of Medicine, 2001). In 2003, the
National Institutes of Health (NIH) Roadmap was announced in which
translation research was a prominent component (Zerhouni, 2003). Through
the Roadmap, many significant programs and major grant efforts have been
funded by the NIH to expedite the process and translation. In spite of billions
of dollars invested by the NIH to fund basic science research each year, the
rate of translation of the results of these research studies into clinical practice
has been low and slow. The results of a study on the translation of basic
science shows that less than 25% of highly promising biomedical discoveries
resulted in at least one published positive randomized clinical trial and less
than 5% were established in clinical practice within 20 years (ContopoulosIoannidis, 2003). Only 14% of new scientific discoveries entered day-to-day
practice and the translation took an average of 17 years (Westfall, 2007). For
instance, one study showed that 15 years after successful clinical trials on
beta blockers for patients recovering from myocardial infarction, these
medications were prescribed for only 62% of patients (Lenfant, 2003). The low
percentage of translation, long translational time periods, and low practical
implementation would likely be reduced and improved if a known process and
clear model of translation of basic science into clinical practice existed and
was used. It is vital to identify the continuum of knowledge translation from the
laboratory to the point of care. Without having enough understanding of this
process, knowledge gets lost in translation and it is difficult to improve the
quality of translation and therefore to reach public health gains.
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2.1.1.) Models of Translational Research
The IOM Translational Research Model:
In 2003, the US Institute of Medicine (IOM) put forth the principles and a
model for translational research. Their translation model (“Clinical Research
Continuum”, CRC) consists of a two-phase process:
1- From basic science to clinical science and
2- From clinical science to public health impact.
The CRC model is based on different perceptions of basic science
researchers and public health agencies on translational research. The first
group believes that translational research involves "the transfer of new
understandings of disease mechanisms gained in the laboratory into the
development of new methods for diagnosis, therapy, and prevention and their
first testing in humans" (Sung, 2003). The second group tends to view
translational research as "the translation of results from clinical studies into
everyday clinical practice and health decision making" (Sung, 2003). IOM
refers to the first phase as "T1" translational research (translation of basic

Figure 2.1. The 2 Translational Blocks in the Clinical Research Continuum
(Sung, 2003).
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research into clinical application) and the second phase as "T2" research
(clinical application to evidence-based practice guidelines).
They also identified “Translational Blocks” acting as obstacles in the clinical
research continuum in their framework (Figure 2.1).
“Blue Highways” on the NIH Roadmap:
While the standard NIH Roadmap for Medical Research included two major
laboratories (bench and bedside) and two above translational steps, Westfall
et al., in 2007, divided the second phase into two separate phases resulting in
a three-phase translational research model (Figure 2.2) (Westfall, 2007):
1- Basic science to clinical science (T1)
2- Clinical practice (T2)
3- Health improvement (T3)
The following figure displaying this model includes examples of the types of
research common in each research laboratory and translational step.

Figure 2.2. Expansion on the NIH Roadmap (Westfall, 2007).
As illustrated in the above figure, the proposed expansion of the NIH
Roadmap (blue) consists of (1) an additional research paradigm (Practicebased Research) and (2) a translational step (T3) to improve dissemination
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and implementation of research discoveries into clinical practice as the
endpoint of the process.
The 3T's Road Map:
Taking into consideration the need for expediting the process of translating
and implementing discoveries into clinical settings, a three-phase model of
translational research has been offered by Dougherty et al., which addresses
the "how" of health care delivery (Figure 2.3) (Dougherty, 2008).

Figure 2.3. The 3T's Road Map - Double-headed arrows represent the
essential need for feedback loops between and across the phases of the
translational research process (Dougherty, 2008).
This model moves from basic biomedical science to clinical efficacy
knowledge (T1). Then, T2 translation focusing on outcomes and comparative
effectiveness research results in clinical effectiveness, and patient-centered
knowledge and evidence which helps develop individualized treatment plans,
more effective "practice guidelines and tools for patients, clinicians and policy
makers".
T3 translation activities focus on how new evidence-based treatment, and
prevention plans and other interventions are rapidly and reliably incorporated
into day-to-day clinical practice and aligned across all levels of the health care
system. This phase of translation aimed to improve the health of individuals
and populations is accomplished by conducting research in domains such as
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measurements, dissemination, and implementation of interventions and
healthcare delivery. Policy change is a major component of T3 activities
required to enhance health outcomes. In this model, the translational steps
T1, T2, and T3 built on each other proceed to improve healthcare delivery
over time. This model also includes feedback loops (as represented by the
bidirectional arrows in Figure 2.3) to explicitly emphasize on the importance of
the bidirectional nature of translational research process.
Biomedical Research Translation Continuum:
Since Drolet et al. believed that none of the prior translation models was
unambiguous and the terminology remained indistinct to both researchers and
physicians, they proposed a model to define and solidify the concepts and
terminology of translation. They called their model “the Biomedical Research
Translation Continuum” (Figure 2.4) (Drolet, 2011).
This model has 4 practical landmarks separated by gaps called "Translation
Chasms". These chasms represent periods in which translation activities are
required to fill the gaps between the phases of research continuum. In the
illustration of the model (Figure 2.4), the "zone of translation" depicts the
collection of translational tasks that have to be conducted to reach public
health impact.
The underlying idea for this model is that a biomedical translation research
continuum starts with basic science discoveries that are supposed to be
translated to create potential clinical uses. The initial step involves the first
translation chasm (T1) in which the basic science discoveries are interpreted
in the context of human medical applications. In most cases, addressing T1
chasm requires in vitro laboratory studies and animal models. This is
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especially the case for genetic scientific discoveries. So, any new basic
discovery entering the continuum is going to be interpreted and translated to
human medical applications. The other translation chasms are also bridged
similarly. For the T2 chasm, potential human applications are followed by
studies such as clinical trials on animal models and humans. In this phase,
the safety and efficacy of the interventions based on the new medical
applications are evaluated. The output of this phase is proven clinical
applications which are going to be implemented and adopted in clinical
practice through bridging the T3 chasm. The ultimate goal is to make positive
impacts on public health.
To see a complete picture of the translation continuum, they have brought up
two examples to examine the entire translation continuum retrospectively.
First, it is the example of aspirin for a specific medical application as a
medication administered after myocardial infarction (MI) to decrease morbidity
and mortality. In this case, initially basic science knowledge from laboratory
discoveries (i.e., "acetylsalicylic acid inhibits prostaglandin synthesis") has to
be translated to proven clinical practice (administration of aspirin after MI),
and, eventually, to individual and public health impacts (decreased mortality).
In this process, initially, basic science knowledge has to be translated to a
medicine. It happens by bridging the T1 chasm. To cross the first translational
chasm (T1), the potential human applications of the medication aspirin should
be identified ("Aspirin inhibits platelet aggregation in vivo via inhibition of
prostaglandin synthesis") and also biochemical mechanisms that the
medication functions in vivo has to be studied in laboratory investigations.
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The next step which comes after development of a human application (e.g.,
"Aspirin prevents post-MI thrombosis by inhibiting platelet aggregation") is to
test the safety and efficacy of the medication by conducting clinical research
studies such as clinical trials. This translational study crosses the second
chasm (T2).
Once the effectiveness of aspirin in decreasing post-MI thrombosis and
mortality is demonstrated through clinical trial studies, the medication could be
implemented and adopted in clinical practice by bridging the third translational
chasm (T3). Then, through practice-based research studies, the public health

Figure 2.4. Biomedical Research Translation Continuum (Drolet, 2011)
impact of aspirin should be investigated to find out if administering this
medication after MI reduces the rate of morbidity and mortality in the
population. In this translational model also, the process of translation is
bidirectional and “bedside to bench” feedback loops are considered as means
to allow integration of new knowledge and also continual improvement of
translation process.
The second example is about the administration of beta blockers after MI
which is well depicted in the following table (Table 2.1).
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Table 2.1. Research Translation Continuum for the administration of beta
blockers after MI (Drolet, 2011).

The Continuum of Translation Research in Genomic Medicine:
In the current omics era, it is believed that recent improvements and
advances in human genomics and related fields would lead in the future to (1)
accelerating the use of new biomarkers derived from gene expression,
proteomic, and other omic technologies, and (2) more genomic applications
for personalized medicine and disease prevention. Although, there is currently
a high interest in evaluating genetic variants for their association with common
chronic diseases, however, the rate of use of genetic tests in clinical practice
and clinical research has increased at a slow pace in last few years (Pagon
2006). To expedite moving genomic discoveries into practice and the delivery
of population-level health benefit, Khoury et al. have proposed a translational
model that classifies genomic translational research into the four following
multidisciplinary phases of translation (Khoury, 2007):
1- from gene discovery to candidate health applications (T1),
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2- from health applications to evidence-based guidelines (T2),
3- from evidence-based guidelines to health practice (T3),
4- from practice to population health impact (T4).
Their phase 4 (one more phase to the Westfall’s model) represents the
population-level evaluation of health outcomes (Figure 2.5).

Figure 2.5. The continuum of translation research in genomic
medicine. HuGE, human genome epidemiology; ACCE, analytic
validity, clinical validity, clinical utility, ethical, legal, and social issues.
(Khoury, 2007)
Although the four phase-array of translational research proposed by Khoury et
al. seems to be a linear process, however, this process takes advantage of
feedback loops and it is likely that similar types of research (e.g., clinical trials,
observational studies) are conducted in different phases.
They have also offered the detailed definitions of some terms used in
translational research models (Table 2.2).
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Table 2.2. Glossary of certain types of “translation research”
involving multiple scientific disciplines (Khoury, 2007).

Translational Research and Knowledge Integration:
Glasgow et al., in 2012, argued that although there are “significant advances
in treatments, the public health benefits associated with these improved
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treatments tend to be modest because they are not widely implemented”
(Glasgow, 2012). Accordingly, they believe there should be more focus on
some aspects of dissemination and implementation research (rigor and
relevance, efficiency, collaboration, improved capacity, and cumulative
knowledge) to be able to accelerate and improve the appropriate integration
of basic science and genomic discoveries into health care and disease
prevention. Consequently, this prohibits incomplete classification of translation
which might result in missing influential and in essence different tasks that
have to be addressed in the later stages of translation, “dissemination” and
“implementation”.
To address this need, they have proposed a different translational research
model with a more differentiated approach to the science of dissemination and
implementation (Figure 2.6). Rather than a linear process of translating
research findings into practice, they have framed the phases of translational
research as a 5-phase model in which research moves into practice and
policy. Having known that research in essence is not a one-way process, they
also believe findings at any phase can impact the other phases and the
translational process is a highly iterative cycle. These 5 overlapping,
interrelated phases span a diverse array of research disciplines, methods and
activities needed to move basic science discoveries to population health.
Each phase moves to progressively broader settings over time and addresses
different questions and requires somewhat different methods to successfully
implement and sustain evidence-based approaches in real-world settings.
Basically, this 5-phase model shows the complexity of translational research
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and its inter- and transdisciplinary nature which requires collaboration among
partners from basic, clinical, population sciences as well as communities.
In the T0 phase, unaddressed health issues and opportunities and the
potential scientific approaches to tackle them are identified. Basically, the
scientific approaches and discoveries could be derived from multiple
disciplines such as molecular, biological, genomic, behavioral, and
epidemiological research studies. Then, it is followed by the T1 phase in
which promising interventions (e.g., clinical tests, drugs, behavioral, and
organizational interventions or policy changes) are tested. In the next phase
(T2), the focus is on finding the effectiveness of the new developed
interventions and whether they positively impact health outcomes. Different
study designs (e.g., clinical trials) and analysis methods are used during this
second research phase to create evidence-based recommendations, policies,
and guidelines published by respective professional associations and groups.
As mentioned in the earlier sections, NIH's primary focus has been on T1 and
T2 research and it usually categorizes the activities during T3 and T4
translational research phases under T2. In this model, the T3 phase includes
research studies designed and conducted to scale up the implementation of
evidence-based recommendations and guidelines into clinical practice
settings. And finally, the T4 phase involves real-world evaluation of the
population health outcomes of the interventions through different translational
studies such as comparative effectiveness and cost effectiveness research
studies. Glasgow et al. mainly focus on dissemination and implementation
and highly believe in the importance of investigation and understanding of the
processes involved in the adoption, implementation, and sustainability of

27

research. According to them, these translational processes and activities
include “dissemination of interventions”, “decisions by healthcare practitioners
or organizations to adopt or use the interventions”, “implementation of the
interventions into standard practice or standard operating procedures of
organizations”, and “maintenance of changes in health care practices by
organizations, individual health care practitioners, and patients”. In their
proposed cyclic model, the translational research process is fueled and

Figure 2.6. 5-phase model of translational research guided by ongoing and
updated knowledge synthesis and integration (Glasgow, 2012).
directed by continuing and updated evidence and knowledge synthesis to
guide dissemination and implementation research.

2.2.) An In Silico Enhanced Model of Translational
Research (iS-TR)
Given the limitations of the other translational research models and the need
to address many complex real-world healthcare questions in short period of
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time, alternative research designs, approaches and models should be
considered in translational research. In silico modeling studies, along with
longitudinal observational studies, are considered as appropriate feasible
means to address the slow pace of translational research (Glasgow, 2012).
Taking into consideration this fact in the context of genomics and specifically
pharmacogenomics, there is a need for an approach that tests newly
discovered genetic variants, via an in silico enhanced translational research
model (iS-TR) to conduct patient-centered outcomes research and
comparative effectiveness studies (PCOR CER). Figure 2.7 depicts the
conceptual framework of our proposed iS-TR which includes an iterative and
bidirectional translational research framework enhanced with an in silico
knowledge synthesis platform to facilitate pharmacogenetic PCOR and CER
studies. Our model and its proposed applications are explained in the
following sections.

Figure 2.7. Conceptual framework of iS-TR
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Based on the iS-TR model, we have developed an in silico translational
research framework to facilitate and expedite the pharmacogenomic
translational research. This framework consists of a few components including
a longitudinal EMR-based anticoagulation research database, a database
miner and analyzer, a population health knowledge base, an anticoagulation
clinical trial simulator, and a CER Knowledge Base (Figure 2.8). In the
following sections, the components of the framework are briefly described.

Figure 2.8. In silico translational research framework: In Silico WiAD PCOR
CER Framework. WiAD: Wisconsin Anticoagulation Database; ETL: Extract,
Transform, Load.
Wisconsin Anticoagulation Database: WiAD
To generate meaningful PCOR, researchers need high-quality data, including
greater clinical detail, longitudinal follow-up, and linkages among data sets
(Navathe, 2011). To advance research data infrastructure, University of
Wisconsin-Milwaukee and Aurora Health Care Research Institute have
collaborated on a multistage project to develop a retrospective EMR-based
longitudinal anticoagulation clinical database (Wisconsin Anticoagulation
Database: WiAD) being used for PCOR on most frequently prescribed
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anticoagulation agents such as Coumadin (Warfarin), Heparin, Ticlopidine
(Ticlid), Clopidogrel (Plavix), Dipyridamole (Persantine), Abciximab (ReoPro),
Eptifibatide (Integrilin), Tirofiban (Aggrastat), or and Dabigatran (Pradaxa).
Aurora Health Care is the largest health care system in Wisconsin operating
15 hospitals throughout the state with more than 3600 licensed beds, 172
physician clinic facilities, and several other health care related entities. It
serves about 1.2 million unique patients each year through 7.8 million patient
encounters per year. So, such an anticoagulation research database
representing Wisconsin State population has provided a powerful tool for
conducting outcome research studies on anticoagulation dosing algorithms.
The details of this database are described in chapter 4.
WiAD-Miner and Analyzer:
An interactive data profiling and population “segmentation” tool “WiAD-Miner
and Analyzer” was developed and used to (a) facilitate the process of patient
cohort selection using different demographic, clinical, temporal, and
geographical inclusion criteria and (b) synthesize hypotheses. This tool also
has some features which are specific to anticoagulation therapy such as a
module which calculates the Time in Therapeutic Range (TTR) for each
individual from the electronic medical record (EMR) data. WiAD-Miner’s
details are covered in Chapter 4.
Population Health Knowledge Base:
WiAD is a database that includes data from a geographically widespread,
diverse racial and demographic patient population across the state of
Wisconsin. A knowledge base including health, demographic and
socioeconomic characteristics of original populations of this patient population
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provides a rich source of complementary information to be used in different
ways for the EMR-based in silico PCOR CER studies such as (a) quality
control and assurance in the process of transforming and integrating data into
the WiAD, (b) generate more accurate virtual patients and patient populations
by the clinical trial simulator, (c) generate more enriched hypothesis. The
information in the knowledge base is provided from different sources such as
the national, state, county and city census data, and state, county and city
health reports. This details and usage of this knowledge base is demonstrated
in chapters 5 and 6.
Pharmacogenetic Clinical Trial Simulator:
Our pharmacogenetic clinical trial simulator consists of the 5 following
adjustable modeling components: 1) A Bayesian network model (BNM) to
produce virtual patient population (“Clinical Avatars”) consistent with desired
target populations, 2) A dose calculator which calculates an initial dose
(clinical and PG-based) for each virtual patient, 3) An INR predictor which is
based on pharmacokinetic/pharmacodynamics (PK/PD) model, 4) A dose
adjuster which adjusts doses by using different protocols based on INRs, and
5) An outcome calculator which measures the desired outcomes (e.g., TTR).
The details of this simulator is described in detail in chapter 5.
CER Knowledge Base:
The outcomes of the simulations using the simulator will contribute to the CER
knowledge base in comparing effectiveness of different anticoagulation
therapy treatment plans and practices from which evidence-based information
can be derived by patients, providers, policymakers, and other stakeholders.
This knowledge is used as a basis for designing and testing different

32

population-based treatment plans in real clinical settings. This details and
usage of this knowledge base is demonstrated in chapters 5 and 6.

2.3.) Anticoagulation and Anticlotting
The phenomenon of coagulation (thrombogenesis) is a crucial component of
the body’s hemostasis. Through this process, blood creates clots. Coagulation
disorders can result in different forms of bleeding (hemorrhage) and
obstructive clotting (thrombosis). Blood coagulation (clotting) is a complex
process involving many clotting factors which activates each other. The
details of the process are depicted and explained in Figure 2.9.
In brief, this process composes of the three following stages:
- Formation of Prothrombinase
Prothrombinase can be formed either through “intrinsic system” or “extrinsic
system” which involves interactions between coagulation factors (e.g., Factor
VIII, Factor IX).
- Conversion of Prothrombin to Enzyme Thrombin
In this stage, prothrombinase converts prothrombin to enzyme thrombin.
- Conversion of Fibrinogen to Fibrin (formation of clot)
Then, thrombin converts fibrinogen into fibrin which forms a mesh to form
clots.
Various substances are required for the proper functioning of the coagulation
cascade (Wikipedia Coagulation, 2014):
- “Calcium and phospholipid (a platelet membrane constituent) are required
for the tenase and prothrombinase complexes to function. Calcium mediates
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Figure 2.9. The Coagulation and Fibrinolytic Pathways. The main coagulation
reactions are divided into the intrinsic and extrinsic systems. Activation of factor
XII on contact with a negatively charged surface initiates the intrinsic
coagulation system. (The activated form of the factor is indicated by “a.”) The
extrinsic coagulation system induces the formation of a complex composed of
factor VII and tissue factor, which is released after tissue injury. Some of these
reactions depend on calcium ions. Thrombin is formed by an enzyme complex
called prothrombinase, composed of factor X, factor V, negatively charged
phospholipids, and calcium ions. Intrinsic and extrinsic activation of the
coagulation cascade leads to the generation of thrombin, the activation of
fibrinogen, the release of fibrinopeptides, the formation of soluble fibrin, and
finally, the formation of factor XIII–mediated, cross-linked, insoluble fibrin. The
main fibrinolytic reactions involve the inhibition of fibrinolysis by plasminogenactivator inhibitor type 1 (PAI-1) and a2-antiplasmin. Fibrinolysis is initiated by
tissue plasminogen activator (t-PA), urinary-type plasminogen activator (u-PA),
and plasmin. Plasmin bound to the surface of fibrin initiates the lysis of
insoluble, cross-linked fibrin, with the subsequent generation of fibrindegradation products. Plasmin bound to the surface of fibrin is better protected
from inhibition by a2-antiplasmin than is plasmin generated in the fluid phase
(Kohler; 2000).
the binding of the complexes via the terminal gamma-carboxy residues on
FXa and FIXa to the phospholipid surfaces expressed by platelets, as well as
procoagulant microparticles or microvesicles shed from them. Calcium is also
required at other points in the coagulation cascade.
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- Vitamin K is an essential factor to a hepatic gamma-glutamyl carboxylase
that adds a carboxyl group to glutamic acid residues on factors II, VII, IX and
X, as well as Protein S, Protein C and Protein Z. In adding the gammacarboxyl group to glutamate residues on the immature clotting factors Vitamin
K is itself oxidized. Another enzyme, Vitamin K epoxide reductase, (VKORC)
reduces vitamin K back to its active form. Vitamin K epoxide reductase is
pharmacologically important as a target of anticoagulant drugs warfarin and
related coumarins such as acenocoumarol, phenprocoumon, and dicumarol.
These drugs create a deficiency of reduced vitamin K by blocking VKORC,
thereby inhibiting maturation of clotting factors. Vitamin K deficiency from
other causes (e.g., in malabsorption) or impaired vitamin K metabolism in
disease (e.g., in hepatic failure) lead to the formation of PIVKAs (proteins
formed in vitamin K absence) which are partially or totally non-gamma
carboxylated, affecting the coagulation factors' ability to bind to phospholipid”.
Anticoagulation Agents:
Anticoagulation agents are a class of medications that are developed to
prevent and reduce blood coagulation and clotting disorders (e.g., DVT: deep
vein thrombosis, PE: pulmonary embolism, MI: myocardial infarction and
IS:ischemic stroke). Anticoagulation agents are administered in different
ways; oral, intravenous, or subcutaneous injection. Different anticoagulants
interrupt the coagulation cascade at various points (Figure 2.10). Vitamin K
antagonists, such as warfarin, typically work on and inhibit several calciumdependent clotting factors, including factors II, VII, IX, and X. Dabigatran
directly inhibits factor IIa (thrombin). Apixaban, betrixaban, edoxaban, and
rivaroxaban inhibit factor Xa.
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Figure 2.10. Coagulation cascade and point of effect of the common
oral anticoagulants. TF: tissue factor. (Makaryus, 2013)
For a few decades, vitamin K antagonists (VKAs) such as warfarin, the most
commonly used VKA, have been used as the main agents for long term
anticoagulation therapy (Steffel, 2006). Anticoagulation therapy using doseadjusted VKAs has been always an effective clinical option to prevent and
treat thromboembolic diseases. However, long term management of VKAs is
challenging as the intensity of anticoagulation represented by measurement of
international normalized ration (INR) can be out of desired therapeutic ranges
for a large amount of treatment period. Despite the widespread use of VKAs,
they have some characteristics that make them difficult to manage, such as
(a) a narrow therapeutic index/window outside of which there is a risk of
bleeding events, or thromboembolism which demands regular frequent
monitoring of INR, (b) a wide inter-individual variability in dose-response due
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to their pharmacokinetics affected by genetic and physiological factors, (c)
different levels of interactions with other medications and foods (Hart, 2007;
Guyatt, 2012).
In addition to VKAs, there are other anticoagulant agents that can be
applicable alternatives such as unfractionated heparin, the low molecularweight heparins (LMWHs), and indirect-acting factor Xa inhibitors (e.g.,
fondaparinux). However, they have some limitations too. The subcutaneous
and parenteral route of administration make them time consuming and less
convenient medications for patients under anticoagulation treatment.
Furthermore, taking into consideration their specific pharmacokinetics, they
need continuous intravenous infusion or daily dose adjustment. Some of them
such as LMWHs have unstable bioavailability under some physiological
circumstances such obesity or renal failure.
Novel Oral Anticoagulants:
These shortcomings and practical limitations of the VKAs and the intravenous
anticoagulant medications have motivated scientists to develop alternative
oral medications called novel oral anticoagulants (NOAs) with quick onset of
action, predictable pharmacokinetics, less need for regular monitoring and
interactions with other medications and foods. NOAs include direct thrombin
inhibitors, such as dabigatran, and factor Xa inhibitors such as apixaban,
edoxaban, and rivaroxaban (Makaryus, 2013).
The VKAs and NOAs act differently in the body. The first group of
medications, inhibit gamma-glutamyl carboxylation of coagulation factors II,
VII, IX, X, and the coagulation inhibitor proteins C and S. On the other side,
NOAs act on some different proteins in the coagulation cascade (Figure 2.10).
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Although NOAs have some benefits over VKAs such as predictable
pharmacokinetic mechanisms which facilitate their dosing without a need for
routine monitoring, their use have not been popular as expected for some
reasons such as their high cost versus VKAs and lack of strategies to rapidly
quantify or reverse their anticoagulant effects (Harder, 2008; Brenner, 2011).

2.4.) Pharmacogenetics
Variability in response to medications creates a significant challenge for
physicians, patients and pharmaceutical companies (Evans, 1999). Factors
involving in the body’s response to a medication are multifold and complex
(Table 2.3) (Ma, 2011). A large number of clinical studies have shown that
variation in genetic make-up of individuals is an important factor affecting the
medication response in the body.
Different factors such as environmental effects, physiological factors (e.g.,
medical conditions) and genetic profile variations are involved in the variation.
The field of pharmacogenetics studies the relationship between individual’s
response variability to medications and genetic variations (Hewett, 2002). This
field of study, especially in the light of the complete human genome
sequence, has motivated many researchers to conduct pharmacogenetic
studies at an accelerating rate in recent years on many medications which
were previously recognized to have unpredictable outcomes and unintended
side effects.
The knowledge of pharmacogenetics helps to understand some of the
underpinning causes of these challenges and also implement personalized
medicine. The main questions asked in the field of pharmacogenetics are:
what are the genes involved in a drug's mechanism of action? how are a
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Table 2.3. Major factors affecting individual medication response (Ma, 2011)
Factors
Genetic Factors
Therapeutic targets
Drug-metabolizing enzymes
Drug transporters
Targets of adverse drug reactions
Factors with indirect effects
Other Factors
Environmental factors
Environmental chemicals,
coadministered drugs, tobacco
smoking, alcohol drinking, and
dietary constituents
Physiological factors
Age, sex, disease state, pregnancy,
exercise, circadian rhythm, and
starvation

Effects
Major variables; stable and inherited
Drug efficacy (pharmacodynamics)
Drug metabolism (pharmacokinetics)
Drug disposition (pharmacokinetics)
Drug toxicity (pharmacokinetics and
pharmacodynamics)
Drug efficacy, pharmacokinetics, and
toxicity
Mostly transient
Drug efficacy, pharmacokinetics, and
toxicity

Drug efficacy, pharmacokinetics, and
toxicity

drug's effects propagated through pathways? how can this information be
applied to characterize "off-target" adverse events? How can
pharmacogenomics information be utilized in prescription and dosing
decisions? (Karczewski, 2012).
In clinical settings, physicians mainly prescribe medications based on their
clinical judgment and evidence resulting from clinical trials. They usually take
into consideration clinical factors (e.g., age, weight, ongoing health condition)
and behavioral characteristics of patients and genetic characteristics are not
considered in many settings. This appears to be the case in anticoagulation
therapy. For example, two groups of patients with similar clinical and
backgrounds and presentations might undergo the same dosing regimen of
anticoagulant clopidogrel (e.g., 75 mg/day) or warfarin (e.g., 5 mg/day). This
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treatment approach might result in a good protection against thromboembolic
events in one group and might cause side effects in the other group.
Pharmacogenetic studies have revealed that the patients under clopidogrel
and warfarin who experience inadequate protection are more likely the ones
who are poor metabolizers of the medications owing to their variant alleles of
genes CYP2C19 and CYP2C9 and VKORC1, respectively (Highashi, 2002;
Aithal, 1999; Rieder, 2005; D'Andrea, 2005; Yuan, 2005; Aquilante 2006). In
the case of warfarin, these findings have resulted in a sheer number of
pharmacogenetic-based (PG-based) dosing algorithms explaining a
significant proportion of the interindividual variability in warfarin dose
requirement (e.g., Gage, 2008; Anderson, 2007; Klein 2009).
After taking a medication, it has to go through different components of the
body to reach its target tissues/cells, then it acts on its target, and eventually
its metabolites and residues are eliminated from the body. The process of
absorbing, distributing, metabolizing, and excretion/elimination are regulated
by pharmacokinetic (PK) genes. Pharmacodynamic (PD) genes regulate the
effect of medications on their targets. Genes regulating PK and PD processes
can be involved and led to desired/intended effects by affecting target cells or
contribute to undesired/side effects by affecting non-target cells.
Pharmacogenetic researchers try to find the genes involved in both the PK
and PD pathways that affect drug action in order to improve dosing and avoid
adverse drug reactions (Karczewski, 2012).
Different stakeholders such as patients, health care providers, pharmaceutical
companies and academics can take advantage and are interested in
pharmacogenetic knowledge. Patients and healthcare providers use
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pharmacogenetic information to make more informed decisions and determine
more accurate medication optimal doses. Using pharmacogenetic discoveries
and knowledge, research teams and pharmaceutical companies are able to
enhance and facilitate safer and target-oriented clinical trials.

2.5.) In Silico Clinical Trial Studies
In silico is a term which is used and referred to tasks performed on computer
or through computer simulation. In silico techniques and methods have been
widely used in different disciplines such as engineering, physics, astronomy,
marketing and economics to foster the process of developing and testing the
performance of systems. The application of simulation in these fields have
resulted in reduction of costs and shorter development cycles.
In last two decades, clinical trials modeling and simulation has gained a lot of
attention. In silico approaches to conduct clinical trials which employ realistic
virtual subjects and typical trial conditions, based on both experimentally
informed disease progress and drug intervention models have been
embraced by both pharmaceutical companies and also regulatory agencies
(Kimko, 2003). It provides an opportunity for researchers to develop and test
hypotheses virtually prior to real-world experiments. Many pharmaceutical
companies use the clinical trials modeling and simulation techniques to
facilitate the development of new drugs and make the drugs more efficient.
Regulatory agencies such as US Food and Drug Administration (FDA) and
European Medicines Agency have recognized the important role of clinical
trials modeling and simulation and have advocated using it to support more
evidence-based study designs and dosing protocols in different target
subpopulations. FDA underscored clinical trial modeling and simulation in its
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2004 Clinical Path Initiative as an opportunity which could improve
predictability and efficiency along the critical path from laboratory concept to
commercial product: “FDA scientists use, and are collaborating with others in
the refinement of, quantitative clinical trial modeling using simulation software
to improve trial design and to predict outcomes.” (FDA, 2004).
From the perspective of European Medicines Agency, the modeling and
simulation of clinical trials and PK/PD data contribute to the regulatory review
process and also drug development because modeling and simulation
(Jönssen, 2010): “allow more efficient utilization of collected clinical data”,
“support informed decision making regarding future studies and study designs
including dose selection”, are beneficial in time and cost savings. Accordingly,
several European guidelines “recommend modeling and simulation as a
useful tool to support dose selection and establish dose recommendations in
special populations”.
Peck et al. have provided the following detailed technical definition for the
clinical trial simulation: “the generation of biomarker or clinical responses in
virtual subjects that take into account (a) the trial design and execution, (b)
pathophysiological changes in subjects during the trial (disease progress
model), and (c) pharmacology (drug intervention model), using mathematical,
statistical and numerical methods and models” (Peck, 2011).
Components of a Clinical Trial Simulation:
A clinical trial simulation generally is composed of three following components
(Holford, 2000):
1- The input–output model consists of submodels that incorporate the drug’s
pharmacokinetics and pharmacodynamics, the disease progression during the

42

trial, the trial endpoints, and the residual variability. Some of these submodels
may include covariate influences on model parameters, which comprise the
covariate distribution model. Basically, the input–output models are functions
that map the set of inputs to the set of outputs.
2- The covariate distribution model describes the distribution of the covariates
and their intercorrelations.
3- The trial execution model consists of the study design elements, and
potential submodels for compliance, protocol deviations, and missing data.

2.6.) Application of the iS-TR to a Patient-Centered
Pharmacogenetic Outcomes Research Problem
Based on the Patient Protection and Affordable Care Act (PPACA, 2010),
Comparative Effectiveness Research (CER) is a national research priority.
Under this Act, the Patient-Centered Outcomes Research Institute (PCORI) is
in charge of supporting the research that takes into account the potential for
differences in the effectiveness of health care treatments, services, and items
as used with various subpopulations, such as racial and ethnic minorities,
women, age, and groups of individuals with different comorbidities, genetic
and molecular sub-types, or quality of life preferences and include members
of such subpopulations as subjects in the research as feasible and
appropriate. Accordingly, PCORI has proposed priorities and research
agenda with focus on CER studies providing opportunities to assess the
benefits and risks of adopting genetic tests in patient subsets (PCORI, 2012).
PCORI has recently published its “Methodology Report” introducing the
PCORI Methodology Standards (PCORI, 2013). These are specific
recommendations for researchers that designate the minimal requirements for
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following PCOR best practices. Under the recommended methods related to
Heterogeneity of Treatment Effect (HTE: a technical term for the fact that
different people do not always respond the same way to the same treatment),
it is recommended to develop methods to use simulation models to (a)
address questions on heterogeneity of treatment effect, (b) address patientcentered comparative effectiveness questions, and (c) to support guidance on
adaptive trials’ complex design specific to PCOR.
Accordingly, we use our iS-TR model and framework to generate robust,
relevant, and timely evidence for patient-centered pharmacogenetic outcomes
research questions. For instance, although the potential clinical value of most
of the PG-based algorithms versus non PG-based “best practice” treatment
plans was assessed through rigorous randomized controlled trials, their
clinical applicability and effectiveness for different target populations have not
been evaluated which leads to an opportunity for PCOR CER studies using
our iS-TR framework.

2.7.) Focus of this study
As part of continuing effort to address health care challenges through patientcentered outcomes research (PCOR), we introduce an in silico translational
research model and framework supporting pharmacogenetic anticoagulation
PCOR CER prediction and validation studies. This framework is designed to
demonstrate how current access to large comprehensive electronic medical
records (EMR) covering diverse patient populations, coupled with novel
modeling and computational simulations could provide an unprecedented
opportunity to conduct in silico identification, validation and comparison of
treatment strategies.
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3.1.) Patient Populations and Subpopulations
As discussed in section 1.3, current research paradigms such as traditional
randomized control trials mostly rely on relatively narrow efficacy data which
results in high internal validity (i.e., extent to which systematic error, bias, is
minimized in clinical trials under optimal conditions) and low external validity
(i.e., extent to which results of trials provide a correct basis for generalization
to other circumstances) (Glasgow, 2006; Juni, 2001; Kessler, 2011). The lack
of comparability between trial participants and nonparticipants has resulted in
a slow pace of translation of new genomic knowledge to clinical settings and
public health. In almost all of the controlled trials, a small fraction of the total
number of patients participate. The participants are usually dedicated
individuals to trial studies who are selected based on strict inclusion and
exclusion criteria. So, the interventions that are successful in trial patient
cohorts may not necessarily translate well to the real-world clinical setting.
This raises questions of the generalizability of the results of clinical trials
which is one of the important and practical aspects of clinical trials (Elting,
2006; Schulz, 2010). There are different approaches that can be taken to
answer the questions, “How can trial results be applied to patients in clinical
practice?” and “How different are the interventions/treatment plans resulted
from a given trial study compared with the other available ones?” For
example, (a) conducting large, population-based effectiveness trials to provide
evidence on the generalizability of clinical trial results and the realistic benefits
of treatments, (b) conducting effectiveness studies that examine how a
therapy/intervention, that works effectively under certain circumstances, works
in clinical practice, (c) developing trials that fit patients seen in practice and
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their participants share the same characteristics as the majority of patients,
and (d) another approach is the development of trials that are targeted and
appropriate to the needs of special populations. Accordingly, continued
investigation is needed to see how results of clinical trials are translated into
nontrial care, to facilitate the dissemination of clinical trials findings, and to
identify ways to achieve faster and more generalizable clinical trial findings.
This has been the case for pharmacogenomics in the last decade too.
Enormous number of clinical trials have been conducted or are currently
under way to test the accuracy of previous dosing algorithms, construct new
dosing algorithms, or test the value of genetic tests in warfarin dosing, with
equivocal results. Several clinical trial studies have shown that PG-based
dosing lead to superior control of warfarin anticoagulation (e.g., Gage, 2008;
Anderson, 2012), whereas a number of prospective studies and controlled
clinical trials have failed to show that genotyping improves warfarin dosing
and anticoagulation control (e.g., Anderson, 2007; Kimmel, 2013). Although in
those clinical trials thousands of subjects have been recruited, the clinical
utility of PG-based dosing of warfarin has been mostly tested in small clinical
trial or observational study populations.
To deal with such a challenge, overcome the study populations’ limitations,
and fill the translational research gaps using in silico trial and comparative
effectiveness studies, in the first step, there is a need to generate realistic
virtual subject populations and subpopulations representing the patient types
that are likely to be studied in the actual studies. Among various methods, we
have used the following methods to create virtual patient populations
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(hereafter “Clinical Avatars”) in our in silico PC-CER translational framework,
introduced in section 2.2.

3.1.1.) Clinical Avatar Model
Background in Bayesian Theory
Simulating patient data (i.e., creating “Clinical Avatars”) poses several
challenges common to big data research including missing values, high
dimensionality and low sample size. We found that a Bayesian machine
learning approach can address these issues in an efficient, effective and
generalizable method. More specifically, our method to generate clinical
avatars relies on constructing a Bayesian belief networks, hereafter called
Bayesian network model (BNM). Using Bayes theorem and extensions of
Bayesian theory, BNMs can accomplish two critical elements necessary for
modeling patient data, pattern learning and parameter learning. Pattern
learning describes a method for discovering graphical representation that
correctly approximates relationships between variables within some set of
data. Parameter learning applies a graphical pattern with the names and
number of categories within the pattern to create a Bayes net. The Bayes net
is composed of distinct states each with unique conditional probabilities as
defined by some graphic pattern and estimates provided by either training
data or evidence.
As recently summarized by Conca Bielza (2014) Bayesian Classification, (i.e.,
pattern learning) offers distinct advantages in modeling healthcare data over
other statistical classification techniques (e.g., ad hoc, regression). Types of
Bayesian classifiers, such as binary, categorical and continuous are used to
capture the structure of data sets found in patient databases. Such classifiers
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also efficiently accommodate missing data as well as feature selection in the
learning and inference stages. Bayesian networks also provide “an explicit,
graphical and interpretable representation of uncertain knowledge…based on
the sound concept of conditional independence (as) an example of a
probabilistic graphical model” (Bielza, 2014). Once the pattern is discovered,
the parameters can be learned efficiently. In the following section, the basis
and method to create Clinical Avatars are summarized: the fundamental
principles of classification, Bayes theorem, Markov Blanket Based DAG
Discovery and Bayesian belief networks.

A.) Data Classification
Classification is a broad term used to describe the process of assigning or
predicting categorical classes and defining their respective relationships.
Classification is a two-step process; the first step is termed the learning step
and the second step is termed the classifier step. During the learning step, or
training phase, a classification algorithm creates a model by learning from a
set of training data (i.e., database tuples) and a set of corresponding classes
C. A tuple, X, is represented by an n-dimensional attribute vector, X = (x1, x2,
…, xn). X is composed of a random set of predictive n-measurements from the
tuple of n-database attributes, such that, ai ∈ Ω ai = {A1, A2, …, An}. Each
tuple, X, is assumed to belong to a predefined class as determined by another
database attribute called the class label attribute called C where

,

,…,

∈ Ωc =

. The class label attribute is categorical in that each value of cn

serves as a category or class. Classification denotes instances where the
class label of each training tuple is provided, are known as supervised
learning (i.e., the learning of the classifier is “supervised” in that it is told to
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which class each training tuple belongs). In contrast Clustering denotes
instances where the class label of each training tuple is unknown, known as
unsupervised learning and the tuples as organized by a specified measure of
similarity. The classification problem consists of inducing a model M from a
random sample of individual tuples called a training set or training tuples D,
where D = {(x(1), c(1)),…, {(x(N), c(N))} of size N from a joint probability
distribution p(X, C).
In the second step, the predictive accuracy of the induced model M is
estimated. To do so, there are multiple measures such as classification
accuracy and sensitivity and ROC curve all of which must validated by
bootstrapping, k-fold cross validation, and/or holding-out a validation set of
data tuples Xj and their associated class labels Cj from the original training
data. Validation tuples are selected from the general data set at random. They
are independent of the training tuples and were not used to construct the
classifier. Then the accuracy of the classifier on the validation dataset is
evaluated by the percentage of test set tuples that are correctly classified by
the classifier. If the accuracy of the classifier is considered acceptable, the
classifier can be used to classify future data tuples for which the class label is
not known or can be used to simulate data tuples.

B.) Bayes' Theorem
Bayes' theorem (also known as Bayes' rule) is a means for calculating the
conditional probability of a random event given some additional information. In
this section, it is described how Bayes theorem could be used for
classification of random events (i.e., tuple X) of a given database. In this
example, X is a tuple of the given database that is identified by measurements
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of its attributes. For such case, we assume there exists a hypothesis
indicating that the data tuple X belongs to a specified class C. Then, our goal
is to determine P(C|X), or the probability that tuple X belongs to class C, given
our knowledge and evidence on the attribute description of X. P(C), P(X|C),
and P(X) are called the prior probability and are estimated from the a set of
statistical evidence. The posterior probability, P(C|X) is calculated using the
following equation based on Bayes' theorem:
|

=

|

As an example, having applied Bayes theorem to issue of correctly
diagnosing prostate cancer, if we select men at random from a male
population and remove their prostates for definitive diagnosis of cancer we
would find the prior probability of prostate cancer, P(has cancer), in the given
male population. If we want to know the probability that any randomly selected
man has cancer without removing his prostate, we would want to know all
relevant information such as age and Prostate Specific Antigen (PSA) level.
We generate a dataset drawn from a random sample of men that includes
data on the patients’ age and PSA level. A given patient with the age of 70
years old and a PSA level of 4.0 ng/mL is represented by tuple X. Suppose a
physician hypothesizes that her patient has prostate cancer. Then the
posterior probability or P((has cancer)|X), indicates the probability that this
random patient will be diagnosed with a prostate tumor given that we know
the patient's age and PSA level. In this case we can use Bayes theorem to
find P((has cancer)|X) when we are given P(has cancer), and P(X|(has cancer))
or the probability that a prior patient is 70 years old and has a PSA level of 4.0
ng/mL, given that we know the patient will be diagnose with a prostate tumor.
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C.) Pattern Learning: Bayes Classifiers, Bayesian Network Classifiers
A Bayes classifier applies Bayes theorem to the classification problem.
Returning to our prostate cancer example, given a random set of variables,
such as sex, income, car model, and age, we seek a model that can predict
the probability of cancer in a randomly selected individual. More generally, the
Bayes classifier defines a model M to a random set of training tuples D, where

D = {(x(1), c(1)),…, {(x(N), c(N))} of size N from a joint probability distribution p(x,
c). The Bayesian approach can be described as a non-deterministic
polynomial-time hard optimization problem under a binary loss function that
minimizes conditional risk based on prior probability (Bielza, 2014). The
optimal model is one that seeks to derive the most probable posteriori class
for any given example xr = (xr1, …, xrn) drawn from the same data source as
the training tuples, or
c

c

In contrast to the heuristic Bayes classifiers, constraint based Bayesian
network classifiers approximate

,

according to a Bayesian network. A

Y

X
Z

W

Figure 3.1. Example DAG
Bayesian network is a graphical depiction of a data called a directed acyclic
graph (DAG) where the nodes of the DAG are the c classes of any given
variable X1,…, Xn, and the edges (or vertices) define the (in)dependence
relationships between those variables. In Figure 3.1, the nodes X, Y, Z, W
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correspond to the class C within a given data set. The arrows that define the
asymmetrical relationships between the nodes X, Y, Z and W describe the
probabilistic conditional dependences between the nodes. In other words, the
prior probability of a given parental node such as X or Y can predict
probability that any given tuple belongs to a particular class of child nodes
such as Z and W. Once a Bayesian network (i.e., DAG) is constructed, it
provides a logical and interpretable framework for learning the probability of
any given set of data. The fact that each variable is conditionally independent
of its non-descendants in the DAG, given its parents, allows the network to
provide a complete representation of the existing joint probability distribution
with the following equation:
,…,

=

|

!

where P(x1, : : : , xn) is the probability of a particular combination of values of
X, and the values for P(xi | Parents(Yi)) correspond to the probability for Yi
based on a set of training data.
There are multiple methods for Bayesian networks to approximate joint

,

conditional probability distributions or

. Naïve Bayes modeling takes

the simplifying assumptions that some class C is the parent of all predictor

X

Y

W

Z

Figure 3.2. Naïve Bayes
variables and there are no independence relationships between the predictor
variables. In Figure 3.2 we see that X is the causal parent to Y, W and Z but it
is assumed that there is no relationship between Y, W, and Z and it is
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assumed that x has no parents. Although naïve Bayes requires very strong
assumptions, it has proven effective in several machine-learning tasks
(Garcia-Laencina, 2013). However, in many models the simplifications prove
too great to effectively model the data. A more complex variant of naïve
Bayes is an ‘unrestricted’ Bayes pattern seen in Figure 3.3. This graphical

X

Y

W

Z

Figure 3.3. Unrestricted DAG
approximation increases the number of conditional relationships between the
nodes and thereby dramatically increases the number of states within the
Bayes net. Models constructed from unrestricted patterns face the problem of
overfitting and subsequent poor parameter learning.
A more sophisticated approach allows that X could have some parent ‘a’ and
there are potential relationships between the variables Y, W and Z. In order to
find the causal parents of X we must search the Markov blanket of X. Once
we find DAG describing the conditional dependencies between classes within
the Markov blanket, we assume this blanket represents the probabilistic
dependences existing within a set of data. That is, the behavior of the true
DAG equates to the DAG discovered within the Markov blanket. This
assumption is known as the faithfulness assumption (Pearl, 1988; Sprites
2000). The problem of classification thus becomes one of relationship
discovery within a projection of some tuple X onto its respective Markov
blanket.
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A key concept in the graphical representation of conditional independence is
the concept of d-separation (Figure 3.4). This concept first described by
(Pearl, 1988) provides the justification for simplified conditional independence
relationships within a given Markov blanket. For example, we say that X and Y

Figure 3.4. D-Separation.
are d-separated if on any directed path between X and Y there is some
variable Z that such that Z is known and is either a diverging parents
connection or is known and is in serial connection between X and Y. X and Y
are also d-separated if there is some common unknown child that X and Y
converge on, and Z has an unknown descendent. Full descriptions can be
found in (Pearl, 2000; Pearl, 2009), while truncated but general description is
explained in (Dawid, 2010).
There are multiple methods for discovering the relationships within the Markov
blanket and subsequently Bayesian network (i.e., DAG) discovery. Many of
these published methods of DAG structure learning have been executed on
real world datasets (Kalisch, 2010). Below we give a brief introduction into
several different methods for conducting DAG structure learning as well as the
assumptions, strengths and weakness. DAG structure learning procedures
are usually highly variable, i.e., the learnt graph tends to change drastically
with even small perturbation of the data. We then elaborate our method
which accommodates the instability of Bayesian search algorithms through a
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combination of ensemble learning techniques each proven to individually
increase the truthfulness of Bayesian search output.
There are three branches to which we classify DAG learning methods
employed on real world data sets, score-based, constraint-based and hybrid
methods. Score based methods have essentially two parts, a scoring and an
aggregating method that seeks to optimize the decided upon scoring
technique. There are several ways of scoring such as negative log-likelihood
score, Akaike information criterion (AIC) score, Bayesian information criterion
(BIC) score, Bayesian Gaussian equivalent (BGe) score (Geiger, 1994). At
each step the search method determines if including, orienting or deleting an
edge between two notes will increase or decrease the score and optimizes for
the lowest score. Because the potential relationships within a highly
dimensional data wrapper are prohibitively large, greedy search algorithms,
particularly hill climbing algorithms are employed. Greedy Hill climbing
algorithms optimize local relationships in a forward step adding edges until a
maximum score is achieved and then a backward step deleting edges until
the scoring criteria can no longer be improved (Chickering, 2002).

D.) Markov Blanket Based Pattern Discovery
Constraint based DAG structure learning views a DAG as the result of a set of
conditional independence tests applied across the Markov blanket of nodes.
As such in contrast to scoring algorithms that approach classifier search as a
simplification of the general classifier optimization problem, constraint based
DAG searches approach classifier search as a feature selection problem. To
select a feature, the data is tested against multiple different hypotheses.
There are many published Constraint based algorithms with variety of
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different assumptions and potential applications. Several of the mostly widely
used algorithms are variants of the PC algorithm (e.g. Conservative PC,
JCPC, PCD etc.), named after its creators Peter Sprites and Clark Glymour.
Additional algorithms that all reside in this branch include Increment
Association Markov Blanket (IAMB) and two IAMB variants (Margaritis and
Thrun, 2000). There is also a large family of constraint-based methods
designed to deal with latent variables (i.e., variables not found within the
dataset). These methods, FCI, FCI variants, IDA and several others methods
all output Partial Ancestral Graphs (PAGs) that can determine if measure
variables could be the result of some unmeasured (latent) variable.
Lastly, a third type of popular Bayesian search algorithms can be considered
combinations of the score and constraint based DAG searches, also called
hybrid methods. In hybrid methods, conditional independence tests are used
to determine edges, but each local test between nodes are used to inform the
proceeding tests. Primarily, the knowledge from each search is used to
impose restrictions on the search space via a scoring system. Hybrid methods
include Max-Min Hill Climbing (MMHC) (Tsamardinos, 2006) and L1MB
(Schmidt, 2007).
Constraint and Hybrid search algorithms can commonly be broken down into
two phases, the search phase and the orientation phase. During the search
phase, the algorithm asks a conditional independence oracle to perform a
routine statistical test, usually either χ2 contingency test or G-test to determine
if a pair Markov equivalent nodes are independent or not. Within the pattern
discovery catalogue of algorithms, there are additional statistical methods for
hypothesis testing that may be better suited for a dataset. Just as with any χ2
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or G-hypothesis test, the user has the ability to set an α-value or significance
value, above which the null hypothesis is rejected. These conditional
independence tests, and therefore the Constraint based and hybrid searches
demands that the data be either entirely continuous or entirely discrete.
The PC family of algorithms performs a backward stepped algorithm that
begins with a maximally connected Markov blanket. Relationships between
the classes within the Markov blanket are then tested. If the statistical test
rejects the null hypothesis the edge between two nodes in the Markov blanket
is maintained. If the test determines the null hypothesis true, the edge is
deleted stepwise until a graph depicting all true relationships. The conditional
independence oracle describes a strategy for passing the tuples through the
series of conditional independence tests that are performed across the
Markov blanket.
If two Markov nodes reject a null hypothesis via the conditional independence
test, the algorithm outputs an undirected edge between two variables. Once
all necessary independence tests have been applied across the Markov
blanket, the algorithm enters the orientation stage. Here the algorithms
determine directionality of the edges via application of the d-separation
principle across triplets of tuples as well as the orientation rules described by
Meek (1995). Orientation of the arrows is particularly susceptible to small
perturbations of the data and can result in a partial failure of the algorithm.
Partial failure would include multiple undirected edges and edges that are bidirectional. When search results demonstrate such a partial failure, a Pattern
Graph can include several symmetrical relationships. Since DAG represents a
collection of asymmetrical relationships, a single search result can suggest
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multiple potential DAG’s.

E.) Parameter Learning: Bayesian Belief Network
A Bayesian belief network (G, Θ) is composed of two elements. ‘G’, a directed
acyclic graph (DAG) and ‘Θ’ a subsequent collection of conditional probability
tables (CPT) defined by the Bayes net parameters draw from the DAG. Figure

FamilyHistory

Smoker

LungCancer

Bronchitis

PositiveXRay

Dyspnea

CPT
P(LC | FH, S)
LC
~LC

FH, S
0.8
0.2

FH, ~S
0.5
0.5

~FH, S
0.7
0.3

~FH, ~S
0.1
0.9

(a)

(b)

Figure 3.5. A simple Bayesian belief network: (a) A proposed causal model,
represented by a DAG. (b) The conditional probability table (CPT) for the
values of the variable LungCancer (LC) showing each possible combination
of the values of its parent nodes, FamilyHistory (FH) and Smoker (S). Figure
is adapted and modified from (Jiawei Han, 2006).
3.5 depicts a modified Bayesian belief network example from (Jiawei Han et al
2006). The DAG defines certain states within a bayes net, the parameters of
which can then be learned. The DAG and subsequent parameters may
correspond to actual attributes given in the data or to "hidden variables"
believed to form a relationship (e.g., in the case of medical data, a hidden
variable may indicate a syndrome, representing a number of symptoms that,
together, characterize a specific disease).
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The belief network in Figure 3.5 includes six binary variables with the ability to
infer the probability of either a ‘PositiveXRay’ or ‘Dyspnea’. For example,
having lung cancer is influenced by a person's family history of lung cancer,
as well as whether or not the person is a smoker, but is d-separated from
bronchitis. Note that the variable ‘PositiveXRay’ is independent of whether the
patient has a family history of lung cancer or is a smoker, given that we know
the patient has lung cancer. In other words, once we know the outcome of the
variable ‘LungCancer’, then the variables ‘FamilyHistory’ and ‘Bronchitis do
not provide any additional information regarding ‘PositiveXRay’. That is, given
the rules of d-separation, p(PositiveXRay | Smoker, Lung Cancer) and
p(Dyspnea | Lung Cancer, Bronchitis). The edges also show that the variable
‘LungCancer’ is conditionally independent of ‘Bronchitis’, given its parents,
‘FamilyHistory’ and Smoker.
Thus, a DAG provides a probabilistic Bayes net that approximate the optimal
inferred probability. A belief network includes one conditional probability table
(CPT) for each variable. Any node within the network can be selected as an

P(FH)
FamilyHistory

P(S)
Smoker

LungCancer

P(LC |FH, S)

Figure 3.6. An Example of CPT for the variable “LungCancer”.
“output” node, representing a class label attribute. There may be more than
one output node. Figure 3.6 includes an example CPT for the variable
‘LungCancer’.
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The CPT, labeled (b) within the Figure 3.5, provides the conditional probability
for each known value of ‘LungCancer’ is given for each possible combination
of values of its parents.
P(LungCancer = yes | FamilyHistory = yes, Smoker = yes) = 0.8
P(LungCancer = no | FamilyHistory = no, Smoker = no) = 0.9
The probabilities that satisfy the specified states within the Bayes net are
called ‘parameter learning’. There are several algorithms for learning, or
estimating, the parameters, Θ, of a network. When the data is complete (e.g.,
without missing values), the Maximum Likelihood Estimator, MLE can be used
to calculate the conditional probability of a given parameter, where D is any
given node within the network

max log

*|Θ

&

This limit of which is calculated via the following, where Nx is the number of
counts within the training data set as defined by pax or the parents of the
desired node.
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A similar version of the MLE is called the MAP-estimator that relies on a
dirchlet distribution of variables. This allows the user to specify with prior
evidence or knowledge the specific distributions or priors of the model.
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Both the MLE and the MAP-estimator demonstrate similar behavior; they both
are asymptotically equivalent and consistent as the counts are varied within
the training model. More importantly both algorithms rely on sufficient
statistics. The concept of sufficient statistics is two fold, both of which are
critical for properly training the parameters of a model. First, if there is no
training data provided to estimate the likelihood of a given parameter the
algorithm has no sensible way for calculating the conditional probability.
These cases are most common in data with significant outliers or subclasses
within the data.
Second, sufficient statistics also implies a subtle rule that assumes there is no
bias within the original training data set. For instance, if we return to our
example Bayesian belief network at the beginning of this section we can
imagine that if we are to sample only individuals that were already in the
hospital instead of the general population, our maximum likelihood estimation
would primarily consist of individuals that did not represent the general
representation of the belief network. Unintended bias is a significant
contributor to weak and ineffective Bayesian modeling.
If the data has missing values the ML and MAP algorithms are unable to
produce estimates. In these cases, parameter learning must be accomplished
via the Estimator Maximizer (EM)-algorithm or some similar variant that has a
sensible means of dealing with the missing data. The EM-algorithm is a twostep algorithm. In the first part, it computes an expected count missing value
based on inference from the Bayesian network.
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Once it computes the value it estimates the probability for the given parameter
using the ML or MAP algorithms. This continues iteratively until the
probabilities converge within some predetermined threshold, usually 0.0001.
When large amounts of data are missing or when multiple latent variables
exist, learning parameters becomes increasingly variable. Additionally, it has
been repeatedly demonstrated that since the EM and similar algorithms have
weaker guarantees than the ML or MAP algorithms, they become trapped in
local maxima (Liao, 2009). Although there are several modified versions of the
EM algorithm that have improved on the original presentation, as of yet, none
provide robust results when missing values for any given parameter rise
above 30% (Kohavi, 1999). Therefore, domain knowledge, and data
preprocessing retain critical importance when constructing the training data to
provide the model.

Method
A.) Bayesian Network Modeling for Clinical Avatars
Stoll and Schubert (Keeler, 2006) suggest a four step semantic chain from
raw data to wisdom. Similarly, our method follows a four-step logic chain to
progress from a set of data to clinical avatars (Figure 3.7). The method can be

Section 1

Section 4

Figure 3.7. Semantic chain from raw data to understanding.
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partitioned into four broad sections: (1) Data and knowledge aggregation and
preprocessing. During this step, the data must be acquired from a source and
characterized alongside any additional information regarding the nature of the
collection method and data dictionary that could unintentionally bias the
resultant clinical avatars. Additionally, and expert knowledge from published
or unpublished sources should be developed and employed to enrich the
patient data. (2) In the second section, an ensemble of Bayes search
algorithms are employed along with the domain knowledge acquired in
section 1 to discover any significant relationships between variables present
in the patient data. The relationships are then mapped graphically in one or
several Directed Acyclic Graphs (DAGs). (3) In section three the DAGs are
used to construct an ensemble of parametric models that allows the
estimation of joint conditional probabilities and subsequent deriving an
instantiated model. Once the ensemble DAGs and conditional probabilities
have been aggregated into data generating models we consider it a Bayesian
network model (BNM). (4) In section four, the BNM is cross validated against
a subset of the original data held out from sections 2 and 3. Each section
therein consists of several steps summarized in Appendix Figure 3.21.
Section 1: Data Preprocessing and Gathering of Domain Knowledge
Before modeling can begin, the appropriate data must be aggregated into a
data wrapper. The method described here is flexible. Almost any type of
healthcare data can be used to train the BNM. However, in accordance with
the “No-Free-Lunch theorem”, (Wolpert, 2008) minor modifications in the
pipeline to accommodate specific data sets will invariably benefit the model.
The quality of the data used to train and validate the BNM will reflect almost
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identically the quality of the BNM produced. It is quite possible to produce a
perfect model from imperfect data, a model with little relevance. Therefore,
despite the empirical principles this method employs, domain and expert
knowledge remain critical. Further, it is paramount that care and thought be
applied during the querying and accumulation of the data before embarking
on the modeling process. Once this is accomplished, the data can be brought
into the pipeline for generating clinical avatars.
This section has two branches performed in parallel. In Part I we accumulated
domain knowledge (i.e., expert knowledge or literature-defined knowledge) to
better understand both the specifics of our data such as the way the data was
gathered, the semantics of the data dictionary and any measurement error as
well as the general relationship between the variables as found in literature
review. In Part II the patient data is characterized and prepared (i.e., data
preprocessing). Data preparation is a multistep process as described in
Appendix Figure 3.21. Once the data has gone through the data
preprocessing procedure it is aggregated into a data wrapper.
Part I:
It has been said, “there can be nothing fully automatic about causal discovery”
(Dawid, 2009). Domain Knowledge, both regarding the nature of the sample,
the techniques involved in imputing or deriving the data and the general
relationships between the variables is all critical for the development of clinical
avatars. Domain knowledge is critical in accurately preparing the data for
modeling. Deciding how to aggregate the data, how to accommodate outliers
and appropriate handle missing values are all depending on the researcher
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making explicit choices about the nature of the data and the intent of the final
model.
Beyond the data preparation, domain knowledge performs three definite
functions within the clinical avatar pipeline. First, domain knowledge can
constrain the search space of the Bayesian search algorithms by imposing
known relationships across the data. The search space can be constrained
via, required causal relationships and forbidden relationships. Required
relationships are defined by a corollary link between variables previously
established in peer-reviewed literature. Forbidden causal relationships restrict
the search from finding false positive causal relationships in the data. The
variables can also have a series of relationships defined by hierarchically
categorizing the variables according to the principles of causation. By
classifying the variables in this manner, the user forbids directed relationships
from higher to lower tiers. Constraints typically make the structure learning
more efficient and can improve the validity of the resultant DAG.
The second function of domain knowledge is to provide directionality to the
arrows across the Bayesian search results. Arrow directionality within a DAG
is a subtle and nuanced subject, the significance of which is discussed in an
upcoming section. Often times Bayesian classifier algorithms produce
ambiguous directional results. There are three sources for this ambiguity
because of the weak guarantees within the proofs necessary for theorems to
be true, uncertainty within the training data and the inherent weak
philosophical underpinnings of causality in the first place. In fact, some
statisticians view causality as nothing more than a convenient concept. As an
additional confounder, there are certain times when the directional causal
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relationship may change over time. To give a short example borrowed from
Sprites (2000), if the variable under consideration is the rotation of a car tire, I
could determine that the function of the car engine is causal parent of the tire
rotation. However, if I were to try and kick-start the engine via pushing the car
down a hill and use the motion of the car to start the engine, then the direction
of the rotation of the tire would be the causal parent to the engine starting.
The result is often a direct cyclic graph and the directionality of certain causal
relationships must be determined via domain knowledge. It is important to
note these ambiguous or time dependent relationships as best as possible
within a given dataset.
Domain knowledge also comes into play while aggregating the Bayes pattern
learning results. Once the results are aggregated, we use domain knowledge
in parallel with empirical methods to determine the edges that should most
likely be pruned. In general, domain knowledge can help support the
simplifying assumption of developing DAG while also preparing the data to
reduce the violations of those assumptions. In all three points of applying
domain knowledge ad hoc to the modeling method there is a varying amount
of uncertainty. However, to account for such inherent uncertainty in the model
we combine several plausible causal structures into the final pipeline.
Part II:
Data Reduction and Characterization:
Here the variables that are desired to be included in the model are segregated
from the dataset. This includes the establishment of a data dictionary to
document the significance of each variable. The goal here is to statistically
describe the nature of each variable following data parsing. It is important to
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pay attention to the outliers and any missing values within the data.
Data Cleaning:
Of particular important in this process is the role of missing values. If there are
no missing values, then we proceed to “Data Discretization and Aggregation”.
Missing data can compromise the robustness of any statistical model and
additional steps must be used to handle missing values. First the nature of the
missing values must be determined. There are three forms of missing values,
‘missing at random’, ‘missing completely at random’ and ‘not missing at
random’. Missing at random denotes cases where missing values are
scattered around the data at random and there are no hidden variables that
contain missing values. ‘Missing complete at random’ denotes datasets where
there is a hidden variables that is not represented in the training data and not
missing at random where all variables are present, but missing values are
concentrated in local classes.
1.) If the missing values are randomly distributed and deleting all patient
cases with missing values does not significantly alter the
representativeness of the data, then delete the all rows of missing data
and proceed to “Data Discretization and Aggregation”. We define
significance as a change in proportion of 30% or greater in any single
variable (Friedman, 97; Ramoni, 2000).
2.) If the missing values are randomly distributed, but deleting the patient
cases significantly alters one or more variables, then proceed to the
following step.
3.) If the missing data is non-randomly distributed or if the missing values
are randomly distributed, but deleting the patient cases significantly

73

alters one or more variables, then imputation should be considered.
The specifics of imputation are outside the scope of this document. If
an evidence based method exists for imputing missing values that the
research is confident in, the researcher should apply those methods
wherever possible.
4.) If the imputation method was capable of increasing data coverage to
>70% in any given variable then proceed to “Data Discretization and
Aggregation”.
5.) If following execution of the imputation method, if any variable has
more than 30% of values missing, then randomly assign values until
data coverage increases to >70%.
Every effort should be made to ensure that missing values are treated in the
appropriate method. Additionally, not all missing values are of equal
importance within the DAG it will train. Variables that are discovered to be the
parent nodes to other child nodes are more sensitive to missing values than
variables in the child nodes. Deleting data with missing values can both
introduce bias into the results and prevent accurate estimation of conditional
probabilities with the training the data. Each data set must be prepared
according to the specific characteristics of the data. Preparation of the data
should be approached as part of the experimental process in developing
clinical avatars.
Data Discretization and Aggregation:
Often healthcare data includes a mix of categorical and discrete data, such as
race and gender, and continuous data such as age and height. The Bayesian
search algorithms we employ require training data that is either entirely
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continuous and normally distributed or entirely discrete. The Aurora Health
Care dataset included a combination of both continuous and discrete
variables, therefore the continuous variables were discretized. The process of
discretizing continuous data is a ubiquitous data preprocessing technique that
must balance information loss inherent in the process with the benefits of
greater processing efficiency. There are numerous discretization methods and
the choice can impact both the posterior probability estimation as well as the
discovery of inherent causal structure in the underlying graph. We employed a
common unsupervised method, EqualWidth that has demonstrated its ability
to produce accurate data mining results for Bayesian search algorithms when
compared to other techniques (García-Laencina, 2013).
Generally, there is a balance between information loss inherent in the
discretization process and the need for sufficient population sizes to estimate
conditional probabilities. For example when EqualFrequency is applied to
normally distributed continuous variables, datums that approach the minimum
and maximum are grouped into bins with more frequent ages. This has the
advantage of providing additional data to determine the conditional probability
of any particular state. In contrast, Equalwidth provides age bins that are
consistent in size but have some bins with low frequency. In regard to learning
the network structure, Sprits noted that a distinct challenge in discretization of
continuous features is that conditionally independent continuous variables
may be transposed into non-conditionally independent discretized foils.
Therefore it is important to evaluate discretization methods that maintain the
underlying causal relationships (Sprites, 2000). In practical application with
the Aurora data, we found consistency and improved performance in
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Bayesian classifier search results using EqualWidth when compared to other
methods.
Section 2: Directed Acyclic Graphs and Ensemble Learning
Weakness within Bayesian Classifier searches:
As outlined above, there are many Bayesian techniques for learning the
causal structure of the variables. However, each of these methods is built
upon several assumptions. For example, the PC algorithm and associated PC
variants (e.g. CPC and JCPC) have the following assumptions: No hidden or
selection variables that would suggest the number of variables grows with the
sample size, if the underlying DAG is sparse, the data is multivariate normal
and satisfies some regularity conditions on the partial correlations (Kalish,
2007) and (Kalich, 2014). In contrast the FCI family of algorithms presumes
that there may be hidden and selection variables; consistent in highdimensional settings if the so-called Possible-D-SEP are sparse (Sprites,
2000), the data is multivariate normal and satisfies some regularity conditions
on the partial correlations. These assumptions are necessary for the
truthfulness of these search algorithms, yet they can often be violated and
produce accurate results (Sprits; 2000; Domingos, 2012). How or to what
degree the search assumptions may be violated and remain truthful is not
consistent between data sets. Additionally, there is no known algorithm for
determining the bounds that any given algorithm can be violated.
Sprites (2000) does however offer a general guide of nine factors that
determine the precision and accuracy of a DAG: 1. The correctness of the
background knowledge, 2. How closely the Causal Markov Condition holds
(e.g., no inter-unit causation, no mixtures of subpopulations in which causal
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connections are in opposite directions), 3. How closely the Faithfulness
Condition holds (e.g., no deterministic relations, no attempt to detect very
small causal effects), 4. Whether the distributional assumptions made by the
statistical tests hold (e.g., joint normality.), 5. The power of the statistical tests
against alternatives, 6. The significance level used in the statistical tests, 7.
The sample size, 8. The sampling method, 9. The sparseness of the true
graphical model. Our goal then is creating a method that can be applied to
any healthcare data set is to produce an evidence based method that can
address the weaknesses in each Bayesian learning algorithm while
simultaneously optimize the nine above conditions to determine the precision
and accuracy of the DAG. In the following section, we describe several
ensemble-learning techniques used in concert for increasing the robustness
of DAG learning when employed on real world data sets.
Bayesian Ensemble Learning
Although there may be one particular algorithm that performs better for one
data set over another, instead of experimenting to find one particular superior
variation, the researcher can include many different algorithms at once with
little additional effort. In many branches of applied machine learning
ensembles have become the standard. As computational power increases
alongside new combinations statistical techniques already developed (as well
as those underdevelopment) the trend is towards ever-larger ensemble
techniques. There are many techniques that have demonstrated improved
results by linearly combining several Bayesian classifiers into an ensemble
technique. The question then becomes what combination of ensemble
techniques can best be applied to develop clinical avatars.

77

There are three widely tested and proven techniques within Bayesian
ensemble learning, bootstrap aggregation (Bagging), Bayesian boosting and
stacking. Bagging is often considered the simplest technique. From one set
of training data, the data is resampled at random and from each resample
passes through a Bayesian search algorithm. Bagging has been shown to
limit increase bias while dramatically increasing variance. There are both
multiple methods for generating the random bootstraps and for combining
results of the Bayesian searches. Boosting builds upon a similar principle as
bagging, however, the results of each classifier result has a weight. The
weights for each training set are varied so the proceeding classifier, training
examples have weights, and these are varied so that each new classifier
focuses on the previously weak results. In essence, boosting using several
weak Bayesian classifiers and combines them into a single strong Bayesian
classifier. In stacking, the outputs of individual classifiers are feed as input into
a second Bayesian classifier. The second Bayesian algorithm then decides
the best way to aggregate the results (Domingos, 2012). Our method includes
the following ensemble techniques, bagging, two distinct methods of
constraining both score and constraint based search algorithms with of
domain knowledge, and lastly Bayesian Model Combination.
The use of multiple bootstraps has been shown to address bias and variance
reduction within the data and therefore reduce the number of false positives
and false negatives (Friedman et al 1999). The demonstration of why bagging
works and its implications has been discussed at length in previous
publications (Domingos, 1997). As noted above, bagging generates an
ensemble of DAGs from the bootstrap resamples of the training data and then
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minimizing the overall distance to the entire ensemble derives an aggregated
DAG. The size, the number of variables and character of those variables has
an important role to play in the method used to bootstrap and segment the
data into validation and training subset. There are several methods for
bootstrapping that have demonstrated optimal results for particular sets of
data. Four of the most common bootstrap methods were compared in a
review by Broom (2012); the classic with replacement bootstrap, the Bayesian
(or parametric) bootstrap, the bias corrected bootstrap and the double
bootstrap aggregation (i.e., bootstrapping a bootstrap). Generally speaking
the Bayesian bootstrap and the classic with replacement bootstrap perform
comparably. There are several conditions that inform the researcher as to
which technique should be applied to which data set (Broom, 2012). Bagging
averages out General Noise features that cannot be cleaned from the data
over progressively larger ensembles. Because we employ a pruning
technique that removes edges with less that 50% commonality, this bagging
also reduces false negatives.
In experimentation with EMR data we employ a “repeated leave one out
bootstrap aggregation” method (Clyde, 2004; Jiang 2007). Holding out data
for cross validation is considered a data mining ‘best practice’ (Belazzi, 2004).
However, when the sample size is small and outliers are important
considerations in the data, holding out any amount of data reduces variance
in the model. Therefore, it is recommended to perform the bootstrap sampling
of the original data prior to the dividing the data between training and
validation subsets. The choice of bootstrap sampling technique can ultimately
impact the quality of the model.
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The bootstraps should be drawn randomly with replacement to subsample of
equal size to the original data. Regardless of what technique is used for
bootstrapping, once the data is bootstrapped, then each bootstrap should be
divided into training and 20% validation subset. The validation data should be
pooled for validation of the BNM, while the training subsets should remain
distinct for DAG training.
The question of how many bootstrap resamples are needed is not easily
answered because it depends on the specific sample size, dimensionality and
characteristics of the data. Previous studies (Friedman, 1999) have used
anywhere from one to two hundred bootstrap resamples to 2500 bootstrap
resamples (Broom, 2012). No experiments to date have determined how
many bootstraps are necessary when using conditional independence
Bayesian search algorithms (such as the PC algorithm) with multidimensional
data. However, our results demonstrate some consistency with the asymptotic
improvement of search results with minimal increase in bias. Generally, the
number of bootstraps should increase as the sample size gets smaller and the
dimensionality gets larger. Across several types of Bayesian search
classifiers, the ability for bagging of any variety to correctly infer causality
breaks down between n=125 and n=250. We found that in healthcare data
with 20 variables can be resampled with as few as 5 bootstraps and
significantly increase variance and improve search results.
As an additional method for increasing variance and correcting for bias in the
generation of clinical avatars we recommend performing an ensemble of
Bayesian classifier search algorithms on each bootstrap of data. Although it is
likely that one search algorithm will produce the most accurate DAG, by
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performing multiple types of Bayesian classifier searches on each bootstrap
we found iterative convergence on particular edges. There are multiple ways
to increases variance and adjust for bias in the selection of Bayes search
algorithms. Since each particular Bayes search algorithm has specific
assumptions (e.g., PC algorithm vs. IAMB) and it may be unknown as to
which assumptions best suit the data, we suggest performing several types of
algorithms on the same dataset. For example, given a set of training data the
CFCI may produce superior results to the CPC algorithm if the data contains
latent variables that affect the conditional probabilistic dependences since the
CFCI does not make the same assumptions of no latent or hidden variables
perturbing the data. If however there are known latent variables but it
unknown definitive whether they affect the probabilistic dependences in the
data, than the CPC algorithm may produce superior results.
If the data has significant non-random missing values, or other forms of
sampling bias, we recommend a second method for broadening the ensemble
of Bayes searches. This method involves constraining some search
algorithms with domain knowledge and allowing other the search algorithms
to perform the search unconstrained the adjusting the orientation of the edges
according to some predetermined tiers (see Section 1 Part II). The PC
algorithm as well as variants of the PC algorithm (e.g., CPC, JCPC) is
receptive to constraining the search space via domain knowledge. If you
impose particular forbidden or required edges on the search space, the
conditional independence oracle will adjust the series of independence tests it
performs across the data. In highly dimensional data sets with limited sample
size, this can increase the variability between search results. An additional
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method involving ambiguity or time sensitive uncertainty within the domain
knowledge is to modify the domain knowledge between certain bootstraps or
groups of bootstrapped data sets. This enriches the hypothesis space that
allows for certain DAGs to be true at certain moments in time and allowing
others to be right at other times. As similarly recommended by Spirites (2000),
we do not recommend the Bonferonni adjustment for multiple hypothesis
tests. However, if perform a large number of searches on the same data
vector, it is possible to increase α to a more stringent parameter such as α =
0.01 or 0.001. In respect to the PC family of algorithms, the graphical output
because increasingly sparse as α value increases.
Once all the necessary searches have been performed on the data, the
resultant DAGs must be aggregated. There are several methods described for
combining Bayesian search results. In accordance with other applications of
Bayesian ensemble learning, we recommend combining all edges for each
bootstrap and then pruning the edges according to some cut off. Depending
on the dataset, some have pruned edges that were returned in greater than
20% of search results, while others have selected edges that received 50% or
more commonality. As of yet, there is not demonstrated empirical technique to
determine how to aggregate edges within an ensemble of Bayesian search
results. Therefore, we recommend applying both the 50% common edges
and/or those edges that are supported by the domain knowledge aggregated
prior to performing the search.
With any data or domain knowledge that has the potential for significant bias,
we recommend performing Bayesian model combination. Bayesian model
combination has been demonstrated to improve search results when
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compared to and combined with other ensemble learning techniques,
(Monteith, 2011). Bayesian model combination is unique from aggregating
multiple search results into one DAG because it allows for multiple potentially
true DAGs to exist given ambiguous training data and or domain knowledge.
Bias can be significant if the original training data contained missing values
approaching 30% in any given variable and/or there was imputation
performed. The essential element of Bayesian model combination is that
instead of converging all Bayesian searches performed in this section into a
single DAG, several resultant DAGs are then used in parallel for section three.
Each DAG is used to derive a parametric model that is input into conditional
probability estimators. Each DAG plus conditional probability will ultimately
generate data via Monte Carlo simulation. The data is then aggregated via
either a Dirichlet weighted distribution or an unweighted distribution. Lastly, to
further demonstrate the robustness of particular classifiers, this aggregation of
data can be searched and the results compared to the DAGs used to model
the input data.
A strength and a weakness of DAG’s are their openness to interpretation. No
fewer than half a dozen different interpretations are used in the application of
DAG’s to various fields and in their theoretical discourse. Standard practice in
Epidemiology dictates that the directed arrows within the DAG have direct
causal meaning, (e.g., “X

Y“ would read as X is the causal parent to Y, or

even stronger, X is the cause of Y) (Evens, 2012). There are three explicit
assumptions that must be undertaken to assume that DAG’s represent a
causal map: 1.) There exists some true DAG that is a causal DAG
representation of the system being studied, 2.) This causal DAG is identical to
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the DAG representative of the probabilistic conditional independence
properties of the system, 3) The third is the faithfulness assumption, that the
causal DAG is a probabilistically faithful representation of the system. A
weaker interpretation has been described as probabilistic conditional
independence of two particular variables and the causal independence of
those same two variables given a third (Sprites, 2008).
In the development of clinical avatars we apply the most robust and
theoretically truthful interpretation of the DAGs. According to a strict
theoretical presentation, A DAG mirrors the symmetric conditional
independence relationships within the data and imposes asymmetric
probabilistic relationships between the variables via geometric interpretation.
The directionality of the arrows, in a purely theoretic plane, has been
described as “artifact…although it plays an important role in the formal syntax
of the model it has no direct counterpart in the world and contributes only
indirectly to the semantic interpretation of the model” (Dawid, 2010). Because
of the ambiguity inherent in any given DAG, the bootstrap aggregation
(“Bagging”) procedure provides more robust clinical avatars. By widening the
hypothesis space to include a greater collection of possibly true results (e.g.,
DAGs), we allow for the final clinical avatar population to be maximally
consistent with conditionally independent relationships within both the data
and the real world representing the data. Any additional reference to specific
strong causal relationships found within the DAG search results are strictly
outside the scope of developing clinical avatars. We do recognize that this
method could be used to guide a more causally complete interpretation of a
given set of data. Applying the clinical avatar pipeline would be useful in

84

inferring causal patterns in a number of fields and datasets. Nevertheless for
the development of clinical avatars this strong assumption is not necessary.
Rather it is more important to find the significant probabilistic relationships that
need to be replicated in order to capture the essence of the data. The
resultant DAG from the executed searches is used to derive a parametric
model that is input into conditional probability estimators. The DAG plus
conditional posterior probabilities will ultimately generate clinical avatars.
Section 3: Estimating Conditional Probabilities via Ensemble learning
Once the DAG is developed in section two there are a variety of
computational efficient Bayesian algorithms that estimate the conditional
probability of each particular state within the DAG. However, as noted in the
introduction section, there are several important assumptions that should be
examined before applying these algorithms to the training data. Again these
assumptions revolved around statistical sufficiency. We found that bagging in
the same manner as completed in section 2 for structure learning, can
dramatically improve the resultant clinical avatars. The original training data
can be bootstrapped via a parametric bootstrap or a classic bootstrap.
However, of critical importance, we recommend again holding out a portion of
the data within the bootstrap to be used for validation of the model.
Even with bagging there are challenges of statistical sufficiency. There are
times when the available training data is not sufficiently large to calculate the
probability of a parameter within the Bayes net. When such an event occurs
there are several ways to refine the model to appropriately accommodate the
available training data. We suggest that the DAG be simplified via removing
edges from the DAG results one at a time in order of confidence until
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sufficient cases exist within training data to calculate conditional probabilities.
There are several methods to determine robustness of an edge within a DAG.
We recommend the following logic flow for pruning edges from the DAG until
there are sufficient cases in the training data to calculate the conditional
probability for all relevant states from the parent nodes.
1.) If ensemble Bayesian searches were performed on the data, delete the
edge that returned the fewest search results
2.) If there were not multiple searches performed, iteratively complete the
search at a more stringent α value until an edge is deleted.
3.) If all search results produce the same causal parents to the point of α =
0.0000001 then use evidence and or domain knowledge to delete the
least robust edge
4.) Lastly, if there is no relevant domain knowledge or unambiguous
evidence then use regression to delete the least robust edge.
Once the DAG has been simplified, the conditional probabilities derived from
the simplified model were then used as input for the original parametric
model.
The second element of statistical sufficiency is the issue of missing values.
Although as noted in the background section, MLE and MAP-estimators
produce stronger results because they are not subject to becoming trapped in
local maxima within high-dimensional datasets, they are unable to
accommodate missing values. Therefore if data has non-random missing
values, and certain parameters have a high concentration of missing values
while others do not have missing values, we recommend that the parameters
without missing values be estimated use MLE or MAP-estimators while the
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parameters with missing values use the EM or EM-variant algorithm to
estimate the parameters. If any sub-parameter within a categorical data set is
also subject to a concentration of missing values greater than 30%, we
recommend using the Median probability for the variable on as a whole if
binary or the average if it is categorical.
Once the parameters of one or more Bayes net are estimated via the training
data, the estimations should be aggregated into a single instantiated model.
Here the conditional probability estimates from several algorithms can be
combined into an ensemble for each bootstrap of data. Each parameter
should be estimated using the most robust technique given the limitations of
the available data. Once each parameter is associated with a conditional
probability, a set of data can be generated using Monte Carlo simulation
techniques. Each bootstrap and instantiated model should have an equal
amount of data generated. We have called these sets of data "preliminary
avatars" since they satisfy the conditions of being simulated patients. But
since the model has not yet been validated they cannot yet be considered
“functional” clones of the original patient training dataset. Each set of
preliminary avatars should be pooled into a signal set of data.
At this point the pooled preliminary avatars may enter final section for
validation. If the preliminary avatars lack a variable, either a latent parent or
hidden descendent, the pooled preliminary avatars should enter a final series
of parameter learning. Here the DAG(s) already developed from section 2 are
again put to use to derive the necessary parametric models that establish the
Bayes net. The pooled preliminary avatars can then been used to again
estimate the conditional probabilities across the Bayes net. At this stage, only
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the MLE or MAP-estimators should be used since there are no missing values
within the dataset. If however there is a similar problem with insufficient
statistics to estimate the conditional probabilities, a similar 4-step strategy
should be used to simplify the conditional dependences within the DAG. This
single Instantiated model can then be used to generate the avatars for section
four.
Section 4: Validation of the BNM
Following the pattern learning as well as the parameter learning, the model is
nearly complete. In section four, the process enters the validation stage of the
method. There are many potential ways to validate the BNM. We suggest that
following data mining best practices, a portion of the data should be held out
for validation. As noted in sections 2 and 3, each bootstrap should have a
portion held out for validation. Validation can proceed via aggregating the
bootstrap portions of the data, or the validation sections can be maintained
distinct and to allow for k-fold validation testing. If the validation data is
pooled, there are several methods for validating the model against the pooled
validation data. Two of the most basic styles of comparisons used to ensure
that the simulated population is representative of the original data. The first is
univariate distribution, or the comparative frequency of a single attribute
between the training data and clinical avatars. The second comparison is the
bivariate frequency distribution between the training and clinical avatar data
sets. Variables in which the Bayesian algorithm determined a causal
connection and are "d-connected" are plotted in frequency histograms.
Different statistical tests should be used to determine variance between the

88

variables. Z-tests can be used for continuous variables and χ2 contingency
test or G-test can be used for discrete variables.
The development of clinical avatars is an iterative process that often requires
perfecting. If significant variance is found in either the univariate or bivariate
distribution, the process is refined until there is no significant difference. At
each section there are several options that may be refined depending on the
type, size and quality of data used to train the Bayesian model. Of critical
importance is the use time and care spent in section one, preprocessing the
data and aggregating domain knowledge. Different styles of data aggregation
and reduction as well as imputation can dramatically change the structure and
output of a Bayesian Network Model. If any significant variation is found in the
first model, the entire structure should be dissolved and the method should be
restarted from section one.
If the clinical avatars have demonstrated no significant variance, then at this
step, the latent or hidden variables should be added to the final instantiated
model in section 3. The variables that are imposed on the Bayesian network
model should be associated with some additional evidence that demonstrates
a probabilistic conditional dependency to a variable(s) existing within the
model. Thus, when the parameters for the additional variable(s) are imposed
on the model the estimated conditional probabilities can be imposed on the
Instantiated model. Once all the desired variables exist within the DAG, and
the relationships within the Bayes net are associated with conditional
probabilities, the BNM is complete and ready to produce an unlimited number
of clinical avatars via Monte Carlo methods.
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3.2.) Clinical Pharmacology
Anticoagulation agents do not directly affect established thrombi. In the case
of occurrence of a thrombus, anticoagulants are usually administered to (a)
prevent the growth of the existing clots and (b) prevent the movement of the
clots which might result in serious and possibly fatal thromboembolic
complications.
Warfarin or coumadin is an anticoagulation agent which inhibits the synthesis
of vitamin K-dependent coagulation factors (i.e., Factors II, VII, IX and X).

Figure 3.8. The structural formula of crystalline warfarin sodium.
Crystalline warfarin sodium (3-(a-acetonylbenzyl)-4-hydroxycoumarin) is a
racemic mixture of the R- and S-enantiomers. Its empirical formula is C19H15
NaO4 (Figure 3.8).
Warfarin is the most commonly prescribed anticoagulant in the world
(Pirmohamed, 2006). The number of dispensed warfarin prescription has
reached to 30 millions and over 2 million patients are on warfarin in the United
States to prevent and for the complications that may occur from
thromboembolism (e.g., stroke, heart attack) (Wysowski, 2007; Guyatt, 2012).
Warfarin is an effective medication but also has some clinical shortcomings.
For instance, a large number of medications and foods interact with it. Many
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commonly used medications interact with warfarin. Consequently, it is
monitored by international normalized ratio (INR) blood tests to ensure safe
adequate doses are taken (Ansell, 2008). An INR beyond the targeted range
predisposes to a high risk of bleeding, while an INR below the therapeutic
target range indicates that the dose of warfarin is insufficient to protect against
thromboembolic events.

3.2.1.) Mechanism of Action
Anticoagulant warfarin inhibits the synthesis of vitamin K dependent
coagulation factors (e.g., Factors II, VII, IX and X) and also the anticoagulant
proteins C and S.
Table 3.1. Half-life of blood factors and proteins involved in coagulation.

Coagulation Factors and Proteins
Factor II
Factor VII
Factor IX
Factor X
Protein C
Protein S

Half-Life (hour)
60
4-6
24
48-72
8
30

Warfarin suppresses the process of coagulation by decreasing the production
and activities of the coagulation factors by inhibition of the regeneration of
vitamin K1 epoxide. Vitamin K is an essential cofactor for the gammacarboxylation of the coagulation factors.

3.2.2.) Pharmacokinetics and Pharmacodynamics
Pharmacodynamics (PD)
Based on the current evidence, warfarin inhibits C1 subunit of the vitamin K
epoxide reductase (VKORC1) enzyme resulting in reduction in synthesis of
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clotting factors as well as vitamin K1 epoxide. This effect is proportional to the
VKORC1 genotypic profile of patients and also the dosage of the medication.
“Therapeutic doses of warfarin decrease the total amount of the active form of
each vitamin K dependent clotting factor made by the liver by approximately
30% to 50%. An anticoagulation effect generally occurs within 24 hours after
warfarin administration. However, peak anticoagulant effect may be delayed
72 to 96 hours. The duration of action of a single dose of racemic warfarin is 2
to 5 days. The effects of warfarin may become more pronounced as effects of
daily maintenance doses overlap. This is consistent with the half-lives of the
affected vitamin K-dependent clotting factors and anticoagulation proteins:
Factor II - 60 hours, VII - 4 to 6 hours, IX - 24 hours, X - 48 to 72 hours, and
proteins C and S are approximately 8 hours and 30 hours, respectively”
(Coumadin, 2011).
Pharmacokinetics (PK)
Warfarin is a racemic mixture of the R- and S-enantiomers. The clearance of
S-enantiomer in the body is much quicker than R-enantiomer. It is also a more
active anticoagulant component compared to R- enantiomer (i.e., 2 to 5 times
more active).
Absorption
Warfarin’s maximum blood concentration is usually attained within 4 hours
after oral administration. Warfarin is completely absorbed after oral
administration.
Distribution
Almost all warfarin binds to plasma proteins. According to the warfarin’s label
(Coumadin, 2011), “using a one compartment model, and assuming complete
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bioavailability, estimates of the volumes of distribution of R- and S-warfarin
are similar to each other and to that of the racemate.”
Metabolism
According to the warfarin’s label (Coumadin, 2011), “the elimination of
warfarin is almost entirely by metabolism. Warfarin is stereoselectively
metabolized by hepatic microsomal enzymes (cytochrome P-450) to inactive
hydroxylated metabolites (predominant route) and by reductases to reduced
metabolites (warfarin alcohols). The warfarin alcohols have minimal
anticoagulant activity. The metabolites are principally excreted into the urine;
and to a lesser extent into the bile. The metabolites of warfarin that have been
identified include dehydrowarfarin, two diastereoisomer alcohols, 4'-, 6-, 7-, 8and 10-hydroxywarfarin. The cytochrome P-450 isozymes involved in the
metabolism of warfarin include 2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. 2C9 is
likely to be the principal form of human liver P-450 which modulates the in
vivo anticoagulant activity of warfarin. The S-enantiomer of warfarin is mainly
metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme.”
CYP2C9 variant alleles have significant effects on the metabolism of warfarin.
The single or multiple variant alleles of this gene (e.g., *1/*2, *1/*3, *2/*2,
*2/*3, *3/*3) decrease metabolism of warfarin through lower CYP2C9
enzymatic 7-hydroxylation of S-warfarin and results in decreased S-warfarin
clearance (Table 3.2, Yasar, 1999).
Excretion
The half-life of R-warfarin ranges from 37 to 89 hours, while that of S-warfarin
ranges from 21 to 43 hours. More than 90% of the received warfarin is
detectable in urine and is excreted through urine in the form of metabolites.
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Table 3.2. Relationship between S-Warfarin Clearance and CYP2C9
Genotype in Caucasians Patients (Yasar, 1999).
CYP2C9 Genotype
*1/*1
*1/*2 or *1/*3
*2/*2, *2/*2, or *3/*3
Total

Number of
Study Subjects
118
59
11
188

S-Warfarin Clearance/Lean Body Weight
(mL/min/kg) Mean(SD)
0.065(0.025)
0.041(0.021)
0.020(0.011)

Elderly
According to different dosing guidelines (e.g., AGSCP Guidelines, 2000), the
use of warfarin in older people requires special consideration as their PT/INR
response to the anticoagulant effects of warfarin is greater than expected. It is
unknown why they are more sensitive to warfarin. Therefore, as patient age
increases, a lower dose of warfarin is usually required to reach the therapeutic
INR level.
Asians
Asian patients may require lower initiation and maintenance doses of warfarin.
In a number of studies, it has been observed that Chinese patients require
lower warfarin dosages to achieve an INR of 2-2.5 (Veenstra, 2005). Some
studies also have shown that the most important determinant of warfarin
dosage in Chinese patients is age (e.g., Veenstra, 2005).
Renal Dysfunction
Given that renal clearance has minor effect body’s response to warfarin, there
is no need to make dose adjustment if a patient had renal failure.
Hepatic Dysfunction
Liver has an important role in the metabolism of warfarin. Accordingly, any
hepatic dysfunction, which usually results in impairment in the synthesis of
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clotting factors as well as decreased warfarin metabolism, can enhance body
response to warfarin.

3.2.3.) Pharmacogenomics
In 2005, Sanderson team reported the results of a meta-analysis of 9 studies
(2775 patients: 99% Caucasian) performed to investigate the CYP2C9 gene
variants-associated clinical outcomes in warfarin-treated patients (Sanderson,
2005). In this meta-analysis, some of the qualified included studies assessed
bleeding risks and the rest of the studies assessed daily dose requirements.
The analysis suggested a higher risk of bleeding risk and lower mean daily
dose of warfarin for patients with either the CYP2C9*2 or CYP2C9*3 alleles.
Patients with CYP2C9*2 and CYP2C9*3 alleles have lower mean daily
warfarin doses and a greater risk of bleeding, 17% and 37% less than the
mean daily dose for patients homozygous for the CYP2C9*1, respectively.
In a prospective study of 219 Swedish patients under warfarin treatment who
were stratified by CYP2C9 genotype, Lindh et al. discovered that the risk of
overanticoagulation (i.e., achieving INR >3) during the first 2 weeks of
warfarin therapy was two times higher for the patients with the polymorphic
variant alleles (CYP2C9*2 and CYP2C9*3) compared to patients with wildtype CYP2C9 (Lindh, 2005).
Many studies have found that patients with some of the VKORC1 gene’s
single nucleotide polymorphisms (e.g., -1639G>A, rs9923231) require lower
initial doses of warfarin. Gene VKORC1 regulates the synthesis of the vitamin
K–epoxide reductase (VKOR) protein which is the target enzyme of warfarin
(Rost, 2004; Li, 2004). The -1639G>A polymorphism alters the biding sites of
the VKOR which results in a reduction in protein expression (Rieder, 2005;
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Yuan 2005). A large number studies have discovered that the variants of
VKORC1 and CYP2C9 genes are individually responsible for 35% to 50% of
the variable dose response to warfarin. For example, Wadelius team reported
an association between VKORC1 gene variations and lower required dose of
warfarin. In this study with a study cohort of 201 white patients under warfarin,
they attributed about 30% and 40% of the variance in warfarin dose to
variations in the VKORC1 gene and variations in VKORC1 and CYP2C9
genes combined, respectively (Wadelius, 2005). Several multivariate analyses
have shown that the addition of patient characteristics, such as age, gender,
height, weight and other medications, to CYP2C9 and VKORC1 accounts for
approximately 50-60% of warfarin dose variability.

3.2.4.) Accounting for Adverse Reactions
Oral anticoagulants, most commonly warfarin, reduce risk to thrombosis and
treat conditions that might lead to stroke, pulmonary embolism, deep vein
thrombosis or other blood clotting related disease. The impact and value of
anticoagulation medication in the U.S. is dramatic. For example, stroke is the
third leading cause of death in the U.S. with over 140,000 deaths annually.
The majority of stroke incidences are due to ischemia (87%) or transient
ischemic attack (TIA, ~5-10%) and are typically managed by the use of
anticoagulation agents such as warfarin, dabigatran, and clopidogrel.
Whatever the patient’s disease or condition leading to a prescription of an
anticoagulation agent, selecting the best combination of drug and treatment
protocol is complicated by the individual differences in anticoagulation
medication response (e.g. >20-fold difference for warfarin) due to genetics,
physiology, and compliance. Consequently, given this characteristic, any
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small increase or decrease in medication dosage might increase the risks of
bleeding or thromboembolic events, respectively (Ansell 2008). In practice,
providers use a combination of experience, scientific evidence and clinical trial
results to develop anticoagulation “best practice” treatment plans designed to
roughly minimize the patient-to-patient response variability and risks across
the provider’s patient population. However, the high degree of patient
heterogeneity causes variations in individual patient response to these “best
practice” drug-protocol approaches. Another factor that makes the
management of warfarin more complex is its interactions with many other
medications and foods. Therefore, warfarin is among the medications with a
high rate of associated adverse reactions (Ansell, 2008).
According to the 2010 FDA-approved warfarin (Coumadin) product label
(Coumadin, 2011), there are a wide range of adverse reactions associated
with warfarin:
- Fatal or nonfatal bleeding from any tissue or organ. Depending on the
severity and location of the bleeding, the complications may present as
paralysis; paresthesia; headache, chest, abdomen, joint, muscle or other pain;
dizziness; shortness of breath, difficult breathing or swallowing; unexplained
swelling; weakness; hypotension; or unexplained shock. One important point
with regard to bleeding during anticoagulation therapy is that it does not
always correlate with PT/INR. In this case, the bleeding might have been
resulted from other disorders such as tumors and ulcers.
- Necrosis of skin and other tissues.
- Infrequent or rare adverse reactions: hypersensitivity/allergic reactions,
including anaphylactic reactions, systemic cholesterol microembolization,
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purple toes syndrome, hepatitis, cholestatic hepatic injury, jaundice, elevated
liver enzymes, hypotension, vasculitis, edema, anemia, pallor, fever, rash,
dermatitis, including bullous eruptions, urticaria, angina syndrome, chest pain,
abdominal pain including cramping, flatulence/bloating, fatigue, lethargy,
malaise, asthenia, nausea, vomiting, diarrhea, pain, headache, dizziness, loss
of consciousness, syncope, coma, taste perversion, pruritus, alopecia, cold
intolerance, paresthesia including feeling cold and chills, tracheal or
tracheobronchial calcification, and priapism.

3.2.5.) Clinical Protocols
The narrow therapeutic range and wide interindividual variability in warfarin
therapeutic dose (such as 4.5–77 mg/week (Wadelius, 2004)) make
anticoagulation management challenging and anticoagulation response
unpredictable. Current clinical best practice relies primarily on empirical
dosing. Accordingly, most patients usually start taking a fixed dose each day
(such as 5 mg/day) during the “initiation phase” of warfarin on the basis of
population averages, regardless of clinical and genetic factors (Garcia, 2005).
Then, based on the INR results, the dose is titrated. This empirical clinical
practice approach requires frequent changes in the dose of warfarin in
response to out-of-therapeutic range INRs and to avoid adverse effects and
maintain therapeutic efficacy. To address this challenge, mainly before the
completion of the Human Genome Project, a number of dosing algorithms that
included clinical variables were developed. Since the successful completion of
the project and in the light of discoveries of polymorphisms in cytochrome
P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1)
which jointly account for about 40-50% of the inter-individual variability in dose
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requirements, a large number of pharmacogenetic-based dosing algorithms
have been also developed. However, the potential benefit of these dosing
algorithms in terms of their safety and clinical utility has not been adequately
investigated in randomized settings.

3.2.6.) Dosage and Administration
The dosage and administration of warfarin must be individualized for each
patient. The warfarin dose management is an iterative process which starts
with administering an initial dose and then is followed with dose adjustments
based on the patient’s INR response to the medication (Figure 3.9).

Figure 3.9. The iterative process of dosing and adjusting warfarin
dose until achieving maintenance dose and INR in therapeutic range.

As discussed earlier, many factors cause warfarin dose variability such as
clinical factors including age, race, body weight, sex, concomitant
medications, comorbidities and diet and genetic factors including CYP2C9
and VKORC1 genotypes. To initiate a warfarin dose, there are different
options such as:
- According to FDA, if the patient’s genotypes are known, we can use the
following table (Table 3.3) to select the initial dose. If the genotypes are not
available, the initial dose of warfarin is usually 2 to 5 mg/day. This dose
should be modified based on consideration of patient-specific clinical factors.
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Table 3.3. Recommended daily warfarin doses (mg/day) to achieve a
therapeutic INR based on CYP2C9 and VKORC1 genotype using the warfarin
label approved by the US Food and Drug Administration (Johnson, 2011).
VKORC1 Genotype
(-1639G>A, rs9923231)
GG
GA
AA

*1/*1
5-7
5-7
3-4

CYP2C9 Genotype
*1/*2 *1/*3 *2/*2 *2/*3
5-7
3-4
3-4
3-4
3-4
3-4
3-4
0.5-2
3-4 0.5-2 0.5-2 0.5-2

*3/*3
0.5-2
0.5-2
0.5-2

- Use any available clinical or PG-based dosing algorithms to calculate
appropriate initial dose or
- Use the standard fixed-dose practice (5mg/day, Loading Dose: 10 mg/day).
After initiating warfarin, the subsequent dosage adjustments must be made
based on INR results until achieving a maintenance dose and an INR in
therapeutic range.

3.2.7.) PK/PD Modeling and Simulation (INR Prediction)
In order to model the pharmacodynamics (PD) and pharmacokinetics (PK) of
a medication, the relationship between drug dose, plasma concentration,
biophase concentration (pharmacokinetics), and drug effect or side-effects
(pharmacodynamics) is characterized, and relevant patient covariates are
included in the model (Figure 3.10). Modeling of pharmacokinetic and

PK
Model
Drug

PD
Model
Concentration

Effect

Figure 3.10. A schema depicting the general relationship of pharmacokinetic
(PK) and pharmacodynamic (PD) models used in clinical pharmacology.
pharmacodynamic can be used to make predictions about the “temporal
profile of the drug concentration” and “its effect” which ultimately helps select
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appropriate dosing protocol and “optimal delivery profile” (Yan, 2013).
A number of studies have been undertaken to model PK and PD of warfarin.
The aim of most of these studies have been to develop population models to
describe the PKs of both S- and R-warfarin and the PK-PD relationship
between warfarin exposure/concentrations and anticoagulant response (i.e.,
INR), including identification of important predictors for a priori dose
individualization of warfarin.
In the next following section before reviewing one of the warfarin’s PK/PD
models, We are going to briefly go over some fundamental concepts of PK
and PD.
Pharmacokinetic Models
Pharmacokinetics (PK) studies the relationship between drug concentration
and its effect on the body. PK principles are often used to reduce toxicity and
improve efficacy during patient care. The suite of tools used in PK studies are
mathematical models, used to quantify the processes of drug Absorption,
Distribution, Metabolism, and Excretion (ADME) in the body. Rates of
reactions and compartmental architecture are two important properties of PK
models that control how these ADME processes are modeled.
Rates of Reaction
The ADME processes can be modeled as either zero-order or first-order
reactions. The order of the reaction is the rate of change of a variable over
time. Consider an example where drug A is modeled. In a zero-order reaction,
the rate of change of drug A would be constant (see equation A), where k* is a
zero-order rate constant. Here the rate of change of A is independent of the
concentration of A. In a first-order reaction, the rate of change of drug A is
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proportional to A (see equation B), where k is a first-order rate constant
(Dhillon, 2006).
DE

= −H ∗

(A)

DE

= −HJ

(B)

DF

DF

The drug’s rate of reaction has important clinical implications. Drugs that have
first-order rate of elimination do not accumulate within the body because as
concentration increases so does the elimination rate. In contrast, drugs with
zero-order rates of elimination will accumulate with continued administration.
However, a first-order reaction can be altered to appear as a zero-order
reaction in such situations as overdosing. At clinical dosages though, most
drugs are first-order reactions, with a few zero-order examples such as
phenytoin and high-dose salicylates.
Compartmental Models
The compartmental architecture of a PK model determines the fate of a drug
after it enters the body. Although the compartments are hypothetical
structures to model the body, they do have underlying biological reasoning to
describe how a drug is processed. In reality, drug concentration and kinetics
will vary with the type of tissue (e.g. brain versus muscle). Therefore, to
accommodate different modeling scenarios there are several types of
compartmental architectures.
One-compartment Model
The one-compartment model represents the body with one compartment and
makes the simple assumption that once the drug is introduced it is
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Figure 3.11. One-compartment model. ka = absorption rate constant, k =
elimination rate constant. Adopted from (Dhillon, 2006).
instantaneously and homogeneously distributed throughout the body (Figure
3.11, Dhillon, 2006). The drug concentration is monophasic and decreases
exponentially with time, or linearly if the log of drug concentration is taken
(Figure 3.12, Dhillon, 2006).

Figure 3.12. (a) Plasma concentration (Cp) versus time. (b)
Time profile of a one-compartment model showing log Cp
versus time. Adopted from (Dhillon, 2006).

Two-compartment Model
The two-compartment models decompose the body into two tissues types: the
central component represents highly perfuse tissue (e.g. heart, kidneys and
lung) and the peripheral component represents tissues that are less perfuse
(e.g. skin, muscle and fat). The two-compartment model allows more complex
drug concentration dynamics than the one-compartment model. Upon
administration, the drug’s concentration has a two phases: it is initially highly
concentrated in the central component but rapidly declines as it distributes to
the peripheral component. After reaching equilibrium between the two
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compartments, the drug then declines more slowly as it is eliminated from the
central compartment. Hence, the drug concentration over time shows a
biphasic response (Figure 3.13, Dhillon, 2006).

Figure 3.13. (a) Plasma concentration versus time profile of a drug
showing a two compartment model. (b) Time profile of a twocompartment model showing log Cp versus time. Adopted from
(Dhillon, 2006).
Multi-compartment Model
The multi-compartment models allow even more complex drug concentration
dynamics. With higher number of compartments there will be more phases in
the drug concentration over time (Figure 3.14).

Figure 3.14. (a) Plasma concentration versus time profile of a drug
showing multi-compartment model. (b) Time profile of a multicompartment model showing log Cp versus time. Adopted from
(Dhillon, 2006).
Pharmacodynamics
Pharmacodynamics studies the drug’s effect on the body by describing how
the drug affects local physiological and biochemical processes in the body. At
the core of the pharmacodynamics approach is the reaction equation (see
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equation 1) describing the relationship between the drug (D), receptor (R),
drug-receptor complex (DR), and the effect (E), where kon and koff are the rate
of drug and receptor association and the rate the complex dissociation,
respectively. Of course more complex kinetics is possible, but even with such
a simple expression some very useful clinical information can be gleaned. The
responsibility of researchers and clinicians is then to tailor the mathematical
model describing the reaction equation to their pharmacodynamics scenario
(Dhillon, 2006).
The expression in equation C has several clinically relevant properties.
A

AU

MT
* + K RRRRRRRRRS
OPPPQ *K → W
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The receptor dissociation rate constant (kD) describes the equilibrium rate
between the rate of kon and koff (equation D). This principal demonstrates, for
example, that if [D] is very high then the receptors are saturated, and no
significant increase in [E] can take place. The idea that there can be a limit to
the amount of effect is quantified with Emax, the maximal effect for all drugs.
There is another, related value denoted EC50, which quantifies the
concentration at which E is 50% of Emax. These constants are important for
determining the relationship between drug concentration and effect, and how
pharmacodynamics models are put into use (Dhillon, 2006).
=*>=K>
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Different pharmacodynamics scenarios dictate the mathematical form
describing equation C. Effect can be sigmoidal or linearly related to drug
concentration depending on modeling assumptions. The most general
equation is shown in equation E, a sigmoidal relationship (Dhillon, 2006).
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C represents the drug concentration, and n is the “Hill” coefficient, determining
the “steepness” of the concentration-effect relationship. Very high values of n
(n>5) can make the relationship so steep as to effectively make the drug have
a binary effect (i.e. the effect is present or not). Equation F represents the
case of n=1 (Dhillon, 2006).
W=
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Equation G simplifies equation 3 to a linear relationship. This may be useful in
situations where C is much less than EC50 and the range of clinical dosage is
very narrow (Dhillon, 2006).
W ≈
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The log of equation G can be taken to yield equation H (Dhillon, 2006).
W = bcd

. log

e

A model describing a log-linear relationship can be useful in situations where
there is high intrinsic variability, but the drawbacks of such models include the
inability to represent the case where C is zero such as in placebo studies. The
fundamental concentration-effect relationships are outlined in Figure 3.15.
Continuous PD models
PD models can be either continuous or categorical, although the focus here is
on continuous models. The type of model used depends on the nature of the
data, such as whether the data is continuous (e.g., blood pressure and
weight), categorical (e.g., grade of adverse event), and the frequency of
measurement. The different concentration-effect relationships discussed
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Figure 3.15. Fundamental concentration-effect relationships. (a) The Emax
concentration-effect relationship that arises from receptor theory for the binding
of a single drug to a single receptor. Fifty percent of the maximum effect is
achieved at the EC50 concentration. (b) The same relationship over a much
wider log-concentration scale. (c) The sigmoid Emax concentration-effect
relationship that arises from receptor theory when there is allosteric inhibition or
simulation of binding. The “Hill factor” n controls the steepness of the middle
part of the curve. (d) A linear concentration-effect relationship that is a
semiempirical but sometimes useful substitute for an Emax relationship when the
range of concentration is relatively small and the drug effect is well below Emax.
Adopted from (Upton, 2014).
above provide crucial flexibility for different pharmacodynamics scenarios, but
more building blocks are needed to accommodate the diverse physiological
context the concentration-effect dynamics take place. Figure 3.16 outlines five
common types of continuous PD models in use.
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Figure 3.16. Representative continuous pharmacodynamic models. (a) A
direct response model where effect is driven by the plasma drug
concentration. (b) An effect compartment model where effect is driven by
the effect compartment drug concentration, which is delayed relative to
the plasma concentration by a first-order rate constant ke0. (c) A turnover
model where drug effect is a balance between an apparent production
rate (kin) and an apparent removal rate (kout). Drug affects the net effect
by altering kin or (kout). (d) A transit compartment model, where the drug
effect is at the end of chain of processes and drug action is on the first
process. (e) A tolerance compartment model, where the drug effect is
described by an effect compartment and the development of tolerance is
described by a slower inhibitory compartment that reduces the net drug
effect with time. Adopted from (Upton, 2014).

Hamberg’s PK/PD Model
The aim of the Hamberg’s study (Hamberg, 2007) was to characterize the
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relationship between warfarin concentrations and international normalized
ratio (INR) response and to identify predictors important for dose
individualization. S- and R-warfarin concentrations, INR, and CYP2C9 and
VKORC1 genotypes from 150 patients were used to develop a population
pharmacokinetic/pharmacodynamic model in NONMEM (Beal, 1994). The
anticoagulant response was best described by an inhibitory EMAX model,
with S-warfarin concentration as the only exposure predictor for response.
Delay between exposure and response was accounted for by a transit
compartment model with two parallel transit compartment chains (Figure
3.17).

Figure 3.17. A two-chain transit compartment PD model used by Hamberg et
al. to describe the INR response to warfarin therapy. Mean Transit Times
(MTTs), Apparent clearance of S-warfarin [CLs], EC50 (concentration
resulting in 50% of Emax), λ is the sigmoidisity factor, describing the
steepness of the concentration–effect relationship, A1–7 indicate
compartment amounts, A1–6 are the compartment amounts in the "long"
transit chain, whereas A7 is the compartment amount in the "short" transit
chain (Hamberg, 2007).

They also found a two-compartment PK model with first-order input and first
order elimination to appropriately characterize the disposition of S-warfarin
(Figure 3.18).
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Figure 3.18. Observed time profiles of S-warfarin
concentrations following administration of a single 10 mg
warfarin dose and at steady state (Hamberg, 2007).
In their study, CYP2C9 genotype and age were identified as predictors for Swarfarin clearance, and VKORC1 genotype as a predictor for warfarin
sensitivity. Accordingly they have modeled the ith individual’s jth observed
INR value (INRij) according to:
INRij=BASEi+INRMAX(1-A6*A7)λ
BASEi is the ith individuals observed baseline INR value whose predictive
covariates are Age, CYP2C9 and VKORC1, INRMAX is the maximum INR
increase from baseline, λ is the sigmoidisity factor, describing the steepness
of the concentration - effect relationship, A1–7 indicate compartment
amounts, A1–6 are the compartment amounts in the "long" transit chain,
whereas A7 is the compartment amount in the "short" transit chain (Hamberg,
2007). According to Hamberg, predicted INR curves show significant steadystate differences across patients with different covariates. They indicated that
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it was not possible to anticipate these differences based on just early INR
assessments.
The following table (Table 3.4) depicts warfarin doses predicted using
Hamberg’s model for 54 individuals with different set of predictive covariates
of CYP2C9 and VKORC1 genotypes for three age groups of 50, 70, and 90
years old. The desired target INR in this effort was 2.5. As an example, the
predictions show the significant difference (20 fold) between a priori doses
(9.08 mg/day vs. 0.47 mg/day) for two individual with different combination of
predictive covariates (“A 50-year-old patient with CYP2C9 *1/*1 and VKORC1
GG genotypes” vs. “A 90-year-old patient with CYP2C9 *3/*3 and VKORC1
AA genotypes”).
Table 3.4. Predicted daily warfarin dose with target INR of 2.5 in three groups
of patients with different set of predictive covariates (i.e., Age, CYP2C9 and
VKORC1 genotypes) (Hamberg, 2007)

The authors indicated that the influence of warfarin therapy on INR response
of the R warfarin was not statistically significant. Therefore, the model only
considered the PK/PD effects of S-warfarin. They concluded that it is
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important to account for CYP2C9 and VKORC1 genotypes and age to
improve a priori and a posteriori individualization of warfarin therapy.
PK-PD modeling for INR response in our in silico framework
We have adapted the PK-PD model from Hamberg (Hamberg, 2007) to
predict the INR response for each clinical avatar at a given warfarin dose. In
order the make the INR model work within our framework, we ported the code
from NONMEM to R. According to the model, we only considered the PK-PD
effects of S-warfarin. We modeled the PK effects using a two-compartment
model with first order input and first order elimination and the PD effects using
a two-chain transit compartment model. Due to limitations on the original
model it has been necessary to make assumptions about the covariance of
the variables because the complete covariance matrix was not provided. We
have used a random log normal distribution to estimate the variability of the
clearance rate, the volume in the central compartment, and the volume in the
peripheral compartment and restricted the range to be within physiological
ranges.
To model the accumulation of warfarin concentration over time (assuming
daily doses), we have used the principle of superposition. Superpositioning
does not require assumptions regarding a PK model or absorption kinetics,
but instead assumes each dose of the drug acts independently and that the
rate and extent of absorption and average systemic clearance are the same
for each dosing interval and that linear PK apply (Gibaldi, 1982). We create a
table of warfarin concentrations over time and summed across the rows at 24hour time intervals to predict the amount of warfarin remaining in the system.
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3.3.) Design of Comparative Effectiveness and Clinical
Trial Studies
A large number of the definitions have been offered for Comparative
Effectiveness Research (CER). According to the Center for Clinical and
Translational Science of Ohio State University, CER is “a field of study that
utilizes data generation (new studies) and synthesis (comparisons of existing
studies) to provide evidence identifying best practices and policies related to
improving health care.” CER studies are generally conducted after
randomized controlled trials (RCTs) (CER Resources, 2014). The focus of
most of RCTs has been to study the efficacy of treatments under ideal
conditions. On the other side, CER studies mostly focus on effectiveness by
comparing one or more treatments, tools, procedures or medications to
determine what works best for which individuals or patient populations under
real world situations. CER studies have gained significant attention in clinical
medicine in last few years since the Patient Protection and Affordable Care
Act (PPACA, 2010) established Patient-Centered Comparative Effectiveness
Research (PC-CER) as a US national medical research priority. Although this
law has provided tremendous resources for CER studies to improve the
evidence base that supports the use of genomic information to improve
healthcare, however, efforts to translate critical genomic discoveries require
prohibitively expensive clinical trial and clinical study validation which are
severely hindered by regulatory, technical and validation barriers not easily
conducted using current clinical-research or clinical enterprise environments.
According to Khoury (2007), the reality is that “a small proportion of human
genomics research has progressed from gene discovery to an evidence-

113

based health application that has been effectively integrated into practice and
has demonstrated health impact.” Based on Tunis (2003), to address this
situation and make the clinical trials’ results more efficient and generalizable,
there is a need for CER studies in which we (1) select clinically relevant
alternative interventions to compare, (2) include a diverse population of study
participants, (3) recruit participants from heterogeneous practice settings, (4)
collect data on a broad range of health outcomes, and (5) pay special
attention to the study time frame.
One "poster" example of this translational complexity and need for a new
approach to predicting a population wide treatment plan is the case of
"optimal" warfarin dosing (~30 million US prescriptions/year) which
demonstrates highly variable individual risks to serious under and over dosing
adverse responses (thrombotic or bleeding event) and rapidly increasing
health care costs associated with warfarin complications estimated at over $1
billion/year (McWilliam, 2006). The clinical potential of genetics has driven
significant scientific and clinical efforts to study the warfarin dosing question.
Key scientific findings have demonstrated significant relationship between
genotypes of VKORC1 and CYP2C9 and the metabolism of warfarin (e.g.
Rieder, 2005). Consequently, the genotype-dosing relationship of warfarin as
one of the emerging collection of pharmacogenomic results has led to a large
number of clinical trials. As a result, various warfarin PG-based dosing
algorithms and protocols have been offered and many outcome metrics (e.g,
INR and TTR) have been tested in different related studies. However, given
that anticoagulation therapy is usually a long term treatment and the fact that
clinical utility of the PG-based warfarin algorithms has been tested only in
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small study populations and highly constrained conditions (Anderson, 2007;
Caraco, 2008; Burmester, 2011; Wang 2012), conducting longitudinal CER
studies including multiple dosing protocols are still necessary to evaluate the
ultimate impact of the available warfarin dosing algorithms on practice and
different populations (i.e., external validity). These studies could address
questions such as how and under which conditions PG-based dosing
algorithms could perform well in certain populations for whom PG-based
algorithms have shown less effective performance compared to other
populations (Schelleman, 2008; Gage, 2008; Cavallari, 2012).

3.3.1.) Longitudinal Studies
Long-term warfarin anticoagulation is commonly used to prevent
thromboembolism in patients with medical conditions such as atrial fibrillation
and venous thromboembolism (e.g., deep vein thrombosis (DVT) or
pulmonary embolism), or when treating patients with mechanical heart valves
(MHVs) (Daniels, 2005). Long-term use of warfarin along with its narrow
therapeutic index and a high risk/benefit ratio necessitate close and long-term
monitoring. Through monitoring, different temporal quality measures are
examined: the patterns of warfarin use in terms of discontinuations and
interruptions, quality of anticoagulation therapy using primary anticoagulation
outcome metrics (e.g., INR and TTR) as well as the relationship of these
patterns with subsequent stroke and bleeding events as secondary and
clinical outcomes. To study these patterns, in addition to prospective clinical
trials, the secondary use of EMR data provides a great opportunity to design
and conduct observational longitudinal studies or retrospective longitudinal
cohort studies. Using treatment data from longitudinal studies, we can
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estimate quantitative and temporal parameters associated with the quality of
anticoagulation therapy. It helps to individualize doses and consistent and
efficient dose adjustment practices using PG-based or non PG-based dosing
protocols. This kind of studies could be conducted not only to study the
effectiveness of different PG-based dosing algorithms for initiating warfarin
doses but also they could be done to address questions such as how long
genotype remains a significant predictor of warfarin dose.
Our in silico translational research framework could take advantage of
longitudinal EMR data of warfarin patients to conduct the CER studies that
could address the effectiveness of different dosing algorithms/protocols over
the period or treatment. It is discussed in more detail in chapters 5 and 6.

3.3.2.) INR and TTR Estimation
Percent Time in Therapeutic Range of INR (TTR) for each cohort of patients
can be determined using any of the following three methodologies (Table 3.5):
1- The fraction of INR's in range (Loeliger, 1985). The fraction of INR's in
range is calculated by taking the number of INR's within target range for all
patients divided by the total number of INR's during selected time interval.
2- The Rosendaal linear interpolation method (Rosendaal, 1993). The
Rosendaal linear interpolation methodology assumes a linear relationship
exists between two INR values and allows one to allocate a specific INR value
to each day for each patient. An average time in range for all patients was
determined. The Rosendaal method has demonstrated to be valid and
reproducible when the level of missing INR values is not high (e.g., ~20%)
(Hutten, 1999).
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3- The cross-section-of-the-files methodology (Ansell, 2004). The method
takes each patient whose INR value is in range at one point in time (the INR
value that was closet the midpoint of the selected interval ± 7 days) divided by
the total number of INR's done on all patients at that point in time. In other
words, it assesses all patients being managed at one point in time by taking
the total of those whose INR is in range and dividing it by the total number of
patients who had an INR at that point in time.
Table 3.5. Advantages and Disadvantages of Methods to Calculate Time-inTherapeutic Range (TTR) (Schmitt, 2003).
Methodology

Fraction on INRs

Cross-section-ofthe-files

Rosendaal linear
interpolation

Advantage

Disadvantage

Simple to calculate
Requires only one INR
value per patient in clinic
population
Not influenced by extent of
INR out-of-range

More frequent testing in
unstable patients may
bias overall results (will
under-estimate TTR of
group)
Does not take into
account days within
target range
Does not consider
individual patients

Simple to calculate
Considers individual
patients
Not influenced by extent of
INR out-of-range

Does not take into
account actual days
within target range
Only considers one
point in time

Takes into account actual
days in target range
Allows one to calculate
INR specific incidence
rates of adverse events

Calculation more
difficult
Makes assumptions
about INR between
actual tests
Does not consider
individual patients
Extreme out-of-range
INR values may bias
overall results
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3.3.3.) Multiple Protocol Studies
Clinical trials have produced a host of treatment protocols for anticlotting
medications such as warfarin, where over 40 protocols were published in the
past 30 years. In practice, providers use a combination of experience,
scientific evidence and clinical trial results to develop anticoagulation “best
practice” treatment plans designed to roughly minimize the patient-to-patient
response variability and risks across the practice’s patient population.
However, the high degree of patient heterogeneity (based on factors such as
race, age, individual medical data, family history and genetics) causes
variations in individual patient response to these “best practice” drug-protocol
approaches. The sheer number of treatment options and risk factors preclude
the full array of clinical trials required to test all combinations of patients and
drug-treatment protocol options. In short, no practical approach to identify the
optimal anticoagulation treatment plan exists for large heterogeneous patient
populations that accounts for individual risk factors; drug and protocol options;
and achieves minimal risk to adverse events such as stroke. Current access
to large comprehensive electronic medical records (EMR) covering diverse
patient populations, coupled with novel modeling and computational
simulations provides an unprecedented opportunity to conduct in silico
identification and validation of optimal treatment strategies.
To address such a challenge, our in Silico WiAD PCOR CER Framework is
used to produce large, representative synthetic patient populations that can
be used to conduct replicated clinical simulations testing and comparing
multiple anticoagulation medication-protocol options.
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3.4.) Model and Simulation Requirements
In our adjustable modular anticoagulation therapy simulation framework
(Figure 3.19), we use a highly adaptable modeling and software application
development paradigm to create models of actual patient populations and
then use those models to produce simulated patient populations (“clinical
avatar” populations) and conduct simulations to predict the clinical validity and
efficacy of genetic tests and algorithms applied to each clinical avatar. The

Figure 3.19. Adjustable Modular Anticoagulation Therapy Simulation
Framework.
mathematical representation of statistically accurate clinical avatar
populations are used to simulate clinical data, warfarin dose (initial and
adjusted doses) and INR response over desired period of time for
anticoagulation treatment courses using different patient populations and a
collection of pharmacogenetic and non-pharmacogenetic dosing algorithms.
Different outcome metrics are calculated and examined to determine which
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algorithm provides the evidence supporting the best clinical outcome for each
patient population.
Next, we will use Aurora Health Care’s patient-based electronic medical
record to assemble hospital, city, county-wide and regional patient
populations. We will use the modeling framework to conduct 90 day
simulations on these hospital patient populations and test the predictions of
over and under dosed patients against data provided by Aurora Health Care.
In addition to the clinical trial simulations, we will also simulate Milwaukee
City, County and South East Wisconsin populations and apply standard health
disparity and geographical analysis to predict the likelihood of higher
incidences of adverse events in geographically and racially diverse sub
populations. We will test these predictions against Aurora’s stratified patient
population to determine accuracy of the population-wide simulations.
Our approach to generate clinical avatars follows the standard applied
mathematical modeling approach (explained in detail in section 3.1.2.):
Analyze and characterize the data; Formulate a phenomenological model that
‘fits’ the data; Test the performance of the model against a sub-collection of
data; Evaluate the accuracy of the model; and Adjust the model based on the
accuracy (or lack thereof) (Blue box in Figure 3.20).
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Figure 3.20. The Applied mathematical modeling schemata to
generate clinical avatars consists of an iterative process of
model development, testing, validation, refinement and repeat.

3.4.1.) Patient Populations
Enormous number of clinical trials have been conducted to test the value of
genotyping on warfarin dosing and treatment. In fact, 364 clinical trials have
been or are being conducted to test the accuracy of previous dosing
algorithms, construct new dosing algorithms, or test the value of genetic
variants in warfarin dosing (clinicaltrials.gov). In those costly clinical trials,
tens of thousands of patients have been or are being recruited. The variety of
trials, objectives, subject populations and results demonstrate a complex
problem that has no obvious solution so far (~100 warfarin trials are still open
as of June 1, 2014).
As mentioned, more than 40 warfarin prediction algorithms that use patient
specific data to predict therapeutic warfarin dosing have been published in the
last three decades. This collection of algorithms contain a number of
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physiological, genetic, clinical lab, and clinical care variables used in one or
more algorithms. We have recorded each variable’s nomenclature, data
constraints, range of values, and data type (Table 3.6). It is a source of
defining which variable (clinical, genetic, personal or family) should be
included in the algorithms.
Table 3.6. General characteristics of the variables used in most of the warfarin
dosing algorithms.
Field

Units

Description

Format

Constraint

Example

Race

n/a

race

Controlled
Dictionary

{White, AfricanAmerican, NativeAmerican, Asian,
Pacific-Islander,
Other, Unknown}

Other

Age

years

age in years

Integer

13 <= x <= 94

25

Gender

n/a

gender

Controlled
Dictionary

{M, F}

M

Height

in

Height in
inches

Integer

56 <= x < = 82

65

Weight

lbs

Weight in
pounds

Integer

100 <= x < = 308

165

BSA

m^2

Body Surface
Area

Real
Number

1.3 <= x <= 2.8

1.6

CYP2C9

n/a

CYP2C9
genotype

Controlled
Dictionary

{*1/*1,*1/*2,*1/*3,
*2/*2,*2/*3,*3/*3}

*1/*1

VKORC1

n/a

VKORC1
genotype

Controlled
Dictionary

{A/A, A/B, B/B}

A/A

CYP2C9*2

n/a

CYP2C9*2
genotype

Controlled
Dictionary

{C/C, C/T, T/T}

C/T

CYP2C9*3

n/a

CYP2C9*3
genotype

Controlled
Dictionary

{A/A, A/C, C/C}

A/C

VKORC1
(1173)

n/a

VKORC1(1173
) genotype

Controlled
Dictionary

{C/C, C/T, T/T}

C/T

VKORC1

n/a

VKORC1(-

Controlled

{G/G, G/A, A/A}

G/A
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(-1639)

1639)
genotype

Dictionary

DVT

n/a

Warfarin usage
indicated for
DVT/PE or not

Controlled
Dictionary

{Y, N}

Y

Smoker

n/a

Smokes or not

Controlled
Dictionary

{Y, N}

Y

Target INR

n/a

Desired INR

Real
Number

x = 2.5

2.5

Amiodarone

n/a

Amiodarone
use or not

Controlled
Dictionary

{Y, N}

Y

Based on our simulation study design, available population dataset that will be used
for training and validation of Clinical Avatar BNM and the required variables in the
simulation model, demographic, clinical, and genetic characteristics of the dataset
are extracted and calculated. Prior to this step, the datasets are carefully vetted to
determine the quality and quantitative properties.

3.4.2.) Parameters
For each study population, we extract and record the clinically and
physiological valid ranges for each variable and create a representative
statistical correlation of the variables important to the study. As explained in
section 3.4.1, these characteristics are crucial to create clinical avatars model
and simulation and PK/PD models. This information along with published
statistics, correlations, and clinical associations will be used to define a clinical
avatar statistical data model representative of a hypothetical population of
warfarin patients. Then the clinical avatar simulation framework is used to
generate clinical avatar populations. Each clinical avatar will reflect a
hypothetical patient’s medical record and the collection of avatars (the clinical
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avatar population) will adhere to the prescribed statistics and inter-variable
correlation structure prescribed by the clinical avatar model.
As an example, Table 3.7 presents the initial statistical distribution of the 5700
warfarin patient medical record datasets in PharmGKB (Whirl-Carrillo, 2012).
The statistical results displayed in the table show the first order analysis
(mean and standard deviation) of the variables assuming independence. The
far right column provides a p-value for tests between the actual PharmGKB
data and representative simulated clinical avatars.
Table 3.7. Statistical characteristics of the PharmGKB warfarin dataset versus
its clinical avatar population.

Parameter

Actual PharmGKB Patients
(n=5700)

Clinical Avatars
(n = 20,000)

0.18% (10)
1.3% (75)
9.9% (559)
36% (2,040)
52.5% (2,974)

0.13% (26)
1.2% (235)
9.8% (1,957)
36.4% (7,282)
52.5% (10,500)

M: 30% (3)
F: 70% (7)
M: 42.7% (32)
F: 57.3% (43)
M: 49.9% (279)
F: 50.1% (280)
M: 60% (1225)
F: 40% (815)
M: 59.3% (1,855)
F: 40.7% (1,272)

M: 34.6% (9)
F: 65.4% (17)
M: 47.2% (111)
F: 52.7% (124)
M: 50.6% (990)
F: 49.4% (967)
M: 59.4% (4,324)
F: 40.6% (2,958)
M: 59.4% (6,353)
F: 40.6% (4,344)

54.8% (3,122)
8.1% (462)
0% (0)
28.7% (1,634)
0% (0)
0% (0)
8.4% (482)

54.2% (10,835)
7.9% (1,583)
0%
29.7% (5,936)
0%
0%
8.2% (1,646)

66.11 ± 4.3
49
80

66.50 ± 4
49
80

PValue

Age
<18
18 – 24
25 – 44
45 – 64
65 – 94
Gender by age
<18
18 – 24
25 – 44
45 – 64
65 – 94
Race
White
African American
Native American
Asian
Pacific Islander
Other
Unknown
Height (in)
Mean
Min
Max

0.75

0.89

0.51

1.2e-8
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Weight (lbs)
Mean
Min
Max
Smoker
White
African American
Native American
Asian/Pac Islander
Other/Unknown
Amiodarone
Yes
No
DVT
Yes
No
VKORC1
A/A
A/B
B/B
CYP2C9
*1/*1
*1/*2
*1/*3
*2/*2
*2/*3
*3/*3

171.58 ± 48.2
66
524

173.51 ± 27.87
92
290

14.4% (324)
20.8% (91)
0% (0)
6.4% (18)
6.5% (16)

14.3% (1,552)
20.9% (332)
0% (0)
5.7% (340)
5.7% (94)

4.5% (258)
95.5% (5,442)

4.6% (921)
95.4% (19,079)

16.4% (817)
83.6% (4,191)

16% (3,203)
84% (16,797)

52.2% (1,245)
25.8% (614)
22.0% (525)

52% (10,404)
26.3% (5,261)
21.7% (4,335)

74.9% (4,155)
13.4% (742)
9% (501)
1% (58)
1.3% (72)
0.4% (22)

75.4% (15, 079)
13.4% (2,676)
8.8% (1,756)
1% (194)
1.1% (227)
0.3% (68)

7.7e31

2.4e11

0.83

0.81

As mentioned in the previous sections, we use PK/PD models to simulate
anticoagulation medication response (e.g., INR). The PK/PD model predicts
treatment outcomes depending on the medication, its metabolism, clearance
and physical properties. As an example, 2 different clinical avatars (that
represent 2 patients) may have different outcomes on the same medicationdosing algorithm and -protocol plan. In addition, the clinical avatars may have
very different outcomes for 2 different medication-protocol plans or even for
the same medication but different dosing protocols. As explained in section
3.2.7, we have implemented a PK/PD model for daily warfarin dosing whose
PK model uses a 2-compartment model with first order input and first order
elimination and its PD model affects using a 2-chain transit compartment
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model. The predictive variables for this PK/PD model are: age, CYP2C9 and
VKORC1 genotypes. So, these three characteristics of the clinical avatars are
used to run the PK/PD model and predict INRs.

3.5.) Outcome Metrics
In anticoagulation therapy studies, a number of outcome metrics are used to
measure the quality of therapy. They generally are categorized into two group;
primary and secondary.

3.5.1.) Primary Outcome Metrics
The main primary outcome is the percentage of time in therapeutic range
(TTR) of international normalized ratio (INR). TTR could be calculated using
different methods explained in section 3.3.2. TTR is the most popular and
widely used quality measure to monitor warfarin management. During the
process of anticoagulation which is usually a long term one, most risk factors
for bleeding or thromboembolic events such as age and underpinning
comorbid conditions cannot be changed and the only modifiable factor that
can be improved to avoid such complications is TTR (Levine, 1998).

3.5.2.) Secondary Outcome Metrics
This group of outcomes are categorized in the two following groups; principal
secondary outcomes and non-principal secondary outcomes. The secondary
outcomes are as follows:
- Occurrence of INR >4 or major clinical events in the first 4 weeks. This
composite outcome measure is a principal secondary outcome measure and
is defined as any INR of 4 or more, major bleeding, or thromboembolism in
the first 4 weeks. The major clinical outcomes to be included in this measure
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are major bleeding and thromboembolism events. The reason this measure is
an important outcome measure is that many studies have shown that there is
a significant correlation between INR >4 and increase risk of bleeding (van
der Meer, 1993).
- Time to first therapeutic INR. This is measure defined as the first INR that is
between the therapeutic ranges of INR depending on the indication of
anticoagulation therapy. Even though it looks that this measure is an
important one but there is no evidence showing a correlation between this
measure and improved clinical outcomes of anticoagulation.
- Time to the determination of a maintenance dose. This is an outcome
measure which is defined as the time to two consecutive INR measurements
in therapeutic range without any change in dose, measured at least 1 week
apart (Kimmel, 2013).
- Time to an adverse event. This measure is defined as the time to occurrence
of adverse events ranging from minor bleedings and thromboembolism (TIA)
to major bleedings and thromboembolism as well as death in specific time
frames (e.g., 4 weeks and 3 months). Bleeding is the most serious
complication of the use of oral anticoagulation in the prevention and treatment
of thromboembolic complications. The definition of this event as used in major
clinical trials is the following one adopted from the Italian Study on
Complications of Oral Anticoagulant Therapy (Palareti, 1996): Major bleeding
is classified as: “fatal (death due to hemorrhage); intracranial (documented by
imaging), ocular (with blindness), articular, or retroperitoneal; if surgery or
angiographic intervention was required to stop bleeding; and if bleeding led to
hemoglobin reduction of 2 g/dL or more and/or need for transfusion of two or
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more blood units. Minor bleeding is all cases of bleeding not classified as
major. Non-relevant (small) bleeding is bruising, small ecchymosis or
epistaxis, occasional hemorrhagic bleeding, or microscopic hematuria.”
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4.1.) Introduction
The Patient-Centered Outcomes Research Institute (PCORI) has proposed
and approved five national priorities for research (Shelby, 2012). The goal of
the fifth priority “Accelerating patient-centered outcomes research and
methodology” is “Improving the nation’s capacity to conduct patient-centered
outcomes research, by building data infrastructure, improving analytic
methods, and training researchers, patients and other stakeholders to
participate in this research.” The PCORI’s “National Priorities for Research
and Research Agenda” encompasses a number of prioritized research areas.
Secondary use of large diverse healthcare EMR data for patient-centered
comparative effectiveness research (PC-CER) is highlighted under the fifth
priority as “The Research that determines the validity and efficiency of data
sources commonly used in PCOR.” The offered examples are: research that
seeks to improve the volume, completeness, comprehensiveness, accuracy,
and efficiency of use of clinical data collected across healthcare systems,
clinical data networks, registries, or payer databases, and the utility of this
data for conducting longitudinal studies of patient outcomes; research that
explores the potential of large clinical data networks to support PCOR; or
research that develops and promotes the utility, performance, and efficiency
of large clinical data networks or registries for supporting patient-centered
outcomes research for patients with rare diseases. This agenda encourages
conducting a spectrum of PC-CER studies including health care disparity in
part by seeking evidence of treatments’ effectiveness across various
populations.
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American Medical Informatics Association (AMIA) has defined secondary use
of data (Safran, 2007) as “non-direct care use of personal health information
(PHI) including but not limited to analysis, research, quality/safety
measurement, public health, payment, provider certification or accreditation,
and marketing and other business including strictly commercial activities.”
Basically, secondary use of data implies use of health data for any purpose or
activity other than direct healthcare delivery such as quality and safety
measurement, clinical and translational research and improvement public
health. Quality EMR data is central to any secondary use of the data and is
essential to the process of decision-making and providing good quality patient
care (Cruz-Correia, 2010). Secondary use of EMR as a means of
retrospective analysis of health data has potentials to accelerate knowledge
translation in healthcare and constitutes a significant part of clinical research.
Currently, secondary use of clinical data is still at its early stage (Prokosch,
2009). National initiatives have been established to extend and facilitate
secondary use of EMR to support clinical research (CDRNs, 2014).
Aurora Health Care (AHC) is the largest health care system in Wisconsin
operating 15 hospitals throughout the state with more than 3600 licensed
beds, 172 physician clinic facilities, and several other health care related
entities. It serves about 1.2 million unique patients each year through 7.8
million patient encounters per year. AHC’s EMR is the most comprehensive
(by size, type of health care and period of time) digitized health care resource
of Southeast Wisconsin’s population capturing urban, suburban, and rural
constituents of all racial, ethnic, and socioeconomic backgrounds. This
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resource provides a unique opportunity to capture data and information vital to
conducting retrospective and predictive PC-CER studies.
UWM and AHC have established a collaboration to conduct a series of
research studies whose goal is to, using AHC electronic medical records
(EMR), demonstrate that in silico pharmacogenetic PC-CERs based on actual
EMR patient data provide predictive evidence useful in detecting “optimal”
anticoagulation dosing protocols that reduce adverse drug responses,
improve overall patient outcomes and reduce health disparities in the Aurora
Milwaukee County patient population. One of the main steps in this
collaboration is to build a longitudinal EMR-based anticoagulation research
database. Such a database is an essential tool in conducting
pharmacogenetic PC-CERs.
However, there are challenges in the re-use of the data captured and stored
in EMR systems for comparative-effectiveness studies as they have not been
originally been developed for research purposes. Some of the most popular
barriers and challenges to the secondary use of EMR data are as follows:
missing data, erroneous data, uninterpretable data, inconsistencies among
providers and over time, and data stored in noncoded text notes (free text)
(Bayley, 2013; Elkin, 2010). Considering the fact that the designed
pharmacogenetic PC-CER studies by UWM and AHC required quality data, a
rigorous multilayer and iterative process of extraction, transformation and
loading (ETL) was designed and performed to ensure the resulted research
database fits the use. In the following sections the ETL process and the
research database are explained.
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4.2.) Methods
The process of developing the anticoagulation research database consisted of
an iterative process of extraction, transformation and loading by the two
teams of Aurora Health Care (AHC) and University of Wisconsin-Milwaukee
(UWM). The first step was to determine the scope of the desired data.

4.2.1.) Determination of Inclusion Criteria and Scope of
Data
After a rigorous literature review, the UWM team developed a data model of
the required patient’s attributes and value sets for extracting the required data
from AHC EMR data repository. Based on some practical facts, the data
model was refined collaboratively by the UWM and AHC teams to be
compatible with the data models and dictionaries of the heterogeneous AHC’s
databases (Table 4.1.). For example, even though the initial data model
included the full lists of National Drug Code (NDC) codes for each of the
included medications or associated ICD-10 codes were considered for clinical
characteristics (e.g., medical indication and comorbidities), the final model
were refined to include medication names and ICD-9 codes given that AHC
data warehouse were not using NDC and ICD-10 codes.
Table 4.1. Patient’s characteristics used to identify patients with evidence of
anticoagulation/anticlotting treatment from AHC’s EMR data warehouse.

Patient Characteristics
Demographics
Gender
Age
Patient’s Zipcode
Patient’s County
Patient’s City
Provider’s Zipcode
Smoking Status

ICD-9 or CPT Codes
Male, Female, Unknown
Year (Age >=18)
5-digit zipcode

5-digit zipcode
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Race
Height
Weight
Date of Visit
Date of Death
Medications
Date Received/Date Prescribed
Medication Type:
- Coumadin (Warfarin)
- Heparin
- Ticlopidine (Ticlid)
- Clopidogrel (Plavix)
- Dipyridamole (Persantine)
- Abciximab (ReoPro)
- Eptifibatide (Integrilin)
- Tirofiban (Aggrastat)
- Dabigatran (Pradaxa)
Dosage
Frequency
Interacting Medications
Date Received/Date Prescribed
Medication Type:
- Amiodarone (Cordarone, Pacerone)
- Simvastatin (Zocor)
- Fluvastatin (Lescol)
- Lovastatin (Altocor, Altoprev,
Mevacor)
- Atrovastatin (Lipitor)
- Rosuvastatin (Crestor)
- Pravastatin (Pravachol)
- Aspirin
Dosage
Frequency
Medical Indications
Date of Indication
Indication Type:
- Orthopedic Procedures

Inch
Pound

Name of the medications

Name of the medications

CPT codes: 77.65, 77.66, 77.67, 77.69,
77.75, 77.76, 77.77, 77.79, 77.85, 77.86,
77.87, 77.95, 77.96, 77.97, 78.05, 78.06,
78.07, 78.09, 78.15, 78.16, 78.17, 78.19,
78.25, 78.27, 78.29, 78.35, 78.37, 78.39,
78.45, 78.46, 78.47, 78.49, 78.55, 78.56,
78.57, 78.59, 79.05, 79.06, 79.09, 79.15,
79.16, 79.19, 79.25, 79.26, 79.29, 79.35,
79.36, 79.39, 79.45, 79.46, 79.49, 79.55,
79.56, 79.59, 79.65, 79.66, 79.69, 79.75,
79.76, 79.79, 79.85, 79.86, 79.89, 80.25,
80.26, 80.27, 80.6, 80.75, 80.76, 81.00,
81.09, 81.30, 81.39, 81.40, 81.42, 81.43,
81.44, 81.45, 81.46, 81.47, 81.49, 81.51,
81.52, 81.53, 81.54, 81.55, 81.56, 81.57,
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- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Atrial fibrillation
- Atrial flutter
- Atrial fibrillation and flutter
- Stroke
- Heart valve replacement
Lab Test Results
INR Test Result
Date of INR Test
Adverse Events/Comorbidities
Date of Event/Comorbidity
Event Type:
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Stroke
- Myocardial infarction
- Bleeding
- Diabetes Mellitus
- Heart Failure
- Hypertension
- Peripheral artery diseases
- Atherosclerosis of aorta
- Coronary artery disease

81.59, 81.61, 81.62, 81.63, 81.64, 81.65,
81.66, 84.10, 84.11, 84.12, 84.13, 84.14,
84.15, 84.16, 84.17, 84.18, 84.19, 84.26,
84.27, 84.28, 84.45, 84.46, 84.47, 84.48,
84.51, 84.58, 84.59, 84.60, 84.61, 84.62,
84.63, 84.64, 84.65, 84.66, 84.67, 84.68,
84.69, 84.80, 84.81, 84.82, 84.83, 84.84,
84.85, 84.91
ICD-9 codes: 451.x, 453.x
ICD-9 codes: 415.1x
ICD-9 codes: 427.31
ICD-9 codes: 427.32
ICD-9 codes: 427.3
ICD-9 codes: 433.x, 434.x, 435.x, 436,
437.1x, 437.9x, 438.x
ICD-9 codes: V43.3
Numeric

ICD-9 codes: 451.x, 453.x
ICD-9 codes: 415.1x
ICD-9 codes: 433.x, 434.x, 435.x, 436,
437.1x, 437.9x, 438.x
ICD-9 codes: 410.x
ICD-9 codes: 431.x, 432.x, 459.0, 578,
578.9, 784.7, 784.8, 786.30
ICD-9 codes: 250.x
ICD-9 codes: 428.x
ICD-9 codes: 401.x
ICD-9 codes: 250.6, 443.x, 785.4
ICD-9 codes: 440-0
ICD-9 codes: 414.0x

4.2.1.1.) Extract, Transform, and Load (ETL) Process
The process of extraction, transformation and loading (ETL) of data is usually
a multilayer, iterative one addressing both data and data models. In this
project, the ETL process was done by both AHC and UWM LPHIG teams.
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4.2.1.1.1.) AHC ETL Process
Once the Internal Review Board (IRB) approval was granted by both AHC and
UWM and a Data Use Agreement was signed by two institutes, the AHC
team, before delivering the data to UWM team, performed an internally
developed ETL process to identify, extract, transform and load patient’s
records into a database. Using the data model depicted in Table 4.1, the AHC
team constructed the extraction algorithms and search strategies to mine
AHC’s hospitals’ and clinics’ EMR data warehouses and retrieved the AHC
EMR for patients treated with anticoagulation/anticlotting agents for the period
of 2002 to 2012 and subsequently all post-treatment events from each patient.
In the process of the transformation, the patient data was de-identified per
IRB approval (allowing zipcode) by an AHC honest broker. This process
resulted in the longitudinal data records of 157,450 patients including: gender,
race, height, weight, age, day of visit, patient's zipcode, patient's city,
provider's zipcode, smoking status, INR, medications received (day, dose,
frequency), interacting medications (Amiodarone, Simvastatin, Fluvastatin,
Lovastatin, Atrovastatin, Rosuvastatin, Pravastatin, Aspirin), medication
indications (by ICD-9 codes for Deep Vein Thrombosis (DVT), Pulmonary
embolism, Atrial fibrillation, Atrial flutter, Atrial fibrillation and flutter, Stroke,
Heart valve replacement and CPT codes for Orthopedic surgery-hip or knee)
and comorbidities (by ICD-9 codes for DVT, Pulmonary embolism, Stroke,
Myocardial infarction, Bleeding). The AHC team loaded the data into an MS
Access database (“Original Access Database”). The data model of the Access
database is depicted in Figure 4.1.
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Figure 4.1. The Data Model of the Original Access Database Provided by
AHC Team.

4.2.1.1.2.) LPHIG ETL Process
Once receiving the Original Access Database, the UWM LPHIG (Laboratory
for Public Health Informatics and Genomics) team performed another iterative
round of ETL process aiming to create the anticoagulation/anticlotting
research database namely Wisconsin Anticoagulation Database (WiAD). The
first round of the ETL process at this stage was to remove complete duplicate
records from the Original Access Database’s tables, identify primary and
foreign keys across the tables and create a relational database in a MySQL
Server which would be a “Base Database” for further processes. The Entity
Relationship (ER) data model of the MySQL Base Database is depicted in
Figure 4.2. This process was followed by another round of transformation
including multiple steps of cleaning up the data and data validation and quality
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control. In this process, few data dictionaries were developed for some of the
attributes’ value sets.
Data cleaning and quality control is an important task in the process of
developing research databases especially when the extracted data come from
heterogeneous data sources. Data cleaning is basically a process in which
errors and inconsistencies in data are detected and removed.

Figure 4.2. Entity Relationship (ER) Data Model of the Base MySQL Database.

Subsequent data cleaning, quality control and quality assurance included an
iterative process of data parsing to detect irregularities; statistical analysis
designed to test population-wide distributions and possible biases; refinement
of inclusion and extraction data mining codes to address irregularities,
possible missing data and detected biases; and ultimately, data
transformation to produce a cohesive set of records capturing all available
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medical records in a consistent format following Weiskopf (2013). According
to Weiskopf different dimensions of data quality are as follows:
- Completeness: “Is a truth about a patient present in the EMR?”
- Correctness: “Is an element that is present in the EMR true?”
- Concordance: “Is there agreement between elements in the EMR, or
between the EMR and another data source?”

Table 4.2. AHC dataset’s data quality issues.
Scope/Problem

Original Data

Missing values

Race = “UNKNOWN”

Misspellings

Medication Name= “warfin”

Awkward Abbreviations

Medication Frequency= “zUBC”

Attribute
Free Text Embedded values

Medication Name= “warfarin 2.5
mg 5 days a week
and 2 mg two days a week”

Miscoded values

Patient zip code= “WI”

Incorrect values

Weight= -165

Violated attribute dependency

Duplicated records
(partial and complete)
Record

City= “Milwaukee”, zip
code=99999
ID=165, Day= 199; Medication=
Warfarin 4 mg, Frequency= QOD;
ID=165, Day= 199; Medication=
Warfarin 4 mg, Frequency= daily
ID= 78, Day= 1101, Medication=
Coumadin, Dose= 3 mg;

Contradicting records
ID= 78, Day= 1101, Medication=
Coumadin, Dose= 4 mg

- Plausibility: “Does an element in the EMR makes sense in light of other
knowledge about what that element is measuring?”
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- Currency: “Is an element in the EMR a relevant representation of the patient
state at a given point in time?”
We identified a number of data quality issues across the AHC dataset stored
in the Base Database. Table 4.2 demonstrates the data quality issues of the
AHC data at attribute and cross-attribute (record) levels.
To address these data quality issues across the AHC’s structured and
unstructured data, the team performed a number of data quality and cleaning
tasks as detailed below.
- Age: Although the AHC data is longitudinal, there was only one Gender and
one Age record for each unique subject stored in table “patients”. The rate of
missing data for age was very low (i.e., 1 subject). However, about 1% of the
whole population (i.e., 2662 subjects) have age value of 0. Subjects with age
of zero or missing age were excluded. Since our age inclusion criteria was
subjects with the age of 18 years old or above, any subject with an age lower
than 18 years old (i.e., 357 subjects) was excluded. The following table (Table
4.3.) shows the age distribution of subjects in the AHC Base Database. As
depicted, the most populated age groups are 65-74 and 75-84 years old
Table 4.3. Age distribution of the subjects in the AHC Base Database.
Age Group (Years)
18-24
25-34
35-44
45-54
55-59
60-64
65-74
75-84
>85

Percentage
1.09
2.46
5.81
14.11
9.92
10.62
22.22
22.70
11.08
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which is consistent with the fact that the prevalence of anticoagulation therapy
increases as people get older and experience more chronic diseases.
- Gender: The gender values were either female or male. Less than 0.01% of
the subjects had no gender information. The subjects with missing gender
were excluded from the study population. Table 4.4 depicts the gender
distribution of the subjects in the AHC Base Database compared to that of in
Milwaukee county (MKE) and Wisconsin (WI). As a quality control measure,
the age distribution of the AHC Base Database was compared with that of
MKE and WI which did not show significant difference (p >0.05).
Table 4.4. Gender Distributions across the three populations of AHC Base
Database, Milwaukee County (MKE) and Wisconsin (WI).
Gender
Male
Female
Missing

AHC Base Database (%)
50.34
49.65
0.01

MKE (%)
48.30
51.70
NA

WI (%)
49.60
50.40
NA

- Race: In the AHC Base Database, each subject had one race record. Race
is a key piece of information for our PC-CER studies. Only 52.85% of AHC
Base Database’s subjects had race information. About 0.01% of the subjects
in table “race” (i.e., 1662 subjects) had no race information. The race values
of the subjects were: White, Black or African American, Asian, American
Indian or Alaskan Native, Native Hawaiian/Other Pacific Islander and
Unknown. The following table (Table 4.5) depicts the racial distribution of the
AHC Base Database’s subjects who had identified race information versus the
racial distributions across Milwaukee County (MKE) and Wisconsin (WI). As a
quality control measure, the racial distribution of the AHC Base Database was
compared with that of MKE and WI. The racial distributions of the Base
Database was not significantly different from that of WI (p >0.05).
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Table 4.5. Race distribution across the AHC Base Database’s subjects and
Milwaukee County’s and Wisconsin’s populations.
Race
White
Black or African
American
American Indian and
Alaska Native
Asian
Native Hawaiian or Other
Pacific Islander
Subjects reporting two or
more races

AHC Base Database (%)
90.41

MKE (%)
65.9

WI (%)
88.4

8.52

27.0

6.5

0.27

0.9

1.1

0.79

3.6

2.4

0.02

0.1

0.05

NA

2.5

1.6

- Height: In the AHC Base Database, each subject has longitudinal height
records with multiple height records for each measurement day which were
not on a regular basis. Each height record contained the attributes
{SURROGATE_ID, DAY, HEIGHT, SOURCE_SYSTEM}. Since height
measurement can vary within a specific time frame due to factors such as lack
of standard protocols, inaccurate measuring, and imprecise equipment set-up,

Figure 4.3. Height records cleaning algorithm.
we created a cleaning algorithm. Before applying the algorithm, first, each
height record was examined to identify and exclude any height record whose
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HEIGHT attribute’s value was missing. Then the height cleaning algorithm
was applied (Figure 4.3).
According to the algorithm, we first removed all height values we considered
biologically implausible (Census Bureau, 2012; Muthalagu, 2014).
Accordingly, we set the plausible thresholds greater than 39.5 inches and less
than 98.5 inches. Then we took the next steps of the algorithm. If all height
records for a single subject in a single day differed (i.e., difference between
minimum height and maximum height for the same day) by less than
measurement error of 1.5 inches (Muthalagu, 2014), then all height records
for that subject for that day were marked correct by the algorithm and the
mean of the height records was calculated representing height value for the
day. For all other days, median height for each day was calculated. The
median height for each day was compared with that of the prior and next
median; when the difference in medians was greater than 1.5 inches for both,
the median height for that day was considered as potentially erroneous
(Muthalagu, 2014). For the days that had an erroneous median height, the
algorithm assigned the nearest correct median height.
The rate of height record completeness for the AHC Base Database was
43.17%. The subjects with height records had 3.07 height records on
average. The average height of the population was 66.09 inches (±7.23).
- Weight: In the AHC Base Database, each subject has longitudinal weight
records with multiple weight records for each measurement day which were
not on a regular basis. Each weight record contained the attributes
{SURROGATE_ID, DAY, WEIGHT, SOURCE_SYSTEM}. Since weight
measurement can vary within a specific time frame due to factors such as
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lack of standard protocols, inaccurate measuring, and imprecise equipment
set-up, we created a cleaning algorithm. Before applying the algorithm, first,
each weight record was examined to identify and exclude any weight record
whose WEIGHT attribute’s value was missing. Then the weight cleaning
algorithm was applied (Figure 4.4).

Figure 4.4. Weight records cleaning algorithm.
According to the algorithm, we first removed all weight values we considered
biologically implausible (Census Bureau, 2012). We set the plausible
thresholds greater than 70 pounds and less than 500 pounds. Then we took
the next steps of the algorithm. If all weight records for a single subject in a
single day differ (i.e., difference between minimum weight and maximum
weight for the same day) by less than measurement error of 10% (Maskin,
2010), then all weight records for that subject for that day are marked correct
by the algorithm and the mean of the weight records is calculated
representing weight value for the day. For all other days, median weight for
each day is calculated. The median weight for each day is compared with that
of the prior and next median; when the difference in medians is greater than
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measurement error for both, the median weight for that day is considered as
potentially erroneous. For the days that have an erroneous median weight,
the algorithm assigns the nearest correct median weight.
The rate of weight record completeness for the AHC Base Database is
49.58%. The subjects with weight records had 7.39 weight records on
average. The average weight of the population was 195.12 pounds (±50.1).
- Medications: In the AHC Base Database’s table “medication”, each subject
has multiple medication records. Each medication record contained the
attributes {SURROGATE ID, DAY, MEDICATION_NAME, FREQ,
DOSE_QTY, DOSE_QTY_UNIT, SOURCE_SYSTEM}. In the table, the entire
columns of {DOSE_QTY, DOSE_QTY_UNIT} were completely blank. The
column {FREQ} was partially complete. The cells under column
{MEDICATION_NAME} were populated with free-text. Before conducting any
cleaning or quality control measures, we had to extract information from the
free-text in cells under column {MEDICATION_NAME} and translate them into
a structured format. Through a text analysis step, the required data from the
free text were extracted and presented in normalized and consistent
structured formats. We used a multistep process which involved parsing the
free texts into their components, normalizing the identified components, and
extraction of the required data elements (i.e., name of medication, dosage,
unit, and route of administration). The rate of incompleteness of the resulted
records was high. Table 4.6 depicts the distribution of medication records by
each medication in the cleaned and controlled medication table and also
presents an example of the rate of completeness (i.e., percentage of each
medication’s records with dosage information). 99.02% of the medications
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records included one of the three medications of warfarin (37.85%), heparin
(36.24%) and clopidogrel (24.93%). Warfarin records which have dosage
information have the highest percentage of whole the records (11%). Although
the number of heparin records was higher than the number of clopidogrel
records, the percentage of clopidogrel records with dosage information out of
whole the records was higher than that of heparin.
Table 4.6. Distribution of number of subjects under each medication and the
rate of medication records’ dosage information completeness.
Medication

Number of
Subjects under
Medication

Rate of the Records’
Dosage Information
Completeness

Warfarin

74,102

70.03%

Heparin

71,537

33.4%

Clopidogrel

61,517

68.03%

Dabigatran

1,793

89.18%

Dipyridamole

2,292

22.9%

Eptifibatide

2886

71.58%

Ticlopidine

434

73.5%

Abciximab

1,310

90.15%

Tirofiban

48

0%

The above table indicates that a big number of subjects have received more
than one medication. The following table (Table 4.7) shows the number of
subjects who have been under treatment with 1 to 6 medications.
Table 4.7. Distribution of subjects by number of medications.
No. of
Medications
No. of Subjects

1

2

75282 16441

3

4

5

6

3049

358

20

1
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- Patient Residence: In the AHC Base Database’s table “patient_residence”,
each subject has multiple residence records. Each residence record
contained the attributes {SURROGATE_ID, DAY, PATIENT_ZIP,
PATIENT_CITY, SOURCE_SYSTEM}. As a quality control measure, the
recorded 5-digit zipcodes were examined against a standard zipcode
dictionary to find any inconsistency between the recorded zipcodes and their
recorded associated cities. It also helped find and exclude invalid numeric or
non-numeric values which were reported as 5-digit zipcodes (e.g., 0, 99999,
WI, MI, *R2Y1, *CV11, *). 83.73% of the whole AHC Base Database’s
population have at least one residence record. The partially (i.e., the same
zipcode on the same day at two different “SOURCE_SYSTEM”s) and
complete duplicated records were also excluded (46.36% of the records).
After the above QC and cleaning process, the average number of residence
records for each subject with residence records was 1.76 (range 1-4). Out of
the subjects with residence record, 3.33% had more than one reported
zipcode. The reported zipcodes were distributed across 44 states with the
highest frequency in Wisconsin, Illinois, Michigan, and Florida. The subjects in
Wisconsin were also distributed across the 72 counties of the state with the
highest frequency in counties Milwaukee, Sheboygan, Racine, Waukesha,
Walworth, and Kenosha. The distribution of the subjects across the states and
the counties have been visualized on two separate interactive Google Maps at
the following URLs:
https://www.google.com/fusiontables/DataSource?docid=1MPew8EhUQvoES
HZJP9RaykxHDm8ir0W7LUhYC4U#map:id=3
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https://www.google.com/fusiontables/DataSource?docid=1OP6Wrdt56g6ZAt0j
Yuyt3i4nc6RbUBFElqVtvnU
The following figure demonstrates a snapshot of the map displaying the
subject distribution across the counties of Wisconsin.

> 10,000

5,000-9,999

1,000-4,999

< 1,000
Figure 4.5. Distribution of AHC Base Database’s subjects across
Wisconsin counties.
- Provider Location: In the AHC base database’s table “provider_location”,
each subject has multiple provider location’s records. Each provider location’s
record contained the attributes {SURROGATE ID, DAY, PROVIDER_ZIP,
SOURCE_SYSTEM}. As a quality measure, the recorded 5-digit zipcodes
were examined against a standard zipcode dictionary to find and exclude any
invalid recorded zipcodes. 54.10% of the whole AHC Base Database’s
population have at least one provider location record. The partially (i.e., the
same zipcode on the same day at two different “SOURCE_SYSTEM”s) and
complete duplicated records were also excluded (3.93% of the records). The
average number of provider location records for subjects with provider
location records was 1.06 (range 1-4). Out of the subjects with provider
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location record, 6.65% had more than one reported zipcode. The reported
provider locations’ zipcodes were distributed across 20 states with the highest
frequency in Wisconsin and Illinois (97.75% and 1.15%, respectively). The
provider locations in Wisconsin were also distributed across the 29 counties of
the state with the highest frequency in counties Milwaukee and Brown
(59.56% and 8.65%, respectively).
- Smoking: In the AHC Base Database’s table “smoking”, each subject has
longitudinal smoking records with multiple smoking records for each record
day which were not on a regular basis. Each smoking record contained the
attributes {SURROGATE_ID, DAY, TOBACCO_USE, SOURCE_SYSTEM}.
The TOBACCO_USE value fields were populated with a large number of
different unstructured data values. To address this issue, a dictionary was
created to refine and translate the recorded values to a set of well-defined
ones (Table 4.8). Almost 68% of the Base Database’s subjects had smoking
status records.
Table 4.8. Smoking Status value dictionary.
Tobacco Use
Current Smoker
Former Smoker < or = to 12 months ago
Former Smoker >12 months ago
Never Smoker
Unknown if Ever Smoked

Smoking
Status
YES
NO
NO
NO
NO

Definition
Currently Smoker
Not currently smoker
Not currently smoker
Never smoker
Unknown

- Indication: In the AHC Base Database’s table “indication”, each subject has
multiple indication records. Each indication record contained the attributes
{SURROGATE ID, DAY, CODE, SOURCE_SYSTEM}. As a quality measure,
first, the reported codes were examined against the published ICD-9 CM 2011
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codes (ICD-9-CM, 2014) to test their validity (i.e., in acceptable range). All of
the reported codes were in acceptable range (Table 4.9).
Table 4.9. ICD-9 Codes for indications of the AHC Base Database's subjects.
ICD-9-CM 2011 Diagnostic and Procedure
Code Class
Myocardial Infarction
410 Acute myocardial infarction
410.0 Of anterolateral wall
410.1 Of other anterior wall
410.2 Of inferolateral wall
410.3 Of inferoposterior wall
410.4 Of other inferior wall
410.5 Of other lateral wall
410.6 True posterior wall infarction
410.7 Subendocardial infarction
410.8 Of other specified sites
410.9 Unspecified site
Pulmonary Embolism
415 Acute pulmonary heart disease
415.1 Pulmonary embolism and infarction
Cardiac Dysrhythmias
427 Cardiac dysrhythmias
427.3 Atrial fibrillation and flutter
Cerebrovascular Disease
432 Other and unspecified intracranial
hemorrhage
432.1 Subdural hemorrhage
433 Occlusion and stenosis of precerebral
arteries
433.1 Occlusion and stenosis of carotid
artery
433.2 Occlusion and stenosis of vertebral
artery
433.8 Occlusion and stenosis of other
specified precerebral artery
433.9 Occlusion and stenosis of unspecified
precerebral artery
434 Occlusion of cerebral arteries
434.1 Cerebral embolism
434.9 Cerebral artery occlusion unspecified
435 Transient cerebral ischemia
435.1 Vertebral artery syndrome convert
435.2 Subclavian steal syndrome convert
435.3 Vertebrobasilar artery syndrome
convert
435.8 Other specified transient cerebral

Indication codes reported
at the AHC Base Database

410.01 410.02 410.11 410.12
410.21 410.22 410.32 410.41
410.51 410.72 410.81 410.82
410.91 410.92

415.11 415.12 415.13 415.19

427.31 427.32

432.1 433.01 433.11 433.21
433.31 433.81 433.91 434.01
434.11 434.91 435.1 435.2
435.3 435.8 435.9 436 437.1
437.9 438.11 438.12 438.13
438.14 438.19 438.21 438.22
438.31 438.32 438.41 438.42
438.51 438.52 438.53 438.6
438.7 438.81 438.82 438.83
438.84 438.85 438.89 438.9
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ischemias convert
435.9 Unspecified transient cerebral
ischemia convert
436 Acute, but ill-defined, cerebrovascular
disease
437 Other and ill-defined cerebrovascular
disease
437.1 Other generalized ischemic
cerebrovascular disease convert
437.9 Unspecified cerebrovascular disease
convert
438 Late effects of cerebrovascular disease
438.0 Late effects of cerebrovascular
disease, cognitive deficits
438.1 Speech and language deficits
438.2 Hemiplegia/hemiparesis
438.3 Monoplegia of upper limb
438.4 Monoplegia of lower limb
438.5 Other paralytic syndrome
438.6 Late effects of cerebrovascular
disease, alterations of sensations
438.7 Late effects of cerebrovascular
disease, disturbances of vision
438.8 Other late effects of cerebrovascular
disease
438.9 Unspecified late effects of
cerebrovascular disease
Gastrointestinal Hemorrhage
578 Gastrointestinal hemorrhage
578.1 578.9
578.1 Blood in stool
578.9 Hemorrhage of gastrointestinal tract,
unspecified
Hemorrhage in Head and Neck
784 Symptoms involving head and neck
784.7 784.8
784.7 Epistaxis
784.8 Hemorrhage from throat
Hemorrhage in Respiratory System
786 Symptoms involving respiratory system
786.3
and other chest symptoms
786.3 Hemoptysis
Phlebitis and Thrombophlebitis
451.11 451.19 451.2 451.81
451 Phlebitis and thrombophlebitis
451.82 451.83 451.84 451.89
451.1 Phlebitis and thrombophlebitis of deep 451.9 453.1 453.2 453.3
veins of lower extremities
453.41 453.42 453.51 453.52
451.2 Phlebitis and thrombophlebitis of
453.6 453.71 453.72 453.73
lower extremities, unspecified
453.74
453.75 453.76 453.77
451.8 Phlebitis and thrombophlebitis of other
453.79 453.8 453.81 453.82
sites
451.9 Phlebitis and thrombophlebitis of
453.83 453.84 453.85 453.86
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unspecified site
453.87 453.89 453.9 459.11
452 Portal vein thrombosis
459.12 459.19 459.31 459.32
453 Other venous embolism and thrombosis
459.81 459.89 459.9
453.1 Thrombophlebitis migrans
453.2 Other venous embolism and
thrombosis of inferior vena cava
453.3 Other venous embolism and
thrombosis of renal vein
453.4 Acute venous embolism and
thrombosis of deep vessels of lower
extremity
453.5 Chronic venous embolism and
thrombosis of deep vessels of lower
extremity
453.6 Venous embolism and thrombosis of
superficial vessels of lower extremity
453.7 Chronic venous embolism and
thrombosis of other specified vessels
453.8 Acute venous embolism and
thrombosis of other specified veins
453.9 Other venous embolism and
thrombosis of unspecified site
454 Varicose veins of lower extremities
455 Hemorrhoids
456 Varicose veins of other sites
457 Noninfectious disorders of lymphatic
channels
458 Hypotension
459 Other disorders of circulatory system
459.1 Postphlebitic syndrome
459.3 Chronic venous hypertension
(idiopathic)
459.8 Other specified disorders of
circulatory system
459.9 Unspecified circulatory system
disorder
Heart Valve Replacement
V43.3
V43.3 Heart valve

The reported CPT Codes in the table “indication” were also examined against
the Current Procedural Terminology (CPT) to test their validity (i.e., in
acceptable range). The following table (Table 4.10) shows the reported the
CPT codes.
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Table 4.10. CPT Codes for indications of the AHC Base Database's Subjects.
CPT Code Class
Orthopedic Procedures

CPT Codes
77.65 77.66 77.67 77.69
77.75 77.76 77.77 77.79
77.85 77.86 77.87 77.96
78.05 78.06 78.07 78.09
78.15 78.16 78.17 78.19
78.29 78.45 78.46 78.47
78.49 78.55 78.56 78.57
78.59 79.05 79.06 79.09
79.15 79.16 79.19 79.25
79.26 79.29 79.35 79.36
79.39 79.56 79.65 79.66
79.75 79.76 79.85 79.86
79.89 80.25 80.26 80.27
80.6 80.75 80.76 81.44
81.45 81.46 81.47 81.49
81.51 81.52 81.53 81.54
81.55 81.56 81.57 81.59
81.62 81.63 81.64 81.65
81.66 84.11 84.12 84.13
84.14 84.15 84.16 84.17
84.18 84.19 84.51 84.58
84.59 84.61 84.62 84.65
84.81 84.84

On average, each subject had 1.83 indication record (range 1-14). The
following table (Table 4.11) depicts the distribution of number of indication
records per subject.
Table 4.11. Distribution of number of indication records among the subjects
with indication records.
Number of Indication
Records/Subject
1
2
3
4
5
6

Number of Subjects (%)
50196 (50.14)
29253(29.22)
12701(12.68)
4990(4.98)
1885(1.88)
688(0.68)
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7
8
9
10
11
12
13
14
Total

251(0.25)
97(<0.001)
23(<0.001)
9(<0.001)
4(<0.001)
1(<0.001)
4(<0.001)
1(<0.001)
100103 (100%)

18.46% of the indication records were reported before patients’ first
prescription start date of an anticoagulation medication at AHC. The
distribution of the reported days of indications are depicted in Table 4.12.
Table 4.12. Distribution of day numbers in which the indications were
recorded before or after patients’ start date of anticoagulation therapy.
Recorded Day of Indication
Within 12 weeks before the start date
Within 4 weeks before the start date
Within 1 week before the start date
On the start date
Within 1 week after the start date
Within 4 weeks after the start date
Within 12 weeks after the start date

Number of Indication Records
(%)
13768(7.51)
11875(6.47)
9426(5.14)
26429(14.42)
35628(19.44)
44986(24.54)
54856(29.93)

The complete duplicated records and partially duplicated ones (i.e., records
with the same indication on different days) were identified and excluded
(17.58% of the records). The following table (Table 4.13) depicts the
distribution of number of unique indications among the subjects with indication
records.
Table 4.13. Distribution of number of unique indications among the subjects
with indication records.
Number of Unique
Indications/Subject
1

Number of Subjects (%)
64360 (64.29)
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2
3
4
5
6
7
8
9
10
11
12
13
Total

25330(25.30)
7056(7.04)
2227(2.22)
730(0.72)
267(0.26)
94(<0.001)
23(<0.001)
5(<0.001)
4(<0.001)
5(<0.001)
1(<0.001)
1(<0.001)
100103 (100%)

- Comorbidity: In the AHC Base Database’s table “comorbidity”, each subject
has multiple comorbidity records. Each comorbidity record contained the
attributes {SURROGATE ID, DAY, CODE, SOURCE_SYSTEM}. As a quality
measure, first, the reported codes were examined against the published ICD9-CM 2011 codes (ICD-9-CM, 2014) to make sure that they were in the
acceptable range of the codes. All of the reported codes were in acceptable
range (Table 4.14).
Table 4.14. ICD-9 Codes for comorbidities of the AHC Base Database's
Subjects.
ICD-9-CM 2011 Diagnostic and
Procedure Code Class
Myocardial Infarction
410 Acute myocardial infarction
410.0 Of anterolateral wall
410.1 Of other anterior wall
410.2 Of inferolateral wall
410.3 Of inferoposterior wall
410.4 Of other inferior wall
410.5 Of other lateral wall
410.6 True posterior wall
infarction
410.7 Subendocardial infarction
410.8 Of other specified sites
410.9 Unspecified site

Comorbidity codes reported at
the AHC Base Database

410.01 410.02 410.11 410.12
410.21 410.22 410.31 410.32
410.41 410.42 410.51 410.52
410.61 410.62 410.71 410.72
410.81 410.82 410.91 410.92

164

Pulmonary Embolism
415 Acute pulmonary heart
disease
415.1 Pulmonary embolism and
infarction
Cerebrovascular Disease
431 Intracerebral hemorrhage
432 Other and unspecified
intracranial hemorrhage
432.1 Subdural hemorrhage
433 Occlusion and stenosis of
precerebral arteries
433.1 Occlusion and stenosis
of carotid artery
433.2 Occlusion and stenosis
of vertebral artery
433.8 Occlusion and stenosis
of other specified precerebral
artery
433.9 Occlusion and stenosis
of unspecified precerebral
artery
434 Occlusion of cerebral
arteries
434.1 Cerebral embolism
434.9 Cerebral artery occlusion
unspecified
435 Transient cerebral ischemia
435.1 Vertebral artery
syndrome convert
435.2 Subclavian steal
syndrome convert
435.3 Vertebrobasilar artery
syndrome convert
435.8 Other specified transient
cerebral ischemias convert
435.9 Unspecified transient
cerebral ischemia convert
436 Acute, but ill-defined,
cerebrovascular disease
437 Other and ill-defined
cerebrovascular disease
437.1 Other generalized
ischemic cerebrovascular
disease convert
437.9 Unspecified
cerebrovascular disease
convert
438 Late effects of
cerebrovascular disease

415.11 415.12 415.13 415.19

431 432.1 432.9 433.01 433.11
433.21 433.31 433.81 433.91
434.01 434.11 434.91 435.1 435.2
435.3 435.8 435.9 436 437.1 437.9
438.11 438.12 438.13 438.14
438.19 438.21 438.22 438.31
438.32 438.41 438.42 438.51
438.52 438.53 438.6 438.7 438.81
438.82 438.83 438.84 438.85
438.89 438.9
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438.0 Late effects of
cerebrovascular disease,
cognitive deficits
438.1 Speech and language
deficits
438.2 Hemiplegia/hemiparesis
438.3 Monoplegia of upper limb
438.4 Monoplegia of lower limb
438.5 Other paralytic syndrome
438.6 Late effects of
cerebrovascular disease,
alterations of sensations
438.7 Late effects of
cerebrovascular disease,
disturbances of vision
438.8 Other late effects of
cerebrovascular disease
438.9 Unspecified late effects
of cerebrovascular disease
Gastrointestinal Hemorrhage
578 Gastrointestinal hemorrhage
578.9 Hemorrhage of
gastrointestinal tract,
unspecified
Hemorrhage in Head and Neck
784 Symptoms involving head
and neck
784.7 Epistaxis
784.8 Hemorrhage from throat
Hemorrhage in Respiratory
System
786 Symptoms involving
respiratory system and other
chest symptoms
786.3 Hemoptysis
Phlebitis and Thrombophlebitis
451 Phlebitis and
thrombophlebitis
451.1 Phlebitis and
thrombophlebitis of deep veins
of lower extremities
451.2 Phlebitis and
thrombophlebitis of lower
extremities, unspecified
451.8 Phlebitis and
thrombophlebitis of other sites
451.9 Phlebitis and
thrombophlebitis of unspecified
site
452 Portal vein thrombosis

578.9

784.7 784.8

786.3

451.11 451.19 451.2 451.81 451.82
451.83 451.84 451.89 451.9 453.1
453.2 453.3 453.41 453.42 453.51
453.52 453.6 453.71 453.72 453.73
453.74 453.75 453.76 453.77
453.79 453.8 453.81 453.82 453.83
453.84 453.85 453.86 453.87
453.89 453.9

166

453 Other venous embolism and
thrombosis
453.1 Thrombophlebitis
migrans
453.2 Other venous embolism
and thrombosis of inferior vena
cava
453.3 Other venous embolism
and thrombosis of renal vein
453.4 Acute venous embolism
and thrombosis of deep vessels
of lower extremity
453.5 Chronic venous
embolism and thrombosis of
deep vessels of lower extremity
453.6 Venous embolism and
thrombosis of superficial
vessels of lower extremity
453.7 Chronic venous
embolism and thrombosis of
other specified vessels
453.8 Acute venous embolism
and thrombosis of other
specified veins
453.9 Other venous embolism
and thrombosis of unspecified
site
454 Varicose veins of lower
extremities
455 Hemorrhoids
456 Varicose veins of other sites
457 Noninfectious disorders of
lymphatic channels
458 Hypotension
459 Other disorders of circulatory
system
459.1 Postphlebitic syndrome
459.3 Chronic venous
hypertension (idiopathic)
459.8 Other specified disorders
of circulatory system
459.9 Unspecified circulatory
system disorder
About 1/3 (37.46%) of the AHC Base Database’s subjects had comorbidity
records. On average within the subjects with comorbidity records, each
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subject had 1.61 comorbidity record (range 1-13). The following table (Table
14.15) depicts the distribution of number of comorbidity records per subject.
Table 4.15. Distribution of number of comorbidity records among the subjects
with comorbidity records.
Number of Comorbidity
Records/Subject
1
2
3
4
5
6
7
8
9
10
11
12
13
Total

Number of Subjects (%)
36118(61.22)
14739(24.98)
5188(8.79)
1851(3.13)
685(1.16)
254(0.43)
109(<0.001)
29(<0.001)
7(<0.001)
2(<0.001)
4(<0.001)
1(<0.001)
1(<0.001)
58988(100%)

18.36% of the comorbidity records were reported before patients’ first
prescription start date of an anticoagulation medication at AHC. The
distribution of the reported days of comorbidities are depicted in table 4.16.
Table 4.16. Distribution of day numbers in which the comorbidities were
recorded before or after patients’ start date of anticoagulation therapy.
Recorded Day of Comorbidity
Within 12 weeks before the start date
Within 4 weeks before the start date
Within 1 week before the start date
On the start date
Within 1 week after the start date
Within 4 weeks after the start date
Within 12 weeks after the start date

Number of Comorbidity Records
(%)
7697(8.13)
6588(6.95)
5215(5.50)
13971(14.75)
20553(21.71)
26782(28.29)
32354(34.17)
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Having compared the records of tables “indication” and “comorbidity”, it was
revealed that 69.26% of the comorbidity records were shared with indication
records. Given this fact, the two quality controlled and cleaned tables were
merged to create a new table called “morbidity”. Each record of this new table
has attributes {SURROGATE_ID, DAY, CODE, SOURCE_SYSTEM}. About
2/3 (65.68%) of the AHC Base Database’s subjects had morbidity records. On
average within the subjects with morbidity records, each subject had 1.71
morbidity records (range 1-13). Table 4.17 depicts the distribution of number
of morbidity records per subject.
Table 4.17. Distribution of number of morbidity records among the subjects
with morbidity records.
Number of Morbidity
Records/Subject
1
2
3
4
5
6
7
8
9
10
11
12
13
Total

Number of Subjects (%)
57116(55.22)
29131(28.16)
11346(10.97)
3756(3.63)
1326(1.28)
468(0.45)
181(0.17)
68(<0.001)
10(<0.001)
3(<0.001)
8(<0.001)
2(<0.001)
1(<0.001)
103416(100%)

38.55% of the morbidity records were reported before patients’ first
prescription start date of an anticoagulation medication at AHC. The
distribution of the reported days of morbidities are depicted in table 4.18.
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Table 4.18. Distribution of day numbers in which the morbidities were
recorded before or after patients’ start date of anticoagulation therapy.
Recorded Day of Morbidity
Within 12 weeks before the start date
Within 4 weeks before the start date
Within 1 week before the start date
On the start date
Within 1 week after the start date
Within 4 weeks after the start date
Within 12 weeks after the start date

Number of Morbidity Records (%)
16430(15.88)
14191(13.72)
11340(10.96)
29200(28.23)
37351(36.11)
44180(42.72)
55412(53.58)

- Interacting Medications: In the AHC Base Database’s table
“interacting_medication”, each subject has multiple medication records. Each
interacting medication record contained the attributes {SURROGATE ID,
DAY, MEDICATION_NAME, FREQ, DOSE_QTY, DOSE_QTY_UNIT,
SOURCE_SYSTEM}. In the table, the entire columns of {DOSE_QTY,
DOSE_QTY_UNIT} were completely blank. The column {FREQ} was partially
complete. The cells under column {MEDICATION_NAME} were populated
with free-text. Before conducting any cleaning or quality control measures, we
had to extract information from the free-text in cells under column
{MEDICATION_NAME} and translate them into a structured format. Through
a text analysis step, the required data from the free text were extracted and
presented in normalized and consistent structured formats. We used a
multistep process which involved parsing the free texts into their components,
normalizing the identified components, and extraction of the required data
elements (i.e., name of medication, dosage, unit, and route of administration).
The rate of incompleteness of the resulted records was high. Table 4.19
depicts the distribution of interacting medication records by each medication
in the cleaned and controlled interacting_medication table and also presents
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an example of the rate of completeness (i.e., percentage of each interacting
medication’s records with dosage information).
99.02% of the interacting medications records included one of the three
medications of warfarin (37.85%), heparin (36.24%) and clopidogrel (24.93%).
Warfarin records which have dosage information have the highest percentage
of whole the records (11%). Although the number of heparin records was
higher than the number of clopidogrel records, the percentage of clopidogrel
records with dosage information out of whole the records was higher than that
of heparin.
Table 4.19. Distribution of number of subjects under each interacting
medication and the rate of medication records’ dosage information
completeness.
Interacting
Medication

Number of Subjects
under Interacting
Medication

Rate of the Records’
Dosage Information
Completeness

Amiodarone

74,102

70.03%

Simvastatin

71,537

33.4%

Fluvastatin

61,517

68.03%

Lovastatin

1,793

89.18%

Atrovastatin

2,292

22.9%

Rosuvastatin

2886

71.58%

Pravastatin

434

73.5%

Aspirin

1,310

90.15%

The above table indicates that a big number of subjects have received more
than one medication. The following table (Table 4.20) shows the number of
subjects who have been under treatment with 1 to 6 medications.
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Table 4.20. Distribution of subjects by number of medications.
No. of Medications
No of Subjects

1
75282

2
16441

3
3049

4
358

5
20

6
1

- INR: In the AHC Base Database, each subject has longitudinal INR records
with multiple INR records for each measurement day which were not on a
regular basis. Each INR record contained the attributes {"SURROGATE_ID",
"EFFECTIVE_DAY", "LAB_DESCRIPTION", "LAB_VALUE",
"SOURCE_SYSTEM"}. Since INR measurement can vary within a specific
time frame due to factors such as different measurement methods (e.g.,
medical laboratory testing, point-of-care testing, patient self-testing), we
created a cleaning algorithm for INR records. Before applying the algorithm,
first, each INR record was examined to identify and exclude any INR record
whose INR lab value was missing. Then the INR cleaning algorithm was
applied (Figure 4.6).

Figure 4.6. INR records cleaning algorithm.
According to the algorithm, we first removed all INR values we considered
technically not acceptable according to the AHC’s laboratory guidelines (i.e.,
0.9 > INRs > 10). Then we took the next steps of the algorithm. If all INR
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records for a single subject in a single day differed (i.e., difference between
minimum INR and maximum INR for the same day) by less than acceptable
measurement variance of 0.5 INR-units (Rasmussen, 2012), then all INR
records for that subject for that day were marked acceptable by the algorithm
and the mean of the INR records was calculated representing INR value for
the day. For all other days, median INR for each day was calculated. The rate
of INR record completeness for the AHC Base Database is 77.03%. The
subjects with INR records had 19.17 INR records on average.

4.2.2.) WiAD Database and Data Load
The next step in the process of developing a research anticoagulation
database was to load the quality controlled and transformed data into a
working database now called "WiAD" standing for "Wisconsin
Anticoagulation/Anti-clotting Database". The database was implemented in a
MySQL Server and i2b2. Two specifics tasks were undertaken in this process:
designing data models consistent with the research needs and also making
some vocabularies and ontologies across the data models to make sure that
the queries run against the implemented databases would consistently return
the data meeting the research oriented criteria.

4.2.2.1.) MySQL Database
WiAD was implemented in MySQL Server as one of its database
management systems. The database could be queried directly through the
MySQL server or it could be done using a tool called WiAD-Miner (explained
in section 4.3.4). The data model of WiAD on the MySQL server is depicted in
Figure 4.7. In this star schema, table “patients” is the core table which
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basically stores non-longitudinal attributes of the subjects (e.g., Gender, Age,
and Race). The other tables store the subjects’ longitudinal attributes.

Figure 4.7. Entity Relationship (ER) Model of the WiAD’s MySQL Database.

4.2.2.2.) i2b2 Database
Our anticoagulation/anticlotting research database “WiAD” was also
implemented in i2b2. The data model provided in the i2b2 database is called
“star schema” where tables are connected as a star. Figure 4.8 shows the star
schema consisting of Observation Fact surrounded by Patient Dimension,
Visit Dimension, Concept Dimension, and Provider Dimension for the WiAD
database.
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In this schema, the Observation Fact table represents a patient object and

Figure 4.8. WiAD's i2b2 Data Model.
other four dimensions represent its attributes such as who (patient
information), when (dates), what (ontology for clinical patients' data) and
where (hospital or treatment facility), respectively.
Table 4.21. Definitions of the concepts of the WiAD’s i2b2 data model.
Concept
surrogate_id
encounter_num
concept_cd
provider_id
day
concept_path
concept_id
concept_name
location

Definition
Patient unique identification number
Patient visit number (surrogate_id + day)
Code for observation of interest (i.e., morbidity,
medications, lab test)
Provider unique identification number
Starting date-time of observation (i.e. “DAY”)
Ontology path for concepts
Unique identification number for concepts
Actual name of the concept
Zipcode of the provider
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In i2b2, ontology represents a data model of a target domain. Ontology is
stored in Concept Dimension table, which contains a symbolic name of an
individual attribute (Concept ID) and a path from a root of ontology to an
individual attribute (Concept Path). Every attribute is allowed to have only one
conceptual path, so that ontology in the i2b2 includes no multiple inheritance.
The following table provides definitions for some of the specific concepts of
the WiAD’s i2b2 data model.
The following table (Table 4.22) details the WiAD’s i2b2 ontology.
Table 4.22. Hierarchical structure of the WiAD’s i2b2 ontology.
Demographics
Demographics\Age\
Demographics\Gender\
Demographics\Gender\Female\
Demographics\Gender\Male\
Demographics\Height\
Demographics\Patient Zipcode\
Demographics\Provider Zipcode\
Demographics\Race\
Demographics\Race\African American\
Demographics\Race\American Indian or Alaskan Native\
Demographics\Race\Asian\
Demographics\Race\Hispanic\
Demographics\Race\Not Asked\
Demographics\Race\Null\
Demographics\Race\Other\
Demographics\Race\Pacific Islander\
Demographics\Race\Unknown\
Demographics\Race\White\
Demographics\Tobacco Use\
Demographics\Weight\
Morbidity
Morbidity\Diagnosis\
Morbidity\Diagnosis\Atherosclerosis of Aorta\
Morbidity\Diagnosis\Atrial Fibrillation\
Morbidity\Diagnosis\Atrial Flutter\
Morbidity\Diagnosis\Bleeding\
Morbidity\Diagnosis\Coronary Artery Disease\
Morbidity\Diagnosis\Deep Vein Thrombosis\
Morbidity\Diagnosis\Diabetes Mellitus\
Morbidity\Diagnosis\Heart Failure\
Morbidity\Diagnosis\Hypertension\
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Morbidity\Diagnosis\Myocardial Infarction\
Morbidity\Diagnosis\Peripheral Artery Diseases\
Morbidity\Diagnosis\Pulmonary Embolism\
Morbidity\Diagnosis\Stroke\
Morbidity\Procedure\
Morbidity\Procedure\Heart Valve Replacement\
Morbidity\Diagnosis\Orthopedic Procedures\
Medications
Medications\Anticoagulation Agent\Abciximab
Medications\Anticoagulation Agent\Clopidogrel\
Medications\Anticoagulation Agent\Dabigatran\
Medications\Anticoagulation Agent\Dipyridamole\
Medications\Anticoagulation Agent\Eptifibatide\
Medications\Anticoagulation Agent\Heparin\
Medications\Anticoagulation Agent\Ticlopidine\
Medications\Anticoagulation Agent\Tirofiban\
Medications\Anticoagulation Agent\Warfarin\
Medications\Interacting Medication\Amiodarone\
Medications\Interacting Medication\Aspirin\
Medications\Interacting Medication\Atrovastatin\
Medications\Interacting Medication\Fluvastatin\
Medications\Interacting Medication\Lovastatin\
Medications\Interacting Medication\Pravastatin\
Medications\Interacting Medication\Rosuvastatin\
Medications\Interacting Medication\Simvastatin\
Lab Test
Labe Test\INR\

4.2.2.3.) Ontology issues
Usually in clinical datasets, there exist different data types in data which can
each be supported by a separate dictionary such as the ones we have
developed for the AHC dataset. The advantage of using ontologies and
dictionaries is that they help standardize raw data and also add logical
hierarchical structure. In the case of i2b2, these are essential component of its
ontology too. In the ideal situation and with the aim of interoperability, the data
are mapped to reference standard dictionaries and ontologies. With the use of
reference standard dictionaries and ontologies (e.g., Drug Bank), we could
subgroup data types then support data elements across all data sources.
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Even though there are different reference dictionaries and ontologies to use
for normalizing and standardizing data (e.g., ICD-9, CPT, LOINC, NDC), the
standard ontologies used are largely based on the data available. For the
AHC dataset, our diagnosis data are coded in ICD-9, so that is the hierarchy
we use in our ontology. The same holds true for procedures. With our
medication and laboratory data, it is not coded in terminology with a standard
hierarchy, so we had to organize the data using other locally developed
dictionaries.

4.2.3.) Data Analysis Methods and Tools
As introduced, WiAD is a longitudinal database which includes subjects’
characteristics, treatment plans and outcomes that have been at multiple
follow-up times. A longitudinal database generally provides multiple or
repeated measurements and records on each subject. Accordingly and given
that such repeated measurements and records are correlated within subjects,
there are needs for special analysis and inference techniques for a
longitudinal dataset. Although longitudinal data are very beneficial but there
challenges in using such data which in some cases are not without cost.
There are several challenges posed (Heagerty, 2014):
- Participants follow-up. There is always the possibility of bias as the
retrospective longitudinal EMR data might include the data of subjects who
might have incomplete follow-up or drop-out during their treatment periods.
Accordingly, the analysis of such data requires special attention to make sure
that the extracted subset of the data meets the assumptions of the study that
it is going to be used for.
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- Analysis of correlated data. Given the nature of the longitudinal of EMR data,
we need to use statistical methods that can account for the intra-attributes
and /or intra-subjects correlations.
- Time-varying covariates. Although longitudinal data provide the opportunity
to study the association between the changes in one subject’s attribute by
changes in other attributes or outcome of interest, the direction of causality
can be complicated by feedback between the attributes.
In the following section, some of the aspects of the longitudinal WiAD data is
presented.

4.2.3.1.) Landscape of the WiAD Data
In the previous sections, it was explained the methods that we have applied to
clean and quality control some of the longitudinal aspects of the WiAD data.
However, there are some aspects of the data that should be managed and
adjusted based on each study’s goals and design. For instance, one of the
potential cross-attribute studies in the WiAD could be to study the correlation
between the changes in warfarin doses and the subjects’ INR values.

Figure 4.9.Warfarin dose changes versus INR values changes for two
WiAD’s subjects.
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However, the fact is that longitudinal data patterns for these attributes are
very complex and affected by different factors so that it requires applying
some specific methods to extract the data records which are appropriate for
such a study. Figure 4.9 demonstrates the warfarin recorded doses versus
INR recorded values for two different WiAD’s subjects.
Taking into consideration that INR is used to monitor different anticoagulation
agents and also the fact that a given patient under anticoagulaton therapy
might receive different types of anticoagulation agents during his/her
treatment period depending on his/her treatment condition (e.g., ambulatory,
in-patient care or surgical procedure), it is important to find the desired
warfarin exposure periods in the EMR data and extract the associated data.
Given this complexity, we have developed some algorithms which help extract
data from WiAD based on desired longitudinal patterns such as treatment
periods (e.g. fixed time or medical procedure periods), treatment indications
which require different target therapeutic INR ranges, and interval and
frequency between successive observed dose records or INR values. These
features have been implemented in WiAD-Miner explained in the next section.

4.2.3.2.) WiAD-Miner
An interactive data profiling and population "segmentation" tool for WiAD
(WiAD-Miner) has been developed in R (R Core Team, 2014) using RStudio
(RStudio, 2014). WiAD-Miner (Figure 4.10) which also has a web application
version includes all the profiling, outcome metric, and related data analysis
functions for anticoagulation agents. WiAD-Miner includes a cohort selection
tool to profile and identify patient subpopulations by any or a combination of
patients' characteristics including gender, age group, race, patient's residence
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zipcode, provider's zipcode, medication, medication exposure, duration of
treatment, number of dose records, frequency of INR values, medication
indication, and comorbidities. WiAD-Miner presents a clear view of each

Figure 4.10. A screenshot of the WiAD-Miner’s interface.
extracted subset by producing statistical characteristics and visual profiling
and allows adjustment of various parameters such as the medication
exposure period definition, triggering a re-profiling and thereafter, recalculation of outcome metrics.

4.2.4.) Estimating Parameters for PK/PD
Our in silico simulation model takes advantage of Hamberg's PK/PD model
(Hamberg, 2007) for individualization of warfarin therapy. As introduced in
Chapter 3, Hamberg et al. have characterized the relationship between
warfarin dose and international normalized ratio (INR) response and they
have identified CYP2C9 genotype and age as predictors for S-warfarin
clearance, and VKORC1 genotype as a predictor for warfarin sensitivity. Our
in silico platform is able to take advantage of domain knowledge and integrate
population characteristics such as genotype distributions if they are not
provided for the study populations. Accordingly and given that WiAD originally
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did not include genotype information, we have derived distribution of required
genotypes for our study populations from some studies such as the one
conducted by Scott (2010). A recent study by Scott (2010) has provided the
allele frequencies of some of the principal genes known to influence
interindividual warfarin dose variability (e.g., CYP2C9 and VKORC1) in
African-American, Asian and White populations. We have used these
information to impose population genotype distribution information into our in
silico platform. Table 4.23 summarizes the CYP2C9 allele and genotype
frequencies.
Table 4.23. CYP2C9 Genotype Frequencies (Scott, 2010).
CYP2C9
African-American
Extensive Metabolizer
*1/*1
75.5
Intermediate Metabolizer
*1/*2
4.3
*1/*3
3.3
*1/*5
2.7
*1/*6
1.7
*1/*8
8.7
*1/*11
2
Poor Metabolizer
*2/*2
*2/*3
*2/*8
*3/*3
*3/*5
*3/*8
*3/*11
*5/*6
*8/*11

0.3
0.3
0
0
0
0
0.3
0.3
0.3

Asian

White

86.3

66

3.9
6.9
0
0
1
0

15.1
9.4
0
0
0
0.9

1
0
0
0
0
1
0
0
0

6.6
1.9
0
0
0
0
0
0
0
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Table 4.24 demonstrates the VKORC1G 1639G>A allele frequencies.
Table 4.24. VKORC1 Genotype Frequencies (Scott, 2010).
VKORC1

African-American

Asian

1639G>A

(%)

(%)

White
(%)

G/G
G/A
A/A

80.3
17.7
2

22.5
21.6
55.9

36.8
45.3
17.9

Table 4.25 summarizes the combined CYP2C9 and VKORC1 genotype
frequencies for some of the study populations such as African-American,
Asian and White. As depicted in the table, a majority of White and Asian
individuals carry a variant of CYP2C9 and VKORC1 compared with AfricanAmerican.
Table 4.25. Combined CYP2C9 and VKORC1 Genotype Frequencies (Scott,
2010).
CYP2C9
Extensive
Metabolizer
Intermediate
Metabolizer
Poor
Metabolizer

VKORC1

African-American

Asian

1639G>A

(%)

(%)

(%)

G/G
G/A
A/A
G/G
G/A
A/A
G/G
G/A
A/A

63.4
0
1.4
20.3
2.9
0.7
0
0.4
0

20.6
0
55
7.9
3
1
2
0
0

41.5
0
13.3
10.3
10.4
4.7
4.7
3.7
0

White

4.3.) Results
This effort has resulted in an EMR-based longitudinal
anticoagulation/anticlotting database, WiAD, using Aurora Health Care’s
electronic medical records. This database is a seminal translational
anticoagulation research tool that support US-prioritized "Secondary Use" of
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electronic medical records to improve health care and comparative
effectiveness research studies. The database could be used to develop and
derive conditional parametric models for WiAD-based studies such as studies
that are presented in Chapters 5 and 6.

4.4.) Conclusion and Future Work
This effort has shown that EMR longitudinal data is a rich resource to develop
research-grade databases. Our effort is aligned with current national
developments such as PCORnet aiming to leverage the secondary use of
EMR data for research purposes. As presented in the next chapters, WiAD
database has significant potential for comparative effectiveness research and
conducting patient-centered outcomes research. In future, we plan to improve
the database by including more cardiovascular associated patient
characteristics and also embedding more robust data transforming and
extraction algorithms.
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5.1.) Introduction
We have developed an in silico pharmacogenetic PC-CER framework for
anticoagulation therapy. The framework includes options to simulate patient
populations ("Clinical Avatars"), multiple initial dosing protocols including PGbased and non PG-based, multiple dose adjustment and maintenance
protocols, PK/PD modeling and prediction of various types of outcome
measures. We have validated the framework against two major warfarin
clinical trials, CoumaGen-I and CoumaGen-II (Anderson, 2007a, 2012b).
Then, we have used our highly adaptable in silico framework to conduct 90day anticoagulation therapy simulations for the Aurora Heath Care (AHC)
state-wide warfarin patient population using a collection of warfarin dosing
protocols to study comparative effectiveness and to identify different optimal
protocols depending on subpopulations defined by patient characteristics.

5.2.) CoumaGen-I Clinical Trial Simulation
5.2.1.) Background and Objective
The details of this study were published by Fusaro (2013) in the journal
Circulation. In this study, the accuracy of the clinical trial simulator of our in
silico PC-CER framework was demonstrated by reproducing the CoumaGen-I
clinical trial outcomes (“CoumaGen-I Simulation 1”), and then the simulator
was used to evaluate a new dosing protocol (“CoumaGen-I Simulation 2”), to
determine whether this new study design was significantly more beneficial for
the same population.
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5.2.2.) Methods
5.2.2.1) Study Design
- The original study. The original CoumaGen-I clinical trial study (Anderson,
2007) was designed as a prospective, randomized study comparing PGbased and standard empirical dosing in patients being initiated on oral
anticoagulation. The study objectives were prospectively to validate a PGbased dosing algorithm (Anderson, 2007) and to assess its impact on INRbased efficacy and safety end points.
In the original study, the inclusion criteria to recruit subjects were as follows:

Figure 5.1. Study design for the original CoumaGen-I clinical trial. PG:
Pharmacogenetic arm, STD: Standard arm.
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age ≥18 years and an indication for anticoagulation with a target INR of 2 to 3.
And the subjects with the following characteristics were excluded: women who
were pregnant, lactating, or of child-bearing potential, those taking rifampin
within 3 weeks, or patients with comorbidities precluding standard dosing
(e.g., advanced physiological age, renal insufficiency/creatinine >2.5 mg/dL,
hepatic insufficiency, terminal disease). Then, the 200 qualified subjects
underwent blind randomization to the pharmacogenetic (PG) or standard
(STD) arm. The study recruited 101 patients into the PG arm and 99 patients
into the standard clinical STD arm. Figure 5.1 illustrates the study design of
the original clinical trial.
- The simulation study. In this study, the two following simulations were
designed and conducted: “CoumaGen-I Simulation 1” and “CoumaGen-I
Simulation 2”. For each of these, with the use of a Bayesian Network Model
(BNM), a sufficient number of clinical avatars (n=200000) was created to
conduct 1000 simulations. For each of the 1000 simulations, 101 avatars for
the PG arm and 99 for the STD arm were randomly recruited from this large
clinical avatar population. Then, following the specific dosing protocol for each
arm explained in the following sections, daily dose and INR for each avatar for
that arm for 90 days were predicted.
CoumaGen-I Simulation 1 followed the dosing protocol as specified in the
original CoumaGen-I clinical trial (Anderson, 2007; Figure 5.1). The standard
arm dosing followed the 10-mg warfarin nomogram from Kovacs (2003) for
days 1 and 2 followed by dose adjustment based on INR according to the
Kovacs (2003) protocol for days 3 to 7. For days 8 to 90, CoumaGen-I used
the Intermountain Healthcare warfarin dosing algorithm. The CoumaGen-I
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pharmacogenetic arm dosing followed a dosing algorithm which required both
clinical and genotype (i.e., CYP2C9 and VKORC1) information to calculate
doses for days 1 and 2. Like the original study, the initial doses were followed
by a dose adjustment based on INR by multiplying standard arm changes by
a pharmacogenetic algorithm coefficient for days 3 to 7. The pharmacogenetic
algorithm coefficient was defined as the ratio of the estimated individual
weekly dose determined by the pharmacogenetic algorithm to the standard
weekly dose of 35 mg. For days 8 to 90, CoumaGen-I used the Intermountain
Healthcare warfarin dosing protocol.
A. CoumaGen-I Simulation 1

B. CoumaGen-I Simulation 2

Figure 5.2. The study design of the CoumaGen-I Simulation 1 and 2.
Black text represents new features compared to the original
CoumaGen-I study, whereas gray text represents those features in
common with the original study as depicted in Figure 5.1. PG:
Pharmacogenetic arm, STD: Standard arm.
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The design of the CoumaGen-I Simulation 2 was different from the original
clinical trial. It was conducted using a third dosing protocol (nomogram)
offered by Wilson (2007). In this study, the same starting doses were used for
days 1 to 2 as in the original CoumaGen-I trial, 10-mg/d for the standard arm
and 2 times the pharmacogenetic dose for the pharmacogenetic arm. For
days 3 to 90, the Wilson protocol was used to increase or decrease the dose
proportionally based on low or high INR values, respectively. The following
figure (Figure 5.2) illustrates the design of the two simulation studies.

5.2.2.2) Clinical Avatar Populations
With regard to the BNM used for creating clinical avatars in this study, some
consideration were made as the original CoumaGen-I’s individual patients’
information were not available. Taking into consideration the subjects’
characteristics required for the dosing algorithms used in this study, the prior
probabilities used for the study’s BNM were based on the statistical
characterization of the patient population including age, sex, weight, height,
race, body surface area (calculated from height and weight), smoking status,
deep vein thrombosis status, amiodarone use status, and genotypes for
CYP2C9*2, CYP2C*3, and VKORC1. The CoumaGen-I trial data used age,
sex, weight, height, deep vein thrombosis, smoking status, and genotypes as
their variables. In the simulation study, some other required prior probabilities
(e.g., amiodarone status) for the BNM were estimated by using data from the
Centers for Disease Control and Prevention and the 2000 US Census. The
extracted prior probabilities were mostly for whites as about 95% of the
original CoumaGen-I trial’s subjects were white.
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Another challenge in developing a BNM for this study which helped produce
physiologically realistic clinical avatars was the lack of joint conditional
probability distributions for the characteristics. To deal with this case, some
external data and information sources were used such as the US Census
2007 to 2008 Table 209 (http://www.
census.gov/compendia/statab/2012/tables/12s0210.pdf) which details height
and weight distributions as functions of age and sex. The extracted normal
distributions from the above sources were transformed to match the actual
population in the CoumaGen-I trial. For instance, the distributions for subjects
40 to 49, 50 to 59, and 60 to 69 years of age were z-transformed and scaled
according to the mean and standard deviation for the CoumaGen-I trial
pharmacogenetic and standard arms, respectively. For use in the BNM, then
a dependency table by sampling from these distributions and calculating the
percentages for each age/sex group was developed. The BNM was
implemented in TETRAD IV (Scheines, 1998) to produce the clinical avatar
populations for the both Simulations 1 and 2.

5.2.2.3.) Measuring Outcome Metrics
The primary outcome metric was Percent Time INR in Therapeutic Range
(“TTR”). Consistent with the original CoumaGen-I study, TTR was defined as
the percentage of time an individual avatar had an INR between 1.8 and 3.2
during the 90-day simulation. Although our simulator could calculate daily INR
values, only INRs on those days in which the INR would have been checked
in the clinic according to the specific protocol were considered.
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5.2.2.4.) Clinical Trial Simulations
As stated in previous sections, in the original CoumaGen-I randomized
controlled trial, the 200 subjects were randomly assigned to two PG (n=101)
and STD (n=99) arms. Accordingly, in the Simulation 1 and 2 studies, the
200,000 clinical avatars were also randomly sampled to recruit 101 and 99
avatars for the PG and the STD simulation arms. The number of created
avatars provided the opportunity to create 1000 parallel arms for simulations.
Then daily dose and INR for each avatar were predicted following a specific
protocol for that arm for 90 days. The predicted doses, INR, INR-monitoring
frequency, and population statistics for each clinical trial simulation and
across all 1000 simulations were recorded to calculate and produce the mean,
standard deviation, and probability value (unpaired t test) for TTR for each
study arm and for the aggregated populations from the 1000 clinical trial
simulations. The simulations produced predictions were then compared with
the CoumaGen-I results. The simulations were implemented in R (R Core
Team, 2013) and run on the affiliated institute’s high performance computing
environment.

5.2.3.) Results
Developing a BNM and then generating clinical avatars were one of the first
steps taken in this study. Table 5.1 demonstrates the characteristics of the
clinical avatar populations generated for both PG and STD simulation arms
versus the characteristics of the PG and STD arms’ populations in the original
CoumaGen-I study.
A few tests were done to show that the clinical avatar populations generated
based on the BNM were statistically similar to the original CoumaGen-I
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population. As depicted in Table 5.1, the distribution of the characteristics
across the PG arms and STD arm are very comparable and statistical test
shows no significant difference (P >0.05). The variable dependency
embedded in the BNM of the populations were also tested to see if they also
persisted in the simulated clinical avatar populations. To do so, a log-linear
model was fitted to all relevant associations and probability values by using
the Pearson χ2 statistic were calculated. The test indicated that there were no
significant differences (P >0.05) between the dependencies in the clinical
avatar populations and the original CoumaGen-I populations (Table 5.1). In
addition, it was tested to make sure that the non-embedded dependencies in
the BNM did not exist in the clinical avatar populations.
Table 5.1. Characteristics of the subjects in the original CoumaGen-I study
versus that of Clinical Avatars generated for both PG and STD arms. DVT:
deep vein thrombosis; PG: pharmacogenetic arm, SD: standard deviation,
STD: standard clinical arm (Fusaro, 2013).

Characteristic
n
Age, y (mean)
Male, %
Weight, kg, mean±SD
DVT, %
White, %
CYP2C9*2, %
CC
CT
TT
CYP2C9*3, %
AA
AC
CC
VKORC1 1173, %
G/G
G/A
A/A

CoumaGen-I Original
Clinical Avatars
PG Arm
STD Arm
PG Arm
STD Arm
101
99
101
99
63.2
58.9
62.5
58.3
49.5
56.6
51.3
55.1
92.1±24.6 94.7±24.2 89.8±24.3 91.9±24.3
18.8
28.3
18.6
28.6
94.1
94.9
94
95
82
18
0

76.5
23.5
0

82.2
17.8
0

76.7
23.3
0

89
10
1

87.6
11.3
1

88.9
10.2
1

87.9
11.1
1

50.5
35.4
14.1

34.7
50
15.3

50.5
35.6
13.9

34.6
50.2
15.2
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The accuracy of the clinical trial simulator of our in silico PC-CER framework
was validated by simulating the original CoumaGen-I clinical trial through
conducting CoumaGen-I Simulation 1 (Figure 5.1 and 5.2A).
The CoumaGen-I Simulation 1 reproduced the primary TTR outcome of the
original CoumaGen-I trial (Table 5.2). It predicted a mean TTR of 70.5% and
72.0% in the STD and PG arms, respectively. Similar to the original
CoumaGen-I trial, the difference between the mean TTRs was not significant
(P >0.05). The results of the CoumaGen-I Simulation 1 showed no statistical
difference between predicted and actual TTRs for CYP2C9 extensive
metabolizer, intermediate metabolizer, and poor metabolizer subsets (P
>0.05). Although the original CoumaGen-I showed a significant 9.8%
reduction in out-of-range INRs for the wild type and multiple variants subgroup
in the PG arm, CoumaGen-I Simulation 1 indicated a nonsignificant 2.7%
reduction in out-of-range INRs for the similar groups.
Through the second simulation, CoumaGen-I Simulation 2, it was tested if a
modification to PG and STD arms of the original CoumaGen-I dosing
algorithms would result in a significant change in outcomes of the two arms.
As depicted in Figure 5.2B, all model and simulation components of the
CoumaGen-I Simulation 1 (i.e., clinical avatars, initial dosing, PK/PD
parameters, and TTR outcome calculations) remained the same with the
exception of the replacement of part of the original CoumaGen-I dosing
protocol with the Wilson protocol (Wilson, 2007) for days 3 to 90. The
simulation, CoumaGen-I Simulation 2, was run and the outcome metrics were
calculated as in the Simulation 1 (Table 5.2).
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Table 5.2. Percent Time INR in Therapeutic Range (TTR) for some
subpopulations in 1000 simulated trials of CoumaGen-I Simulations 1 and 2.
Subpopulation
All Avatars, %, mean±SD
CYP2C9, %, mean±SD
Extensive Metabolizer
Intermediate Metabolizer
Poor Metabolizer

CoumaGen-I Simulation 1
PG Arm
STD Arm
72±26.6
70.5±26.8
76±23.6
72.4±26
65.6±29.9

73.6±21.8
72.4±26.2
65.9±29.6

CoumaGen-I Simulation 2
PG Arm
STD Arm
78.8±11.9
73.7±13.6
85.6±10.2
76.9±10.4
71.7±11.2

85.6±9.9
75.4±10
63.2±12.1

The mean TTR for the PG arm was significantly higher than the STD arm in
the CoumaGen-I Simulation 2 (78.8% versus 73.7%; P< 0.05, respectively),
demonstrating that the Wilson protocol, which adjusts dose based on
percentage change, predicted better management of the clinical avatars and
was able to achieve a stable TTR for a longer period of time.
The CoumaGen-I Simulation 2 PG protocol resulted in a higher mean TTR
across all the genotype subsets than the corresponding CoumaGen-I
Simulation 1 PG protocol (Table 5.2). For all patients, the difference between
the STD arms in the CoumaGen-I Simulation 1 and 2 was 3.1%, indicating
similar TTR results despite different protocols. Conversely, the difference in
TTR for the PG arm was 6.8% higher, indicating that the Wilson protocol was
more accurate at maintaining a therapeutic dose within the 90-day clinical trial
time window. The CoumaGen-I Simulation 2 also exhibited a smaller TTR
standard deviation for each genotype subset than the CoumaGen-I Simulation
1, indicating that the INR range was better controlled by the use of the Wilson
protocol.

5.2.4.) Conclusion
This study showed that the clinical trial simulator was useful to study and
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evaluate anticoagulation therapy options and “provide evidence to optimize
the clinical trial for patient efficacy and reduced risk” (Fusaro, 2013).

5.3.) CoumaGen-II Clinical Trial Simulation
5.3.1.) Background and Objective
In this study, the accuracy of the clinical trial simulator of our in silico PC-CER
framework was re-examined again by reproducing the CoumaGen-II clinical
trial outcomes (“CoumaGen-II Simulation 1”), and then the simulator was used
to evaluate a new dosing protocol (“CoumaGen-II Simulation 2”), to determine
whether this new study design was significantly more beneficial for the same
population.

5.3.2.) Methods
5.3.2.1) Study Design
- The original study. The original CoumaGen-II clinical trial (Anderson, 2012)
comprised 2 prospective clinical trial comparisons: (1) a blinded, randomized
comparison of 2 refined PG warfarin dosing algorithms and (2) a clinical
effectiveness comparison of PG-guided therapy with use of either PG
algorithm with a parallel, standard (STD) dosing (Figure 5.3). The primary end
points of interest were Percent Time INR in Therapeutic Range (TTR) and
also percentage of out-of-range (OOR) INRs during up to 90 day treatment
period. In the original study, the inclusion criteria to recruit subjects were as
follows: age ≥18 years, and an indication for initiation of warfarin
anticoagulation. And the subjects with the following characteristics were
excluded: women who were pregnant, lactating, or of child-bearing potential,
those taking rifampin within 3 weeks, or patients with comorbidities precluding
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standard dosing (e.g., creatinine >2.5, hepatic insufficiency, active
malignancy, advanced physiological age, expected survival <6 months);
noncompliance risk; and those deemed inappropriate for PG-guided dosing
for any other reason.
Based on power calculations, the minimum recruitment target for the
randomized, PG-guided comparison was set at 500 patients. All qualifying
parallel control patients were included, anticipated to number >=1000.
Eventually, 504 qualified subjects were recruited and underwent blind

Figure 5.3. Study design for the original CoumaGen-II clinical trial.
PG: Pharmacogenetic arm, STD: Standard arm.
randomization to two PG arms; PG-1 and PG-2. The subjects for the
standard-dosing arm were retrospectively identified by a query to the EMRs of
3 hospitals. Patients ≥18 years of age initiating warfarin therapy with a
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baseline and at least 1 follow-up INR level between days 3 and 14 were
selected. The query resulted in identification and extraction of EMR records of
1911 subjects for the STD arm. Figure 5.3 illustrates the study design of the
original clinical trial.
- The simulation study. In this study, the two following simulations were
designed and conducted: "CoumaGen-II Simulation 1" and "CoumaGen-II
Simulation 2". For each of these, with the use of a BNM method described in
section 5.2.1.1, a sufficient number of clinical avatars was created to conduct
1000 simulations for each of the three arms; PG-1 (n=257000), PG-2
(n=247000), and STD (n=1900000). For each of the 1000 simulations, 257
avatars for the PG-1 arm, 247 avatars for the PG-2 arm and 1099 avatars for
the STD arm were randomly recruited from their associated generated clinical
avatar populations. Then, following the specific dosing protocol for each arm
explained in the following sections, daily dose and INR for each avatar for that
arm for 90 days were predicted.
CoumaGen-II Simulation 1 followed the dosing protocol as specified in the
original CoumaGen-II clinical trial (Anderson, 2012; Figure 5.4). For the STD
arm, it was assumed that retrospectively selected subjects in the original
CoumaGen-II trial received warfarin standard initial dose of 5mg/day for days
1 and 2 and then the doses were adjusted using the same standard INRbased dose-modification algorithm developed and promoted by Intermountain.
The CoumaGen-II PG-1 and PG-2 arms used modified versions of the IWPC
(2009) dosing algorithm which required both clinical and genotype (i.e.,
CYP2C9 and VKORC1) information to calculate doses for days 1 and 2. Like
the original study, the initial doses were followed by (a) a dose adjustment
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algorithm based on INR according to the Kovacs (2003) protocol for days 3 to
7 for PG-1 arm and (b) a dose adjustment algorithm based on Lenzini (2010)
PG-based dosing algorithm for days 3 through 7 for PG-2 arm. For days 8 to
90 in both PG-1 and PG-2 arms, the Intermountain Healthcare warfarin dosing
protocol were used.

Figure 5.4. The study design of the CoumaGen-II Simulation 1. Black text
represents new features compared to the original CoumaGen-II study, whereas
gray text represents those features in common with the original study as
depicted in Figure 5.3. PG: Pharmacogenetic arm, STD: Standard arm.
The design of the CoumaGen-II Simulation 2 was different from the original
clinical trial. It was conducted using a third dosing protocol (nomogram)
offered by Wilson (2007). In this study, the same initial doses for days 1 to 2
and the same adjustment doses for days 3 through 7 were used as in the
original CoumaGen-II trial. For days 3 to 90, the Wilson protocol was used to
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increase or decrease the dose proportionally based on low or high INR
values, respectively. The following figure (Figure 5.5) illustrates the design of
the CoumaGen-II Simulation 2.

Figure 5.5. The study design of the CoumaGen-II Simulation 2. Black text
represents new features compared to the original CoumaGen-II study,
whereas gray text represents those features in common with the original study
as depicted in Figure 5.3. PG: Pharmacogenetic arm, STD: Standard arm.

5.3.2.2) Clinical Avatar Populations
Similar to CoumaGen-I clinical trial simulation study (Section 5.2), for the
BNM used for creating clinical avatars in this study, the same considerations
were made as the original CoumaGen-II’s individual patients’ information were
not available. Taking into consideration the subjects’ characteristics required
for the dosing algorithms used in this study, the prior probabilities used for the
study’s BNM were based on the statistical characterization of the patient

202

population including age, sex, weight, height, race, body surface area
(calculated from height and weight), smoking status, deep vein thrombosis
status, amiodarone use status, and genotypes for CYP2C9*2, CYP2C*3, and
VKORC1. The CoumaGen-II trial data used age, sex, weight, height, deep
vein thrombosis, smoking status, and genotypes as their variables.
In the simulation study, some other required prior probabilities (e.g.,
amiodarone status and genotype distributions) for the BNM were estimated by
using some sources such as data from the Centers for Disease Control and
Prevention, the 2000 US Census or some evidence on genotype distributions
used for STD arm clinical avatar populations (e.g., Scott, 2010). The other
details which were taken into for development of BNM in CoumaGen-I
simulation study were also applied to this study too. The BNM was
implemented in TETRAD IV (Scheines, 1998) to produce the clinical avatar
populations for the both Simulations 1 and 2.

5.3.2.3.) Measuring Outcome Metrics
The primary outcome metric was Percent Time INR in Therapeutic Range
(“TTR”) and Percent Out-Of-Range INR (“%OOR”). Consistent with the
original CoumaGen-|I study, TTR was defined as the percentage of time an
individual avatar had an INR between 1.8 and 3.2 during the 90-day
simulation. Although our simulator could calculate daily INR values, only INRs
on those days in which the INR would have been checked in the clinic
according to the specific protocol were considered.

5.3.2.4.) Clinical Trial Simulations
As stated in previous sections, in the original CoumaGen-II randomized
controlled trial, the 504 recruited subjects were randomly assigned to two PG
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arms; PG-1 (n=257) and PG-2 (n=247). In addition, in the original study, 1911
subjects were retrospectively recruited from the EMRs for the STD arm.
Accordingly, in the Simulation 1 and 2 studies, the three clinical avatar
populations were randomly sampled to recruit 257, 247 and 1911 avatars for
the PG-1, the PG-2 and the STD simulation arms. The number of created
avatars provided the opportunity to create 1000 parallel arms for simulations.
Then daily dose and INR for each avatar were predicted following a specific
protocol for that arm for 90 days. The predicted doses, INR, INR-monitoring
frequency, and population statistics for each clinical trial simulation and
across all 1000 simulations were recorded to calculate and produce the mean,
standard deviation, and probability value (unpaired t test) for TTR for each
study arm and for the aggregated populations from the 1000 clinical trial
simulations. The simulations produced predictions were then compared with
the CoumaGen-II results. The simulations were implemented in R (R Core
Team, 2013) and run on the University of Wisconsin-Milwaukee’s high
performance computing environment.

5.3.3.) Results
Table 5.3 demonstrates the characteristics of the clinical avatar populations
generated for PG and STD simulation arms along with the characteristics of
the PG and STD arms’ populations in the original CoumaGen-II study.
A few tests were done to show that the clinical avatar populations generated
based on the BNM were statistically similar to the original CoumaGen-II
population. As depicted in Table 5.3, the distribution of the characteristics
across the PG arms and STD arm are very comparable and statistical test
show no significant difference (P >0.05). The variable dependencies
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embedded in the BNM of the populations were also tested to see if they also
persisted in the simulated clinical avatar populations. To do so, a log-linear
model was fitted to all relevant associations and probability values by using
the Pearson χ2 statistic were calculated. The test indicated that there were no
significant differences (P >0.05) between the dependencies in the clinical
avatar populations and the original CoumaGen-II populations (Table 5.3). In
addition, it was tested to make sure that the non-embedded dependencies in
the BNM did not exist in the clinical avatar populations.
Table 5.3. Characteristics of the subjects in the original CoumaGen-II study
versus that of Clinical Avatars generated for PG and STD arms. DVT: deep
vein thrombosis; PG: pharmacogenetic arm, SD: standard deviation, STD:
standard clinical arm.

CoumaGen-II Original
Clinical Avatars
PG-1 Arm PG-2 Arm STD Arm PG-1 Arm PG-2 Arm STD Arm
n
257
247
1911
257
247
1911
Age, y (mean)
61.3
59.9
51.5
60.9
59.4
51.1
Male, %
46.3
47.6
48.5
46.9
48.3
49.1
Weight, kg, mean±SD 93.1±23.9 92.3±24.5 91.3±28 92.1±23.1 92.9±23.5 90.9±27.5
DVT, %
29.6
29.6
33.7
28.9
29.2
33.9
White, %
95.3
95.6
91.4
95.6
96.1
91.1
CYP2C9*2, %
CC
79
77.6
NA
79.5
77.2
78.3
CT
17.9
20.3
NA
17.7
20.9
19.1
TT
2.7
1.2
NA
2.8
1.9
2.6
CYP2C9*3, %
AA
86.3
86.1
NA
85.9
86.6
86.2
AC
13.3
13.1
NA
13.7
13.1
13.2
CC
0.4
0.8
NA
0.4
0.3
0.6
VKORC1, %
G/G
32
38.1
NA
31.5
38.8
35
G/A
49.6
47.5
NA
50.3
46.7
48.6
A/A
18.4
14.3
NA
18.2
14.5
16.4
Characteristic

The accuracy of the clinical trial simulator of our in silico PC-CER framework
was validated again by simulating the original CoumaGen-II clinical trial
through conducting CoumaGen-II Simulation 1 (Figure 5.3 and 5.4). Similar to

205

the results of the original CoumaGen-II, the CoumaGen-II Simulation 1 study
showed that the PG-2 dosing algorithm was noninferior compared with the
PG-1 dosing algorithm at 1 and 3 months (P >0.05, Table 5.4). It also verified
the same for %OOR INR at 1 and 3 months (P >0.05).
Through the second simulation, CoumaGen-II Simulation 2, it was tested if a
modification to PG and STD arms of the original CoumaGen-II dosing
algorithms would result in a significant change in outcomes of the three arms.
As depicted in Figure 5.5, all model and simulation components of the
CoumaGen-II Simulation 1 (i.e., clinical avatars, initial dosing, PK/PD
parameters, and TTR outcome calculations) remained the same with the
exception of the replacement of part of the original CoumaGen-II dosing
protocol with the Wilson protocol (Wilson, 2007) for days 8 to 90. The
simulation, CoumaGen-II Simulation 2, was run and the outcome metrics were
calculated as in the Simulation 1 (Table 5.4).
Table 5.4. Time INR in Therapeutic Range (%TTR) and Out-Of-Range INR
(%OOR) across the 1000 trials of CoumaGen-II Simulations 1 and 2.

Outcome Metric
TTR, %, mean±SD
1 month
TTR, %, mean±SD
3 months
OOR, %, mean±SD
1 month
OOR, %, mean±SD
3 months

CoumaGen-II Simulation 1
PG-1
PG-2
STD
Arm
Arm
Arm
64.6±
62.9±
41.5±
19.8
17.6
13.5
66.1±
64.5±
42.3±
18.5
19
13.8
35.4±
37.1±
58.5±
11.5
11.4
12.2
33.9±
35.5±
57.7±
10.3
10.7
11.1

CoumaGen-II Simulation 2
PG-1
PG-2
STD
Arm
Arm
Arm
68.2±
67.4±
55.1±
10.9
11.2
13.4
70.4±
69.4±
56.5±
9.3
10.1
11.8
31.8±
32.6±
44.9±
8.6
9.1
7.8
29.6±
30.6±
55.1±
6.4
7.9
7.8

The 1-month and 3-month mean TTRs for the PG-1 and PG-2 arms were
significantly higher than the STD arm in the CoumaGen-I Simulation 2 (70.4%
and 69.4% versus 73.7%; P< 0.05, respectively), demonstrating that the
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Wilson protocol, which adjusts dose based on percentage change, predicted
better management of the clinical avatars and was able to achieve a stable
TTR for a longer period of time.
The CoumaGen-II Simulation 2 PG protocols resulted in a higher mean TTR
across all the genotype subsets than the corresponding CoumaGen-II
Simulation 1 PG protocol. The CoumaGen-II Simulation 2 also exhibited a
smaller TTR standard deviation across all three arms than the CoumaGen-II
Simulation 1, indicating that the INR range was better controlled by the use of
the Wilson protocol.

5.3.4.) Conclusion
We have developed a pharmacogenetic clinical trial simulation framework for
warfarin dosing and validated the framework against the CoumaGen-II clinical
trial. We also demonstrated the utility of our framework by simulating the
same clinical trials with the use of a relatively more aggressive dosing
protocol and predict that the PG arms are likely to perform significantly better
than the STD arm. The framework provides an opportunity to assess
alternative strategies such as different dosing protocols, study population, or
outcome metrics before applying them in real world.

5.4.) Aurora Health Care Anticoagulation Therapy
Simulation
5.4.1.) Background and Objective
The complexity of anticoagulation therapy and various existing treatment
options especially the new PG-based dosing protocols create a serious barrier
to hospitals of identifying and adopting an "optimal" anticoagulation treatment
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plan for their heterogeneous patient population. To address this challenge, we
designed a study to take advantage of our pharmacogenetic PC-CER in silico
framework to simulate a number of anticoagulation therapy scenarios for the
state-wide AHC patient population. Our approach included extraction of
representative warfarin patient data from WiAD, collect and codify AHC's
warfarin dosing protocols, run clinical simulations to compare the predicted
outcomes of different dosing protocols including the AHC's, and then identify
the overall best population-wide treatment plan for different subpopulations.
- AHC warfarin Dosing Protocols
AHC has an institution-wide standardized warfarin best practice treatment
protocol that has been in effect for the last decade in different treatment
facilities of the institute. The AHC protocol called “Aurora Anticoagulation
Clinic Guideline for Ambulatory Warfarin Management” (AACG–AWM) has
some special characteristics compared to the other dosing protocols used in
our previous simulation studies. In the following, some details about the
protocol are offered.
AACG-AWM has two dosing protocols where each has three main
components: initial dose (days 1 and 2), 1st INR in range, and INR-based
Dose Adjustment. According to the protocol, a fixed dose of warfarin is
prescribed for days 1 and 2 following the instructions in table 5.5.
Table 5.5. AHC warfarin dosing protocol - AACG-AWM.
Initial dosing for days 1 and 2.
Patients sufficiently healthy to be treated as outpatients
= 10mg/day
Patients 65+ years of age
≤ 5mg/day
Patients at any age and with multisystem disease, known liver
disease, taking drugs that are likely to increase warfarin effect,
≤ 5mg/day
have had prior at-goal treatment response with low doses or
have baseline INR readings above 1.1
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Two days post warfarin initiation, INRs are monitored daily or every other day
until the INR >= 2.0 or as indicated by referring physician. When this is
achieved INR testing follows the chronology below (Table 5.6).
Table 5.6. AHC warfarin dosing protocol - AACG-AWM. 1st INR in range.

Number of days the INR and warfarin
dose remain stable and therapeutic
2
7
14-21
28-35
42
56
84

Days until the proceeding INR test
3-5
7
14
28
42
56
84 (absolute max number of days
between tests)

Based on this protocol, any adjustment of dosage is based on INR records in
last few days prior to dose adjustment. This aspect makes the AACG-AWM
different from other doing protocols such as CoumaGen-I and -II (Anderson
2010a, 2012b) as they take into consideration only the INR value that was
recorded just prior to dose adjustment. Figure 5.6 provides details on the third
component of the AACG-AWM protocol which instructions on INR-based dose
adjustment.
The AACG-AWM protocol has some other components such as the following
which were not taken into consideration in the process of codifying the
protocol as they either were not providing objective measures or the WiAD
dataset did not provide relevant information on them.
- Drug Interaction Considerations with Warfarin
- Herbal/Natural Medicine Interaction Considerations with Warfarin
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- Other Factors That May Affect INR.

Figure 5.6. AHC warfarin dosing protocol - AACG-AWM. INRbased dose adjustment. Adjusting dosage for patients with INR
goal of 2.5 (range 2.0 – 3.0).

5.4.2.) Methods
In this study, our primary hypotheses were as follows:
(1) Any warfarin dosing algorithm that provides some measure of
personalization will demonstrate improved predicted clinical outcomes (as
defined by TTRs and %OOR INRs within 90 day period) compared with
current AHC ‘best-practice’ dosing algorithm across the entire AHC
population. We defined personalization as any demographic, clinical or
genetic variable applied across a medication dosing protocol.
(2) Predicted clinical outcomes (as defined by TTRs %OOR INR’s within 90
day period) will improve proportionally to the degree dose personalization
across the entire AHC population.

5.4.2.1.) Study Design
To test these hypotheses, we designed a five-arm simulation study (Figure
5.7) in which the study arms (AHC, Clinical, PG-1, PG-2, and PG-3 arms)
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have different levels of personalization depending on required subjects’
characteristics for warfarin dose adjustments. As depicted in Figure 5.7, each
arm’s dosing protocol composed of three components. These components are
fixed, clinical-based or PG-based. In the first arm (AHC arm), the initial dosing
was solely based on the age and health condition of the subjects whereas in
the other arms it was based on either clinical characteristics (i.e., Clinical arm)
or clinical characteristics along with genotypic profile of the subjects (i.e., PG1, PG-2 and PG-3 arms). In the first three arms, the dose adjustment
algorithm used was the AHC one. For the arms PG-2 and PG-3, the dose
adjustment algorithm was a PG-based one used in EU_PACT clinical trial
(Pirmohamed, 2013). Although the maintenance dosing algorithms (days 6 or
8 through 90) for all of the five arms were non PG-based, the AHC
maintenance dosing algorithm was used for the first 4 arms and the last arm’s
maintenance dosing was based on the Intermountain dosing algorithm
(Anderson, 2012).

Figure 5.7. Study design for the five simulation trial arms.
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- Study Population
Using WiAD-Miner, we identified and extracted the EMR records of all the
subjects who were under warfarin at AHC and had complete demographic
and clinical records. This query resulted in 14,206 subjects.
- Study Power Analysis:
Taking advantage of our in silico framework, we had the opportunity to test
our hypotheses against a wide variety of subpopulation such as minority
subpopulations which had not participated in significant numbers in recent or
past warfarin clinical trials (e.g., African American). With these subpopulations
identified, we calculated the statistical characteristics of each subpopulation.
Accordingly, we found out that the smallest subpopulation of interest was
African-American male (i.e., 1.9% of whole extracted WiAD warfarin
population). A power analysis was conducted to calculate the sufficient
number of avatars to reject our null hypothesis for this subpopulation (AfricanAmerican males). Our power analysis showed that we needed to have at least
250 African American male avatars within each arm (Significance level 0.05
two-sided, SD 0.2, Power 0.9, INR Improvement [Difference in means] 0.06).
Consequently, the calculation resulted in a minimum number of 13,015
avatars for each arm.

5.4.2.2) Clinical Avatar Populations
For the purpose of this study, we applied the clinical avatar modeling method
described in section 3.1.1 to the WiAD warfarin population data to generate
clinical avatars. As mentioned in chapter 3, our BNM pipeline consists of four
broad sections: (1) Data preprocessing, and Knowledge aggregation; (2)
Develop Directed Acyclic Graphs (DAGs) via Ensemble Learning; (3)
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Estimating conditional probabilities via ensemble learning; (4) Validation of the
BNM and imposition of variables. In the following section, the application of
our methodology to the WiAD warfarin population is described in detail.
Following our clinical avatar model described in chapter 3, clinical avatar
modeling and generation were done for AHC warfarin patient population (i.e.,
WiAD warfarin cohort). As mentioned in chapter 3, our BNM pipeline consists
of four broad sections: (1) data and knowledge aggregation and
preprocessing; (2) semi-supervised Bayesian pattern search to develop a
Directed Acyclic Graph (DAG); (3) applying the DAG to estimate joint
conditional probabilities and deriving an instantiated model; (4) the BNM must
be validated against a subset of data not used in developing the BNM. In the
following section, our methodology for the WiAD warfarin cohort is described
in detail.
Section 1: Data preprocessing, and Knowledge aggregation
This section has two branches performed in parallel. In Part I we accumulated
domain knowledge (i.e., expert knowledge or literature-defined knowledge) to
better understand both the specifics of our data such as the way the data was
gathered, the semantics of the data dictionary and any measurement error as
well as the general relationship between the variables as found in literature
review. In Part II the patient data from WiAD was characterized and prepared
(i.e., data preprocessing). The data preparation is a multistep process as
described in Figure 5.8. Once the data has gone through the data
preprocessing procedure it is aggregated into a data wrapper.
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Figure 5.8. Step-by-Step procedure for Section 1
Part I:
We undertook a complete literature review searching Google scholar and
PubMed using key words such as “Race and Smoking” and “BMI and Age”,
similar to those variables found in the Aurora Data. We filtered for articles that
provide explicit results on populations determined to be similar to the AHC
patient population. We then filtered for results that linked the same specific
variables as those found in the WiAD data through an asymmetric conditional
probabilistic relationship. In Figure 5.9A and 5.9B we demonstrate the results
of the literature review and then how these relationships are implemented in
the TETRAD program (Scheines, 1998). Figure 5.9A shows a total of 7
asymmetric conditional probabilistic relationships discovered through literature
review. An asymmetric conditional probabilistic relationship is not strictly
causality nor do we require this strong assumption to be true in the
development of clinical avatars. Each of the required edges, shown in the
green directed arrows are each related to evidence cultivated through the
literature review that were determined to relate direct to the patients in the
WiAD database (Fiore, 1989; Kuskowska; 1992; Marot, 2011).
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In Figure 5.9B we see the description of knowledge tiers within TETRAD. The
tiers allow use to inform the algorithm that certain relationships are both
forbidden and/or asymmetric. As implemented for the AHC data, we suggest
that IF a conditional dependency is discovered between “HEIGHT” and

Figure 5.9A. Domain Knowledge
expressed as required causal
relationships in green arrows

Figure 5.9B. Domain Knowledge
expressed as causal tiers of hierarchy

“RACE”, Then the relationship must be such that “RACE” given its position in “Tier
1” is the causal parent of “HEIGHT” given its position in “Tier 2”. Similarly any
potential relationship between a higher tier variable must be directed towards a lower
tier variable and never in the reverse direction.

Part II:
Data Discretization and Aggregation:
Often healthcare data includes a mix of categorical and discrete data, such as
race and gender, and continuous data such as age and height. The Bayesian
search algorithms we employ require training data that is either entirely
continuous and normally distributed or entirely discrete. The WiAD data
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included a combination of both continuous and discrete variables, therefore
the continuous variables were discretized. The process of discretizing
continuous data is a ubiquitous data preprocessing technique that must
balance information loss inherent in the process with the benefits of greater
processing efficiency. There are numerous discretization methods and the
choice can impact both the posterior probability estimation as well as the
discovery of inherent causal structure in the underlying graph. We employed a
common unsupervised method, EqualWidth that has demonstrated its ability
to produce accurate data mining results for Bayesian search algorithms when
compared to other techniques (García-Laencina, 2013).
Once the data has been fully preprocessed it is loaded into TETRAD the
program we use to implement the BNM search and relationship discovery.
The final step before completing the Bayesian search, is to load the
processed data as a data wrapper. A data wrapper converts the data from a
flat structural file to a relational file that describes the data as tuples. Data
wrappers are standard in data mining practices because it allows for
maximum dimensionality to be passed through the search algorithm.
Section 2: Directed Acyclic Graphs via Ensemble Learning
Bayesian search algorithms are based on a number of assumptions that often
times breakdown when applied to real data. We address the weakness of the
Bayesian search algorithms, along with certain bias and variance problems
within the aurora data by eliciting established methods for using ensemble
learning such as described in Part III section 2. The step-by-step logic of
section 2 is described in Figure 5.10. We apply an ensemble learning
technique called, bootstrap aggregation (Bagging) to address the instability of
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Bayesian classifier searches. From one set of training data, the data is
resampled at random.

Figure 5.10. Developing a DAG from Training Data
The choice of bootstrap sampling technique (e.g., Parametric vs. classic
bootstrap) can ultimately impact the quality of the model. We implemented a
classic (Unweighted) bootstrap because imputation and missing values were
non-existent, and there was limited bias within the selected EMR dataset. The
classic bootstrap is completed from the original data wrapper after it has been
loaded into TETRAD. In Figure 5.11, the data is labeled as
“WiAD_Warfarin_Cohort Data” before entering the pipeline. This data
wrapper is then aggregated into five distinct bootstraps and subdivided into
80% and 20% subsets with 80% used as the training data. The bootstraps are
labeled as “Training_DATA1… Training_DATA5” in Figure 5.11. The
bootstraps were resampled to the same size n=14,206 as the original dataset.
The 80% training data, n=11,365, was used as input into 5 Bayesian
searches, labeled “Search1…Search5”. Knowledge that was previously
loaded during the preprocessing phase is also applied evenly across the
search algorithms to constrain the search space.
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Figure 5.11. Bootstrapping and performing
searches constrain by knowledge in TETRAD
Additionally, in experimentation with EMR data we employ a “repeated leave
one out bootstrap aggregation” method (Clyde, 2004; Jiang, 2007). Holding
out data for cross validation is considered a data mining ‘best practice’
(Belazzi, 2004). However, when the sample size is small and outliers are
important considerations in the data, holding out any amount of data reduces
variance in the model. Therefore, it is recommended to perform the bootstrap
sampling of the original data prior to the dividing the data between training
and validation subsets.
Each resampled training data subset was used as input with the previously
described domain knowledge to a Bayesian search algorithm. The results of
each search are aggregated and the results are pruned to yield a resultant
DAG. We employed the Bayesian search algorithm called the Conservative
PC algorithm (CPC) found within the TETRAD publicly available software. The
CPC algorithm is a variant of the PC algorithm that has an additional step that
provides additional autonomous arrow directionality. The PC and CPC
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algorithm perform conditional independence tests between each variable
except those required or forbidden within the knowledge box. The conditional
independence tests are then applied across the data wrapper to discover
potential causative relationships. Additional details, the pseudo code and
inherent assumptions of the PC and CPC algorithm can be found in (Sprites,
2000) and within TETRAD. All searches were completed with an α=0.05.
We generally recommend using multiple Bayes search algorithms for each
bootstrap of data to address the inherent instability in the search results.
However, in application to the WiAD dataset, we determined that the CPC
algorithm sufficient for the following reasons: There was limited number of
dimensions (i.e. variables) in the data in proportion to the sample size. Also,
because all missing values were deleted from the training dataset, a major
source of algorithm instability was addressed in preprocessing. Lastly, CPC
was determined to best fit the data, and there was limited variation between
bootstrapped search results.
After the 5 CPC pattern searches were performed on the data, the DAGs
were converted into matrix with the originating state comprising the columns
and the destination states the rows. Each directed arrows, or edges of the
DAGs were cataloged in a matrix for comparison. Edges are selected based
on those that received 50% or more commonality and/or are supported by
evidence discovered prior to performing the search. The results of the Five
CPC searches are shown in Figure 5.12. The weight of the arrow corresponds
to the number of times the search output confirmed an existing edge. The two
arrows that are dashed from Gender

Tobacco and Race

Weight had

fewer than 50% search results and therefor were not included in the
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aggregated DAG. The resultant DAG shown in Figure 5.12 is then used in
parallel for section three, labeled “AHC_DAG” in Figure 5.14.

Figure 5.12. Results from 5 CPC searches.
Section 3: Estimating Conditional Probabilities via Ensemble learning
The step-by-step logic of section 3 is described in Figure 5.13. The dashed

Pool Validation Subsets
Aside and Do Not Use
for Modeling

Use DAG(s) to Derive
Parametric Model (PM)
for Each Bootstrapped
Dataset

Pool Preliminary Avatars

Use Ensemble Bayes
Estimator Algorithms on
Each Bootstrap

Generate Equal Amount
Data (Preliminary
Avatars) from Each
Bootstrapped Model

Section 3

Bootstrap Data:
Divide Each Bootstrap
into Training and
Validation Subsets

Figure 5.13. Developing a DAG from Training Data
arrow indicates a final recursive step described at the end of this section. The
first step in section 3 is to again bootstrap the original data set the same
number of times as performed in section 2. The bootstraps were resampled to
the same size n=14,206 as the original dataset. Because the justification for
selecting a bootstrap procedure is the same in this section as for section 2,
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we performed 5 classic bootstraps with replacement holding out 20% of each
bootstrap for validation in section 4, (identical bootstrap to section 2). The
bootstraps were performed in TETRAD as seen in Figure 5.14 represented by
(“Training_Data6… Training_Data10). The DAG derived from section 2,
“AHC_DAG” was used to develop a parametric model (PM) for each of the
bootstraps.

Figure 5.14. Parameter learning in TETRAD

The parameters, or conditional probabilities of the Bayes net were estimated
for each bootstrap using the ML Bayes estimator for each bootstrap as shown
in Figure 5.14 noted by the “Estimator1… Estimator5”). At this stage the
algorithm produced a partial failure. An example of this problem is highlighted
in Figure 5.15 for particular parameters of “WEIGHT” within the BNM. The
partial failure of the estimator algorithm is highlighted by the red rectangles
within the partial estimated Bayes net. In the resultant DAG from section 2,
“WEIGHT” is a descendent of three Variables, “HIEGHT”, “AGE” and
“GENDER”. The partial failure is associated with the problem of insufficient
statistics to provide estimates within those particular parameters highlighted in
red. In this case, the training data did not provide the estimation algorithm with
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any cases from these particular parameters (e.g, there existed no patients
with the characteristics “Gender=Female, Age=0, Hieght=0” within the

Figure 5.15. Partial failure of Estimator Algorithm for the variable “WEIGHT”
bootstrap of the training data).
To address this situation, and satisfy the parameter learning for this BNM, we
simplified the model by removing edges related to “WEIGHT” according to the
four-step logic pattern found in the general description of the method. In this
case, there were three edges related to “WEIGHT”. Since all three edges
were retuned every search result performed in section 2, we began by
increasing α from a value of α=0.05, to a more stringent value of α=0.00001.
We then used the domain knowledge aggregated in section 2 to delete further
edges stepwise until sufficient cases existed within training data to calculate
conditional probabilities. In doing so we increase the number of cases in the
training data to calculate the conditional probability for all relevant states from
the parent nodes. The resultant DAG, named “SIMPLIFIED_AHC_DAG” was
used to derive PM and estimate the conditional probabilities of the simplified
Bayes Net shown in Figure 5.16. Figure 5.17 highlights our example of the
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variable “WEIGHT”. We see that the edges “AGE” and “GENDER” were
removed while the edge between “HEIGHT

WEIGHT” remained. The

conditional probability for each discretized category of weight was then
estimated strictly based on the discretized categories of height.

Figure 5.16. Parameter learning with insufficient statistics
The conditional probabilities derived from the simplified model were then used
as input for the original parametric model. For example, within the more
complicated Bayes net we experienced a partial failure when the training data
did not have any counts for patients that have “Gender=Female, Age=0,
Height=0”. The Estimated conditional probability for this parameter was
derived from the simplified Bayes net – using weight estimations strictly from
its probabilistic relationship to Height. This procedure was repeated for
“Tobacco” and “Height” until all parameters within the original Bayes net were
satisfied with conditional probabilities for each bootstrap of data.
Once the parameters of each Bayes net were satisfied within an instantiated
model (labeled IM within Figure 5.16), 100,000 preliminary avatars were
generated from each trained model. The preliminary avatars were then pooled
in equal proportion into a set of “POOLED_PRELIM_AVATARS”. We elected
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to use an equal weighting scheme because, similar to the reasons for
performing a classic bootstrap, the bias was considered minimal. The pooled
preliminary avatars were then passed through a final round of estimation. The
resultant “AHC_DAG” developed in section 2 was then used to derive the PM
that was used as input to the estimator. Because of outliers within the data
this second round of estimation again faced the problem of insufficient
statistics that resulted in partial failure of the estimator algorithm. This, despite
the large sample size of pooled preliminary avatars passed through the
Estimator algorithm. We addressed the problem in an identical manner to the
first round of parameter learning. We used a simplified DAG to reduce the
conditional parents and substituting the conditional probabilities for the
simplified state for those states within the parametric model that suffered from
the partial failure. We used the same simplified DAG previously developed
and shown in Figure 5.17.

Figure 5.17. Simplified DAG and subsequent parameter learning
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The parameters were then aggregated in the “TRAINED_AHC_BNM” shown
in Figure 5.18. This BNM was then used to develop 100,000 clinical avatars
via Monte Carlo simulation techniques that were used as input to section 4 for
validation purposes.

Figure 5.18. Final round of parameter learning

Section 4: Validation of the BNM and Imposition of Variables
The first step of this section involves validating the model with some set
validation data shown in Figure 5.19. We performed a “repeated hold-out
classic bootstrap” in both section 2 and section 3. A total of 5 classic (i.e., with
replacement) unweighted bootstraps were performed in section 3. The
bootstraps were resampled to the same size n=14,206 as the original dataset.
Each described previously, each bootstrap was randomly divided in 80% and
20% subsets. Therefore a total of 5 validation data sets each with the same
size, n=2,841 were aggregated into a data wrapper labeled
“POOLED_VALIDATION_DATA” in Figure 5.21. This set of validation data
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was then used to compare the 100,000 clinical avatars for validation
purposes.
There are two types of comparisons used to ensure that the simulated
population is representative of the original data. The first is univariate

Begin Iterative
Process If Avatars
Demonstrate
Significant
Variance

Impose
Additional
Avatars
Characteristics

Section 4

Cross Validate
Preliminary
Avatars with
Validation Data

Clinical Avatars

Figure 5.19. Validating the BNM and generating Clinical Avatars

distribution, or the comparative frequency of a single attribute between the
training data and clinical avatars. The second comparison is the bivariate
frequency distribution between the training and clinical avatar data sets.
Variables in which the Bayesian algorithm determined a causal connection
and are “d-connected” are plotted in frequency histograms. We found no
significant variance in either the univariate or bivariate distribution, the
process is refined until there is no significant difference. The comparative table
is provided in the results section.
The final step in the development of clinical avatars involves imposing any
additional characteristics on the BNM validated against the pooled validated
data. In Figure 5.20, we demonstrate how two genotypes, CYP2C9 and
VKORC1 are imposed on the BNM derived from the WiAD database.
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Figure 5.20. Final AHC DAG following Genotype Simulation.

The probabilistic dependent relationship between “RACE
“RACE

CYP2C9” and

VKORC1” are demonstrated in (Scott, 2010). Additionally, the

parameters that describe the conditional probability parameters are described
in (Scott, 2010). The validated structure and parameters that include all
clinical avatar parameters including genotype are demonstrated in the
Instantiated BNM titled “AHC_BNM_GENOTYPE” in Figure 5.21. This model
was then used to generate 1,500,000 clinical avatars via Monte Carlo
simulation techniques that were entered into the simulation platform.

Figure 5.21. Section 4 as implemented in TETRAD

5.4.2.3.) Measuring Outcome Metrics
In this study, we calculate a number of outcome metrics. A primary outcome
metric is Time in Therapeutic Range (TTR) for patient INR. There are two
methods for calculating TTR, such as INR check points and linear
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interpolation (Rosendaal, 1993). Additional outcome metrics include the
following: 1&2.) Percent time INR higher than therapeutic range using both
INR check points and linear interpolation methods, 3&4.) Percent time INR
lower than therapeutic range using both INR check points and linear
interpolation methods, 5.) Number of INR predictions, 6.) First day INR higher
than therapeutic range, 7.) Percent INR in therapeutic range by day 5, 8.)
Percent INR in therapeutic range by day 9, 10.) number of dose adjustment,
11.) relative risk of ischemic stroke, and lastly 12.) relative risk of intracranial
hemorrhage.

5.4.2.4.) Clinical Trial Simulations
For each study arm, a 90 day simulation was performed for each Clinical
Avatar using each of the five PG and non-PG protocols. All results were
stored in a structured format representing the 100 x 90 day study simulations
for each clinical avatar in the study subpopulations. Simulation records
included: clinical avatar record, simulated INRs and dose values (1 per day for
each of 90 days) and calculated outcome metrics. All simulations were
implemented in R (R Core Team, 2014) and performed on the UWM’s high
performance computing research cluster Avi (UWM, 2014).

5.4.3.) Results
In the following table we present the statistical characteristics of the clinical
avatars and the WiAD warfarin study population. The statistical analysis
indicates no significant difference between these two populations by the
characteristics.
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Table 5.7. Characteristics of the WiAD warfarin study population versus WiAD
warfarin clinical avatar population. SD: standard deviation.

67.3 ± 14.43

WiAD Warfarin
Clinical Avatar
Population
67.2±14.47

Weight, lb, mean±SD

199.24 ± 54.71

199.24±54.6

Height, in, mean±SD

66.78 ± 4.31

66.53±4.32

53.14
46.86

53.10
46.90

95.17
4.222
0.3378
0.1759
0.0007

95.19
4.202
0.4010
0.1890
0.0001

90.33
9.66

90.67
9.33

88.45
11.54

88.49
11.51

99.97
0.03

99.98
0.02

NA
NA
NA
NA
NA
NA

67.39
14.86
9.25
1.97
6.51
0

NA
NA
NA

38.36
44.18
17.45

Characteristic
Age, y, mean±SD

Gender, %
Female
Male
Race, %
White
Black or African-American
Asian
Am. Indian/Alaskan
Pacific Islander
Tobacco, %
No
Yes
Amiodarone, %
No
Yes
Fluvastatin, %
No
Yes
CYP2C9*2, %
*1/*1
*1/*2
*1/*3
*2/*3
*2/*2
*3/*3
VKORC1, %
G/G
G/A
A/A

WiAD Warfarin
Population

The following figure demonstrates the mean predicted TTR of the 100
simulations for each arm. The comparison of the results of linear interpolated
TTR across the whole clinical avatar population for all 5 arms is shown in
Figure 5.22. The PG-1 arm produced the highest mean predicted TTR, at
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77.43%. The Clinical arm and PG-3 arm produced similar but significantly
different (p<0.05) mean predicted TTRs at 69.76% and 67.4%, respectively.
PG-2 and AHC arms produced significantly inferior mean predicted TTRs
(P<0.05) at 62.99% and 57.16% respectively.

Figure 5.22. TTR (Rosendaal) across the whole clinical avatar
population for the 5 simulation arms.
Gender differences are consistent between all five arms. That is, males
perform similarly in AHC, Clinical, PG-1, PG-2 and PG-3 when compared to
females in those same arms. Interestingly, when the genders are also
segregated by race as shown in Figure 5.23, gender difference remains
consistent between white and African-American subpopulations. All five arms
demonstrate significant difference between African-American males versus
white males and African-American females versus white females (P<0.05).
For all four subpopulations, PG-1 demonstrated superior predicted percent
TTR. AHC arm demonstrates the largest difference between race and gender
groups while PG-3 demonstrates the smallest difference between African-
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American and white racial groups. African-American males and AfricanAmerican females demonstrate no significant difference between PG-3 and
AHC dosing arms.

Figure 5.23. TTR (Rosendaal) across the whole clinical avatar population for the 5
simulation arms by gender and race.

Results for clinical avatars when segregated by CYP2C9 genotype are shown
in Figure 5.24. Poor and intermediate metabolizers demonstrate significantly
lower TTR when compared with the wild type *1/*1 CYP2C9 extensive
metabolizer. All three PG-based subpopulations produced superior mean
TTR’s within the PG-1 arm. Similarly, all three produced inferior mean
predicted TTR’s in the AHC arm. For extensive metabolizers, which are a
majority of the AHC population, the clinical arm produced the second highest
mean predicted TTR, followed by the PG-3 arm and the PG-2 arm. For
intermediate and poor metabolizers, the PG-3 arm produced the second
highest predicted mean TTR’s and the clinical and PG-2 arm produced similar
TTR results.
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Figure 5.24. TTR (Rosendaal) across the whole clinical avatar
population for the 5 simulation arms by CYP2C9 genotype.
Extensive Metabolizer: *1/*1, Intermediate Metabolizer: *1/*2,
*1/*3, *2/*3, Poor Metabolizer: *2/*2, *3/*3.

In the final figure (Figure 5.25) we look the percent of time above therapeutic
range and the percent of time below therapeutic range as calculated by linear
interpolation. The results are shown for the whole population as well as two
subpopulations white race and African-American subpopulations. The AHC
arm produced the highest predicted time above therapeutic range for the
whole population and white and African-American subpopulations. While PG3 arm produced the lowest time above therapeutic range for the whole
population and white clinical avatars. While the arms PG-1 and PG-3
produced similar time above therapeutic range specifically for the AfricanAmerican subpopulation.
In contrast, the PG-2 and PG-3 produced the highest mean time, greater than
20%, with subtherapeutic INR for the whole population and the white and
African-American subpopulations. The AHC arm and the PG-1 arm produced
similar predicted times subtherapeutic range for the white population and for
the white population, but African-American demonstrated greater time below

232

therapeutic range in the PG-1 arm when compared to the AHC arm. The
clinical arm produced results that demonstrate slightly greater predicted time
below therapeutic range when compared to the PG-1 arm. Therefore, white
subpopulations demonstrate the least time subtherapeutic range in AHC and
PG-1 arms while African-American subpopulation demonstrates the least time
in subtherapeutic range specifically in the AHC arm.
a

b

Figure 5.25. (a) Percent Time INR higher than therapeutic range across the
five simulation arms by race. (b) Percent Time INR lower than therapeutic
range across the five simulation arms by race.

5.4.4.) Conclusion
We have simulated a total of five clinical trial arms, replicating each arm 100
times. We simulated 1.5 million clinical avatars for each arm bringing the total
simulated population to 7.5 million. We found that the PG-1 arm produced
superior predicted clinical outcomes across the whole AHC population and all
relevant subpopulations within the study population. When comparing the top
performing arm (i.e., PG-1) to the current Aurora Health Care best practice
warfarin dose protocol (i.e., AHC arm), we demonstrate superior TTRs for the
whole population and all subpopulations. Therefore, we confirm our primary
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hypothesis that there exists several warfarin dosing algorithms that provide a
measure of personalization, in this case PG-based and clinically-based, that
improved clinical outcomes across the entire AHC population.
The superiority of the PG-1 arm was mirrored in the secondary outcome
metrics of predicted time above therapeutic range and predicted time below
therapeutic range. The PG-1 arm produced lower predicted time above
therapeutic range when compared to the AHC arm for all populations and
subpopulations, reducing the risk of intracranial hemorrhage and other forms
of bleeding. The PG-1 arm produced similar predicted time below therapeutic
range for the white subpopulation, however, the African-American
subpopulation did experience significantly greater percentage time below
therapeutic range, thereby diminishing its pharmacological effectiveness.
We performed a total of four clinical trial arms that included some degree of
warfarin dose personalization (Clinical, PG1, PG-2 and PG-3). We defined
personalization as any demographic, clinical or genetic variable applied
across a medication dosing protocol. The PG-2 and PG-3 clinical trial arms
included patient specific dose personalization at both the initial dose
prediction and the adjustment stage of the algorithm. In contrast, PG-1 and
Clinical arms only included warfarin dose personalization at the initiation stage
of warfarin therapy. As noted above PG-1 produced superior clinical outcome
metrics for all subpopulations within the AHC study population. Additionally,
the clinical arm produced non-inferior clinical outcome metrics to the PG-2
arm and PG-3 arm for the whole AHC population. However, PG-based
subpopulations did demonstrate superior outcomes with the PG-2 and PG-3
arms.
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Nevertheless we must reject our second hypothesis that predicted clinical
outcomes improve proportionally to the degree of dose personalization across
the entire AHC population. While personalization in general provides superior
outcomes when compared to a “one-size fits all” approach for the AHC bestpractice warfarin management, greater inclusion of personal characteristics
within the dosing algorithm does not improve clinical outcome metrics across
the whole AHC population for primary outcome metrics.
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6.1.) Background and Significance
The Patient Protection and Affordable Care Act (PPACA, 2010) established
Patient-Centered Comparative Effectiveness Research (PC-CER) as a US
national medical research priority. Under PPACA, the Patient-Centered
Outcomes Research Institute (PCORI, 2014) was charged to support
research that investigates effectiveness and outcomes of health care
treatments, medical services, and clinical care in subpopulations
(Methodology Committee of PCORI, 2012). Subpopulations may be defined
by race, ethnicity, gender, age, and medical and physiologic inclusion criteria
such as disease, comorbidities, genotype or cancer molecular subtype.
Current PCORI research focus includes secondary use of electronic medical
records (EMR) to build clinical research databases (Selby, 2012) to conduct a
spectrum of PC-CER studies including health care disparity in part by seeking
evidence of treatments’ effectiveness across various populations.
Socioeconomic status (SES) is one of the most powerful drivers of populationlevel health outcomes and lower SES is consistently associated with poorer
health outcomes (Adler, 1994a, 2008b). Consequently, one such CER area is
health care outcome disparity observed across SES-based on education and
income (PCORI, 2014). Another PC-CER area of immense interest to
biomedical scientists and medical geneticists is the use and value of genetic
tests, data and information intended to improve public health. No studies to
date have tested if genetics can reduce SES-based health disparity outcome.
Warfarin treatment effectiveness studies have potentially high health SESbased disparity impact when comparisons include genetic-based against
other “best practice” means of achieving therapeutic dosing. Warfarin’s
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therapeutic dosing is complicated by a narrow therapeutic index and large
interindividual dose variability (up to 20-fold depending on genotypes,
physiology, and compliance (e.g. Anderson, 2007; Momary, 2007; Wu,
2007)). Compared to controlled clinical trial studies, optimization of warfarin
dosing in the clinic using a “best” practice protocol is challenging due to
variances in treatment monitoring (Mega, 2014) and must be balanced to
prevent thromboembolism while avoiding overdosing that increases risk to
bleeding events (Flaherty, 2007; Lip, 2011).
PC-CER human subject studies to improve anticoagulation outcomes by
optimal selection of warfarin dosing protocols is impractical (too large,
complex and costly) if designed to test all or even many of the published
pharmacogenetic-based (PGx) and non-PGx dosing algorithms applied to
important (and numerous) CER subpopulations. We have created and
validated a pharmacogenetic clinical trial modeling and simulation platform
(Fusaro, 2013) to conduct in silico complex CER simulations to test PGx
treatment protocols against key patient subpopulations with a goal to predict
improved treatment outcomes. In this study, we extend the application of the
platform to include EMR data of a representative large US healthcare system
with diverse population to conduct a CER study between warfarin treatment
protocols. In addition to typical CER study design factors, we profile the study
population by SES and indicate how outcomes may be affected by
educational and income status as experienced in Milwaukee.

6.2.) Objective
We create an anticoagulation patient EMR database from patients treated by
warfarin at Aurora Health Care system (AHC), a Milwaukee based network,
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where an institution-wide standardized warfarin best practice treatment
protocol has been in effect for the last decade. Thereafter, we use the
database to identify SES outcome disparity and as input to our simulation
platform that models patient subpopulations, individual patient treatment and
outcomes, simulates use of multiple anticoagulation protocols, predicts patient
and population outcomes, and tests those predictions against patient data
extracted from the database. We then execute an in silico study that tests four
warfarin dosing protocols against two (simulated) EMR-based SES
subpopulations to predict if any of the four protocols reduces the outcomes
disparities. This PC-CER study demonstrates how large comprehensive
EMRs covering diverse patient populations, coupled with novel modeling and
computational simulations, provides opportunity to conduct and in part
validate, in silico CER in diverse populations.
We first provide a general description of the in silico approach, then describe
and apply the methods used to test differences between PGx versus non-PGx
anticoagulation treatment in a diverse Milwaukee population, and finally,
demonstrate how the results can be used to demonstrate treatment outcomes
such as “percent Time in Therapeutic Range” (TTR) of International
Normalized Ratio (INR) and frequency of INR tests (Gouin-Thibault, 2010;
Koertke, 2003; Sawicki, 1999; White, 1989; Horstkotte, 1998) and validation
stratified by various factors including SES.

6.3.) Materials and Methods
The in silico PC-CER approach starts with extraction of EMR patient data
pertinent to the objective of the study. In this study, we extract and transform
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anticoagulation patient records from AHC over the period 2002-2011 (Figure
6.1 Panel A. AHC EMR).

Figure 6.1. Our two component in silico PC-CER approach consists
of a process for the secondary use of EMR data (Panel A) and a
study design and simulation platform (Panel B). The iterative use of
the two components can be applied to comparative effectiveness
and healthcare disparity research.

Next, we uploaded the data into a minable database (Wisconsin
Anticoagulation Database, WiAD, Figure 6.1, Panel A.) and created a data
mining application (WiAD-Miner). The in silico approach then requires a study
design complementary to the objective of the PC-CER and uses our
previously published Pharmacogenetic Clinical Trial Simulation (PCTS)
platform (Figure 6.1, Panel B), (Fusaro, 2013) and an iterative PC-CER
modeling workflow that couples the strength of the EMR database with the
simulation platform (Figure 6.1.). Testing and validating proposed improved
treatment protocols against best practice are represented by dotted lines in
Figure 6.1. Herein, we present the methods for each component of the in
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silico PC-CER approach when applied to test if genetics can reduce SESbased outcome disparity in anticoagulation therapy.

6.3.1.) Secondary Use of Large Diverse Healthcare EMR
AHC is the largest health care system in Wisconsin serving approximately 1.2
million unique patients each year through 7.8 million patient encounters per
year. AHC’s EMR is the most comprehensive (by size, type of health care and
period of time) digitized health care resource of Southeast Wisconsin’s
population capturing urban, suburban, and rural constituents of all racial,
ethnic, and socioeconomic backgrounds. This resource provides a unique
opportunity to capture data and information vital to conducting retrospective
and predictive PC-CER studies. However, the same factors that make AHC’s
EMR extremely valuable (size, scope and longitudinal extent) to PC-CER
objectives in general, create great difficulty in capturing the targeted data
important to a particular PC-CER study. Consequently, we have created a
modular and replicable method to identify, extract, transform and load process
and tools to mine EMRs and produce a highly enriched PC-CER
knowledgebase that provides both input to and validation of our CER studies.

6.3.1.1.) EMR Extraction, Transformation, and Loading
The AHC EMR was mined to extract all patients with evidence of prescription
of: Coumadin (Warfarin), Heparin, Ticlopidine (Ticlid), Clopidogrel (Plavix),
Dipyridamole (Persantine), Abciximab (ReoPro), Eptifibatide (Integrilin),
Tirofiban (Aggrastat), or Dabigatran (Pradaxa) over the period of 2002 to
2011. Patient data was de-identified per IRB approval (allowing zipcode) by
an AHC honest broker before distribution to the research team. Longitudinal
data records of 157,450 patients including: gender, race, height, weight, age,
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day of visit, patient's zipcode, patient's city, provider's zipcode, smoking
status, INR, medications received (day, dose, frequency), interacting
medications (Amiodarone, Simvastatin, Fluvastatin, Lovastatin, Atrovastatin,
Rosuvastatin, Pravastatin, Aspirin), medication indications (by ICD-9 codes:
Orthopedic surgery-hip or knee, Deep Vein Thrombosis (DVT), Pulmonary
embolism, Atrial fibrillation, Atrial flutter, Atrial fibrillation and flutter, Stroke,
Heart valve replacement) and comorbidities (by ICD-9 codes: DVT,
Pulmonary embolism, Stroke, Myocardial infarction, Bleeding). Subsequent
data cleaning, quality control and quality assurance include an iterative
process of data parsing to detect irregularities; statistical analysis designed to
test population-wide distributions and possible biases; refinement of inclusion
and extraction data mining codes to address irregularities, possible missing
data and detected biases; and ultimately, data transformation to produce a
cohesive set of records capturing all available medical records in a consistent
format following Weiskopf (2013). Representative of our process was the
complex method to produce consistent primary and secondary anticoagulation
outcome metrics such as longitudinal metric TTR in targeted range and
frequency of INR values. INR frequency is required to assess outcome
metrics from EMR data since patients seen in the best practice clinical setting
typically do not experience the same frequency of INR monitoring and
corresponding dose adjustment as experienced for the controlled clinical trial
setting (Mega, 2014).
All extracted INR values and frequency were tested against physiological,
treatment and compliance consistency criteria such as exclusion criteria: (a)
INR values ≤ 1.2 since such values are likely unrelated to warfarin therapy
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(White, 1989), (b) INR values ≥ 10 consistent with the upper limit of AHC lab's
reference range and (c) problematic INR values during fixed 5mg/day warfarin
exposure periods (Sagreiya, 2010). We also profiled patients by defined
treatment periods (e.g. fixed time or medical procedure periods) during which
TTR calculations are likely well defined. For example, the warfarin exposure
period was defined by a combination of time period and frequency of INR
values (at least two INR values in a 90 day window). For those individuals
“profiled” by the defined treatment period, the TTR was calculated using the
linear interpolation method of Rosendaal (1993). This method assumes a
linear relationship between two consecutive INR results, assigns an INR value
to each day between successive observed INR values, and determines the
proportion of time for which the INR is below, within or above the therapeutic
range (i.e., time in which patient INR values were between 2 and 3). Then, the
individual warfarin exposure period TTRs and mean TTR ( TTR ) was
calculated for each patient.

6.3.2.) WiAD and WiAD-Miner
After rigorous data extraction, quality control and transformation, the deidentified patient record “cleaned” data (157,450 records reference above),
tagged profiles and related metadata were loaded into WiAD. The WiAD
patient subpopulation of AHC includes 49.65% female and 50.35% male with
mean age of 67.99 yo (female) and 65.22 yo (male). WiAD patients are
geographically distributed across all 72 counties of Wisconsin and WiAD’s
racial distribution is consistent with that of the state. 47.8%, 10.4% and 1.9%
of WiAD patients have evidence of only 1, 2, or 3 medications respectively. In
addition to the AHC patient data, WiAD includes complementary data such as
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Wisconsin population statistics, demographics, and US census data to
expand the “knowledgebase” and provide more robust information for the
subsequent simulations and predictions. An interactive data profiling and
population “segmentation” tool (WiAD-Miner) includes all the profiling (e.g.
warfarin only exposure patients), outcome metric (e.g. TTR based on
warfarin exposure period) and related data analysis functions described
above and developed in R (R Core Team, 2013). WiAD-Miner includes a
cohort selection tool to profile and identify patient subpopulations by any or a
combination of patients’ characteristics including gender, age group, race,
patient's residence zipcode, provider's zipcode, medication, medication
exposure, duration of treatment, number of dose records, frequency of INR
values, medication indication, and comorbidities. WiAD-Miner allows
adjustment of various parameters such as the medication exposure period
definition, triggering a re-profiling and thereafter, re-calculation of outcome
metrics.

6.3.3) Pharmacogenetic Clinical Trial Simulator (PCTS)
Our pharmacogenetic clinical trial simulator (Figure 6.1. Panel B) consists of
the 5 following adjustable modeling components: 1) A Bayesian network
model (BNM) derived from a study population to produce the virtual patient
population (“Clinical Avatars”) consistent with study population, 2) A module
that sets study conditions such as number of subjects, initial dosing, length of
study, number of replications, and similar, 3) A circulating medication
concentration and INR predictor based on appropriate
pharmacokinetic/pharmacodynamics (PK/PD) model (e.g. Hamberg, 2007), 4)
A treatment dose algorithm that uses INR or other pertinent physiological
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variables and invokes a treatment protocol (see details for warfarin treatment
below), and 5) A study healthcare outcome calculator (e.g., TTR). This fivecomponent simulator was validated by significant testing against major
pharmacogenetic anticoagulation clinical trials such as CoumaGen-I and –II
(Anderson, 2007a, 2012b). The validation included statistically consistent
clinical simulations and predictions against the published 90 day, multitreatment protocol CoumaGen-I results (Fusaro, 2013). All simulations were
implemented in R (R Core Team, 2013) and performed on the local high
performance computing research cluster Avi (UWM, 2014). The PCTS
platform includes the generation of Clinical Avatar populations that mirror the
study population’s statistical characteristics and are consistent with the EMRs
of actual patients. Thereafter, the representative synthetic patient populations
are used to conduct replicated clinical simulations testing multiple
anticoagulation medication-protocol options.

6.3.4.) Study Population
In this study, WiAD-Miner was used to identify all WiAD patients exposed only
to warfarin from 2002-2011 whose records include complete demographic
(e.g. race) and geographic data (n=16,900), hereafter this group is called the
WiAD warfarin population. For the purpose of calculating treatment outcomes
and identification of SES status in this study, the WiAD warfarin population
subjectswhose records satisfied the following criteria were selected (a) the
inclusion criteria: (1) zipcode in Milwaukee, (2) treatment periods between two
successive INR values of 90 days or less and (b) the exclusion criteria: (1)
periods of warfarin exposure interruptions (e.g., hospitalization), and (2) 1
week before and 3 weeks after warfarin exposure interruptions. With these
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criteria, WiAD-Miner identified 1085 WiAD warfarin population subjects who
were then socioeconomically profiled by SES levels across the three
“Milwaukee SES zipcode” groups as defined in the 2012 Milwaukee Health
Report (Chen, 2012) resulting in a “lower SES” (n=191), “middle SES”
(n=716) and “upper SES” (n=178) subpopulations.

6.3.5.) In Silico PC-CER Study Design
The PC-CER Study design is based on the comparative effectiveness
research aim to detect protocols that improve outcomes and minimize
disparity. The PCTS simulation platform requires three specifics:
Medication(s) and treatment protocols to be tested; Subpopulation(s) to be
studied; and the length of the treatment period and the treatment outcomes.
Warfarin dosing protocols typically include three components - an early (1-2
day) warfarin loading dose “initial” protocol followed by a relatively short dose
“adjustment” protocol (typically 3-5 days) followed by the therapeutic dose
“maintenance” period as needed for treatment. For these simulations, we use
four three-component warfarin dosing protocols over a fixed 90 day simulation
period: non-PGx CoumaGen-I Standard (Anderson, 2007) PGx CoumaGen-I
PG (Anderson, 2008), PGx CoumaGen-II PG-2 Arm (Anderson, 2012) and the
PGx Wilson as defined in Fusaro (2013) denoted CG-I STD, CG-I PG and
CG-II PG-2, and “Wilson” respectively (Figure 6.2).
Clinical Avatars Study Population: The Milwaukee lower SES and the
Milwaukee upper SES subpopulations as defined above were used in this
study. A BNM was developed and trained on the WiAD warfarin population.
The BNM method is described in Fusaro (2013). The Directed Acyclic Graph
(DAG) produced by fitting the WiAD warfarin population to the optimal BNM
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was used to produce all clinical avatars used in this study. The BNM's
conditional probability table ("CPT") was adjusted to reflect the correlation
structure found in the data of the two subpopulations. CPT prior probabilities
for the BNM require statistical characterization of the subpopulation including
age, gender, weight, height, race, body surface area (calculated from height
and weight), tobacco use status, amiodarone use status, and genotypes for
CYP2C9 and VKORC1. Statistics of the demographic and clinical information
for each of the subpopulations were calculated by WiAD-Miner. The genotype
statistics came from a study which determined individual and combined
frequencies of important genetic variants associated with warfarin metabolism
in several racial and ethnic groups (Scott, 2010). Using the BNM and related
R software, we created a sufficient number of clinical avatars (191 x 1000
replicates for lower SES and 178 x 1000 replicates for upper SES) to conduct
one thousand parallel simulations of each arm of the study (Figure 6.2).
PC-CER Simulation: For each Clinical Avatar study set (191 lower clinical
avatars and 178 upper clinical avatars), a 90 day simulation was performed
for each Clinical Avatar using each of the four PGx and non-PG protocols. All
results were stored in a structured format representing the 1000 x 90 day
study simulations for each clinical avatar in the study subpopulations.
Simulation records included: clinical avatar record, simulated INRs and dose
values (1 per day for each of 90 days) and calculated TTRs using Rosendaal
method (Navathe, 2011). Statistical analysis was applied across the 1000
replicated simulations between the two SES groups.
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Figure 6.2. The study’s design with 4 arms.

6.3.6.) Statistical Analysis
All statistical analyses were conducted with R (R Core Team, 2013).
Statistical significance was set at p<0.05, unless otherwise noted. Single
factor differences between subpopulations were tested using either a
parametric (unpaired t-test, for normal distributions) or a nonparametric test
(Wilcoxon-Mann-Whitney, for non-normal distributions). Comparisons
between the simulated cohorts for TTR were made by using one-way ANOVA
tests along with the Tukey post-hoc honestly significant difference (HSD) test
to examine the TTR variances across the SES-based subpopulations. Two
way ANOVA test was used to detect possible interactions between
characteristics race and SES on TTR for data corresponding to the WiAD’s
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cohorts. Results are expressed as mean ± standard error of the mean (SEM)
unless otherwise specified.

6.4.) Results
6.4.1.) General Characteristics of WiAD Warfarin Cohorts
A total of 369 warfarin patient were identified across the Milwaukee lower SES
(n=191) and upper SES (n=178) groups (2nd and 3rd columns of Table 6.1).
Mean (SD) age of upper and lower SES patients were 73.74 (14.4) and 61.69
(16.18) respectively. There was no significant difference (p>0.05) in either
gender or height but average weight and tobacco use of the lower SES was
higher than the upper SES cohort. The racial profile of the lower SES cohort
was very different from the upper SES cohort (e.g. 53.9% versus 93.8%
white).

6.4.2.) General Characteristics of Clinical Avatar Cohorts
The statistical characteristics of the clinical avatars simulated to represent the
study subpopulations, are presented in the 4th and 5th columns of Table 6.1.
All demographic and clinical characteristics of the clinical avatar cohorts were
statistically the same as the Milwaukee warfarin lower and upper SES study
cohorts. Genotype frequencies were matched to those published for
populations equivalent to the AHC (Scott, 2010).

6.4.3.) WiAD Warfarin Cohorts’ Outcome Metrics
The outcome metrics for this study were TTR and number of INR (Figures 6.3
and 6.4). Lower SES cohort had significantly lower TTR compared to Upper
SES (39.82%±1.9 vs 48.88%±1.83, P<0.05). Lower SES cohort had
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Table 6.1. Basic characteristics of the WiAD warfarin and clinical avatars
cohorts. (1) The WiAD warfarin cohorts’ genotypes were imputed using
Scott’s distributions, correlations and joint distributions (Scott, 2010).
Characteristics
Number of Patients
Age, year, mean (SD)
Gender, female %
Weight, kg, mean
(SD)
Height, in, mean (SD)
Race, %
White
African American
Asian
Tobacco use, %
Amiodarone use, %
DVT, %
VKORC1, %
A/A
G/A
G/G
CYP2C9, %
*1/*1
*1/*2
*1/*3
*2/*2
*2/*3
*3/*3

WiAD Warfarin Cohorts
Milwaukee
Milwaukee
Lower SES
Upper SES
191
178
61.6 (16.1)
73.74 (14.4)
59.1
56.1
91.2 (26.2)
84.5 (24.7)

Clinical Avatar Cohorts
Lower SES

Upper SES

191
61.29 (15.9)
59.2
94.4 (25.4)

178
73.38 (14.3)
57.4
87.7 (24.6)

66.13 (4.2)

66.25 (4.9)

66.28 (3.7)

65.78 (3.7)

53.9
44.5
1.6
10.9
12.0
26.1
(1)
10.5
32.5
56.8
(1)
70.4
10.1
6.5
3.6
1.1
0.7

93.8
5.6
0.6
5.0
12.9
17.4
(1)
16.9
43.5
39.4
(1)
66.5
14.4
9.0
6.2
1.8
0.2

53.8
44.8
1.3
10.7
11.4
29.7

93.9
5.4
0.6
5.3
13.2
18.4

9.7
33.0
57.2

16.4
42.1
41.2

71.1
8.6
6.0
3.0
1.0
1.1

67.4
13.3
8.5
5.4
1.9
0.3

significantly lower number of INR than Upper SES (7.0 vs 13.0, median,
respectively, p<0.05). No significant interaction between SES group and race
on TTR was present (two-way ANOVA, p<0.05). In the absence of interaction
with race, SES had significant effect on TTR .

6.4.4.) Clinical Avatar Cohorts’ Outcome Metrics
Figure 6.3 presents the Milwaukee lower (left panel) and upper (right panel)
SES clinical avatar cohorts’ TTR computed for CG-I STD, CG-I PG, CG-II PG2 and Wilson in order.

252

Figure 6.3. Averaged TTR for lower and upper SES clinical avatar cohorts by
dosing protocol (left and right panel). Capped vertical lines represent standard
error of the mean. For both cohorts, the Wilson protocol’s TTR was
significantly higher than any other protocol (ANOVA, p<0.05).
For the lower SES cohort, all PGx protocols produced significantly higher
results than the non-PGx protocol and the Wilson protocol was highest
(42.41±2.26 vs 52.04±2.24, 56.53±1.93, 73.84±1.52, ANOVA, p<0.05). The
same result was true for the upper SES cohort (38.85±0.74, 52.58±0.53,
52.46±0.44, 75.66±0.49, ANOVA, p<0.05). The averaged TTR predicted by
the Wilson protocol for the two clinical avatar cohorts were not significantly
different. The average 90 day frequency of INR predicted for each protocol
was shown in Figure 6.4 (Lower SES, left panel, Upper SES, right panel).
For the lower SES cohort, the CG-I STD protocol predicted significantly higher
frequency of INR than either CG-I PG or Wilson protocol (10.2±0.4 vs
9.4±0.16 and vs 8.7±0.3, ANOVA, p<0.05). Whereas in the upper SES clinical
avatar cohorts, the predicted frequency of INRs were not different.
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Figure 6.4. Averaged frequency of INRs for lower and upper SES clinical
avatar cohorts by dosing protocol (left and right panel). Capped vertical lines
represent standard error of the mean. For both cohorts, the Wilson protocol’s
frequency of INRs was significantly lower than any other protocol (ANOVA,
p<0.05).

6.4.5.) Comparison between WiAD Warfarin Cohorts and
Clinical Avatar Cohorts
Averaged TTR was not significantly different between the Milwaukee lower
SES cohort (calculated from EMR data) under current AHC non-PGx best
practice protocol when compared to the equivalent clinical avatar cohort under
the CG-I STD dosing protocol (39.82%±1.9 vs 42.41±2.26) and was
significantly less than the three PGx protocol predictions (39.82%±1.9 vs
52.04±2.24, 56.53±1.93, 73.84±1.52, ANOVA, p<0.05). Averaged TTR for the
Milwaukee upper SES cohort is significantly more than that predicted for the
upper SES clinical avatars using CG-I STD (48.88%±1.83 vs 38.85±0.74) and
significantly less than that predicted using the Wilson protocol (48.88%±1.83
vs 75.66±0.49).
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6.5.) Discussion
In this study, we present an in silico pharmacogenetic anticoagulation PCCER approach applied to a patient-centered outcomes simulation that
produced a prediction that was validated with patient data acquired directly
from a large hospital transaction electronic medical record system. We
applied this approach to a well-documented health disparity cohort defined by
a Milwaukee SES index. Upper and lower SES patients treated by warfarin
using the healthcare system’s best practice dosing protocol were extracted
from the EMR and simulated to predict treatment outcomes under four
different warfarin dosing protocols. The approach we used in this study
includes three key elements (Figure 6.1.): a) High quality EMR derived data
set and data mining environment (WiAD) from which clinical-trial like outcome
metrics are extracted; b) Means to conduct complex multi-factorial
anticoagulation simulation study designs (PCTS) and predict outcome metrics
from multiple treatment protocols; and c) Means to test the predicted outcome
metrics against those derived from the EMR (WiAD-Miner).
It has been suggested that meaningful patient-centered outcomes research
need high-quality data, including greater clinical detail, longitudinal follow-up,
and linkages among data sets (Navathe, 2011). An important result of this
work is the dynamic collection of anticoagulation treated patient data and
related information encapsulated in WiAD in support of our PC-CER study.
WiAD includes over 150,000 Wisconsin resident patients spanning some ten
years of anticoagulation diagnosis, treatment and outcome data derived from
the Aurora Health Care EMR and all data was processed using a two-step
extraction and transformation method including completeness, correctness,
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and concordance (Weiskopf, 2013). We used WiAD to select the two
Milwaukee warfarin SES subpopulations and calculate both TTR and number
of INRs. The lower SES subpopulation’s TTR was significantly less than the
upper SES subpopulation’s TTR beyond any interaction based on race or
ethnicity alone. This result is consistent with the Milwaukee Heath Report
2012, which indicated that dramatic health disparities by SES exist and persist
within Wisconsin’s largest city (Chen, 2012). Our results demonstrate that this
disparity is correlated to SES and may be explained by doctor-patient
relationships as demonstrated in previous studies (Schouten, 2006; Bates,
2009).
The 90-day warfarin therapy simulation predicted similar outcome for the
standard non genotype-based dosing protocol (non-PGx CG-I STD) to those
calculated for the lower SES subpopulation using the EMRs. Surprisingly, the
approach also predicted a similar level of averaged TTR (38.85%) for the
upper group under the standard protocol as the lower subpopulation even
though the upper subpopulation’s EMR-calculated averaged TTR was much
higher (48.88%). This result indicates that the actual outcomes of upper SES
group in the healthcare system is much higher than one would predict with
consistent application of the same protocol across all patients independent of
SES. In addition, the predictions suggest that the warfarin genotype-based
Wilson protocol would produce the highest averaged TTR across the two SES
subpopulations while requiring a significantly lower frequency of INR values
for the lower SES subpopulation. Consistent with our predictions for a revised
CoumaGen-I trial (Fusaro, 2013). the Wilson protocol produced the best
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outcomes of all protocols and simultaneously dramatically reduced the health
disparity between the lower and upper SES subpopulations.

6.6.) Conclusion
Multifactorial PC-CER clinical trials designed to test the optimal treatment
against multiple subpopulations create a complex and costly paradigm whose
results will guide improved healthcare. Part of this complexity can be
addressed using judiciously developed and validated mathematical modeling
and simulations. Herein, we demonstrated the value of using EMRs to extract
clinical-trial like anticoagulation outcome metrics and detect possible
disparities within the study population. We applied the approach to a study
population that includes individuals who historically experience health
disparity to simulate patient outcomes using one non-PGx and three PGx
protocols. Our results indicate that the Wilson genotype-based warfarin
protocol applied systematically to all patients, improves outcomes overall and
reduces the observed health disparity. If validation studies designed to test
these predictions prove true, then the optimal warfarin protocol translated into
the healthcare setting will improve best practice as suggested in Figure 6.1’s
dotted lines. The combination of in silico studies followed by carefully
designed targeted validation studies, suggests a powerful approach to
improve healthcare overall and reduce health disparity in particular.
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7.1.) Conclusion
The concept of “translational research” is relatively new. In a commentary in
JAMA, Woolf has pointed out that “translational research means different
things to different people” (Woolf, 2008). The newly established NIH’s
National Center for Advancing Translational Sciences has defined
“Translation” as “the process of turning observations in the laboratory and
clinic into interventions that improve the health of individuals and the public from diagnostics and therapeutics to medical procedures and behavioral
changes” (NCATS, 2014). According to their definition, translational science is
“the field of investigation focused on understanding the scientific and
operational principles underlying each step of the translational process”
(NCATS, 2014). As such, translational research models are designed to
“translate” discoveries identified through basic science studies (whether
gained in animal models of human disease or through human studies), to
knowledge concerning the potential value of the discovery’s application in
medicine.
Translational research in genomics, specifically pharmacogenomics as one of
the first clinical applications of the new genomic era, aims to move promising
genomic applications to clinical and public health practice for population
health benefit (Cleeren, 2011). Despite the demonstrable benefits of many
new genomic discoveries, there have been gaps between the explosive
growth in scientific discovery and technology and the implementation of this
new knowledge. It is widely recognized that the current translational process
is slow, very expensive and often results in an incomplete transfer of research
findings into practice, and consequently failure of comparative effectiveness

263

studies used to translate the findings into substantial changes in patient care
and health disparities (Khoury, 2007). A study aiming to evaluate the
predictors of and time taken for the translation of highly promising basic
research into clinical applications, over a 15-year period, showed that only
about 5% of the basic science findings were licensed for clinical use and only
1% were extensively used for the licensed indications (Contopoulos-Ioannidis,
2003).
Although a large number of translational research models have been
developed over the time, however, no existing model has adequately
addressed the pressing need to create a process and pragmatic approach
that will cover the ever expanding collection of high-throughput, individualized
data that is generated by ever advancing technology. In short, the deluge of
big data especially in the light of expanding electronic medical record systems
(EMRs) and genomic era has overwhelmed the antiquated models and
processes designed to translate important and growing data and evidence to
the healthcare setting. These models are further weakened when considering
the important area of patient-centered, comparative effectiveness research
and the potential disparity of outcomes when coarse applications are applied
to diverse populations. Given these facts and the need to address many
complex real-world healthcare questions in short periods of time, it seems that
alternative research designs and approaches should be considered in
translational research.
Taking into consideration these facts, in this dissertation, I have proposed an
iterative and bidirectional agile translational research model enhanced with an
in silico knowledge synthesis model (iS-TR) to facilitate pharmacogenomic

264

patient-centered comparative effectiveness research (PC-CER) studies. I
have hypothesized that retrospective EMR analysis and subsequent
mathematical modeling and simulation predictions (a) may facilitate and
accelerate the process of generating and translating pharmacogenomic
knowledge, (b) may be applied to determine comparative effectiveness of
anticoagulation treatment plan(s) tailored to well defined target populations,
and (c) may result in a decrease in overall adverse risk and improve individual
and population outcomes.
To test the hypotheses, I have developed an In Silico PC-CER Approach for
warfarin pharmacogenomics knowledge. The two-component In Silico PCCER Approach consists of a process for the secondary use of “Big EMR Data”
resulting in a unique anticoagulation database, Wisconsin Anticoagulation
Database (“WiAD”), and also a study design and clinical trial simulation
platform. Once the simulation platform was validated by replicating and
reproducing the results of two major warfarin pharmacogenomic clinical trials
of CoumaGen-I and II (Anderson, 2007a, 2012b), the Approach was applied
(a) to predict optimal anticoagulation treatment plan for the Aurora Health
Care’s large heterogeneous patient population, and (b) to an anticoagulation
therapy outcomes disparity in City of Milwaukee recognized as the most
segregated metropolitan area in the country with a significant SES-based
health disparity.
The studies’ results have demonstrated that the In Silico PC-CER Approach
taking advantage of retrospective EMR analysis and subsequent
mathematical modeling and simulation prediction could facilitate and
accelerate the process of generating and translating pharmacogenomic
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knowledge on comparative effectiveness of anticoagulation treatment plan(s)
tailored to well defined target populations (leading to a decrease in overall
adverse risk and improve individual and population outcomes). Accordingly,
we have concluded that the combination of in silico studies followed by
carefully designed targeted validation studies would be a powerful approach
to conduct PC-CER studies, improve healthcare overall and reduce health
disparity in particular.

7.2.) Limitations
The In Silico PC-CER Approach provides many opportunities and we have
demonstrated that it could be used as an effective approach to improve and
facilitate translational research. However, given the complexity of the
anticoagulation therapy in real clinical settings especially for warfarin, transfer
of knowledge and evidence produced by the Approach to the real world
clinical setting requires clinical judgment of the healthcare providers.
Even though the Approach provides a great opportunity to conduct
comparative effectiveness studies on heterogeneous study populations;
however, real world clinical conditions will obviously vary and do not perfectly
reflect the content or performance of the Approach. For instance, several
foods and herbal supplements can interact with warfarin and affect its
effectiveness. The current Approach does not include modules to take into
consideration this kind of factors in its predictive outcomes.

7.3.) Future Work
In next few months, I will focus on improving the In Silico PC-CER Approach.
One important step will be to expand and enrich WiAD by extracting and
including more clinical information of the subjects allowing us to take
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advantage of other predictive models such as CHA2DS2-VASc for risk of
ischemic stroke (Lip, 2010) and HAS-BLED for risk of bleeding (Pisters,
2010). The other task will be to design and conduct some validation studies of
the predicted subpopulation anticoagulation treatment plans produced by the
In Silico PC-CER Approach.
I am also interested in applying the In Silico PC-CER Approach to other fields
such as cancer recurrence and progression. The Approach also has great
potential to be used as the basis of a Decision Support System for clinicians.
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